EVER would like to thank all of its past and present sponsors. We would especially like to thank the following companies, many of which are our long-term supporters, for their generous sponsorship in 2016. Thanks to their kind support EVER can continue to encourage research and dissemination of knowledge concerning the eye and vision by means of meetings, publications and exchange of information.

EVER 2016 - programme book
## The power of simplicity

### Rethinking glaucoma management

**GALLOMA GE IMPLANT**

---

### HERMES RHODES 1 RHODES 2 RHODES 3 RHODES 4 GALLINI 1 &2 GALLINI 4 GALLINI 5

<table>
<thead>
<tr>
<th>Time</th>
<th>Session/Track</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00 - 10:00</td>
<td><strong>EURO 1: Neuro-ophthalmology</strong></td>
<td>Hermes</td>
</tr>
<tr>
<td>10:00 - 11:00</td>
<td><strong>EURO 2: Neuro-ophthalmology</strong></td>
<td>Hermes</td>
</tr>
<tr>
<td>11:00 - 12:00</td>
<td><strong>EURO 3: Neuro-ophthalmology</strong></td>
<td>Hermes</td>
</tr>
<tr>
<td>12:00 - 13:00</td>
<td><strong>EURO 4: Neuro-ophthalmology</strong></td>
<td>Hermes</td>
</tr>
<tr>
<td>13:00 - 14:00</td>
<td><strong>EURO 5: Neuro-ophthalmology</strong></td>
<td>Hermes</td>
</tr>
<tr>
<td>14:00 - 15:00</td>
<td><strong>EURO 6: Neuro-ophthalmology</strong></td>
<td>Hermes</td>
</tr>
<tr>
<td>15:00 - 16:00</td>
<td><strong>EURO 7: Neuro-ophthalmology</strong></td>
<td>Hermes</td>
</tr>
</tbody>
</table>

---

### Exhibition area

**Friday, October 7, 2016**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session/Track</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30 - 10:00</td>
<td><strong>GALLOMA GE IMPLANT</strong></td>
<td>Hermes</td>
</tr>
<tr>
<td>10:00 - 11:00</td>
<td><strong>EURO 1: Neuro-ophthalmology</strong></td>
<td>Hermes</td>
</tr>
<tr>
<td>11:00 - 12:00</td>
<td><strong>EURO 2: Neuro-ophthalmology</strong></td>
<td>Hermes</td>
</tr>
<tr>
<td>12:00 - 13:00</td>
<td><strong>EURO 3: Neuro-ophthalmology</strong></td>
<td>Hermes</td>
</tr>
<tr>
<td>13:00 - 14:00</td>
<td><strong>EURO 4: Neuro-ophthalmology</strong></td>
<td>Hermes</td>
</tr>
<tr>
<td>14:00 - 15:00</td>
<td><strong>EURO 5: Neuro-ophthalmology</strong></td>
<td>Hermes</td>
</tr>
<tr>
<td>15:00 - 16:00</td>
<td><strong>EURO 6: Neuro-ophthalmology</strong></td>
<td>Hermes</td>
</tr>
<tr>
<td>16:00 - 18:00</td>
<td><strong>EURO 7: Neuro-ophthalmology</strong></td>
<td>Hermes</td>
</tr>
</tbody>
</table>

---

### Saturday, October 8, 2016

<table>
<thead>
<tr>
<th>Time</th>
<th>Session/Track</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30 - 10:00</td>
<td><strong>GALLOMA GE IMPLANT</strong></td>
<td>Hermes</td>
</tr>
<tr>
<td>10:00 - 11:00</td>
<td><strong>EURO 1: Neuro-ophthalmology</strong></td>
<td>Hermes</td>
</tr>
<tr>
<td>11:00 - 12:00</td>
<td><strong>EURO 2: Neuro-ophthalmology</strong></td>
<td>Hermes</td>
</tr>
<tr>
<td>12:00 - 13:00</td>
<td><strong>EURO 3: Neuro-ophthalmology</strong></td>
<td>Hermes</td>
</tr>
<tr>
<td>13:00 - 14:00</td>
<td><strong>EURO 4: Neuro-ophthalmology</strong></td>
<td>Hermes</td>
</tr>
<tr>
<td>14:00 - 15:00</td>
<td><strong>EURO 5: Neuro-ophthalmology</strong></td>
<td>Hermes</td>
</tr>
</tbody>
</table>

---

### Hermes

**GALLOMA GE IMPLANT**

---

**Date of preparation: July 2016**

**INT/0457/2016a**

**XEN is a medical device class III CE 0086. Please consult your local directions for use.**

Adverse events should be reported to your local regulatory authority and Allergan office. XEN is not commercially available in France.
Dear EVER members, colleagues and friends,

2016 heralds an exciting and animated month of October as EVER and EUPO (the European Professors of Ophthalmology group) come together for a grand event. This meeting is not to be missed!

As in previous years, EVER offers a varied menu of fundamental fare and house specialties. These include board preparation sessions, clinical courses, topic-specific symposia, state-of-the-art research platforms, keynote lectures and a broad palette of scientific posters. The “extra” in 2016 will be the EUPO courses dedicated to neuro-ophthalmology and strabismus. These are CME accredited courses which will run in parallel with the EVER scientific program during Friday and Saturday (October 7-8). EUPO courses are intended to assist the preparation of young ophthalmologists for the European Board of Ophthalmology examination and also serve as excellent refresher courses for any practicing ophthalmologist.

I am delighted to announce that EVER offers open general admission to EUPO courses for all EVER meeting registrants (without an increase in registration fee from the previous year!). Likewise, EUPO attendees will have open access to the EVER program on those 2 shared days. And as EVER and EUPO boast a strong international faculty, this is a win-win situation for all!

At EVER, we strive for growth, advancement and improvement in ophthalmology and visual science. This may sound like the oft-heard rally cry of “more, bigger and better” which, in practice, often translates to harried, stressed and rushed. Rest assured that EVER is none of that. The beautiful relaxed atmosphere of the French Riviera is once again home to the EVER meeting. Over 4 sunny days in Nice, after the scientific day, enjoy a stroll through the fresh market, take a dip in the Mediterranean waters and savor tasty gourmet dishes on an open terrace.

So join me at EVER-EUPO 2016. It will be a stimulating experience!

Aki KAWASAKI
President EVER 2016
L’innovation en Ophtalmologie va bien au-delà des médicaments

Téléchargez l’Application Retina Base pour tablettes tactiles sur l’App Store® ou le Google Play® et découvrez plus de 120 cas cliniques de pathologies rétiniennes rédigés par des experts, disponibles en Français et en Anglais.

- Naviguez à travers l’organisation planétaire des pathologies et cas cliniques.
- Recherchez facilement les clichés grâce au moteur de recherche intuitif et filtrez les résultats par mot-clé, technique d’imagerie et auteur.
- Recevez les notifications dès que de nouveaux cas sont disponibles.

Rendez-vous sur www.viaopta.fr pour découvrir ou redécouvrir tous les services ViaOpta™ dédiés à l’ophtalmologie
Word from the president ................................................................. 1
About EVER .................................................................................. 4
Composition of the board 2016 ...................................................... 8
Congress information ................................................................. 10
Grants and prizes ....................................................................... 14
Floorplan ..................................................................................... 16
Partners of EVER ....................................................................... 18
About the programme book ....................................................... 20
Scientific sections 2016 .............................................................. 21
Industry Sponsored Symposia ..................................................... 22
Courses ....................................................................................... 23

**Wednesday, October 5** .................................................................. 25
Noon session .................................................................................. 26
First afternoon session ................................................................. 30
Opening Ceremony ....................................................................... 35
Second afternoon session ............................................................ 36
European Ophthalmology Heritage Lecture - Luc MISSOTTEN .......... 40
Keynote Lecture - Robert MACLAREN ....................................... 41
Welcome reception ..................................................................... 43

**Thursday, October 6** .................................................................... 45
First morning session .................................................................... 46
EVER-Acta lecture - John GREENWOOD ....................................... 51
Second morning session .............................................................. 52
Luncheon session - CIS ................................................................. 56
Keynote Lecture - Shigeru KINOSHITA .......................................... 59
First afternoon session ................................................................. 60
Poster session 1 ........................................................................... 65
Second afternoon session ............................................................ 74
Evening session .......................................................................... 79

**Friday, October 7** ......................................................................... 81
First morning session .................................................................... 82
Keynote Lecture - Marcela VOTRUBA .......................................... 87
Second morning session .............................................................. 88
First afternoon session ................................................................. 92
Poster session 2 ........................................................................... 97
Second afternoon session ............................................................ 106
Section Business Meetings ......................................................... 107
Second afternoon session ............................................................ 108
General Assembly ....................................................................... 113

**Saturday, October 8** ................................................................... 115
First morning session .................................................................... 116
Ophthalmic Research Lecture - Marie-José TASSIGNON ............... 119
Second morning session .............................................................. 120
Poster session 3 ........................................................................... 121
First afternoon session ................................................................. 130
Prize award ceremony and Closing Remarks ................................ 133

**EUPO Course programme overview** ....................................... 134-135

Presenting first authors .................................................................. 147
Presenting all authors ................................................................... 153
Authors by Country ....................................................................... 163
Congress time schedule ............................................................... 164-165
Sponsors ....................................................................................... back cover
The European Association for Vision and Eye Research, EVER, is a non-profit organisation. The aims of the association are to encourage research and the dissemination of knowledge concerning the eye and vision by means of meetings, publications and exchange of information. EVER is the leading ophthalmological research association in Europe which covers all areas of ophthalmology and the visual sciences. It provides an umbrella for other ophthalmological societies to meet during its annual congress and is an excellent place for networking.

**Membership**

EVER currently has members from 50 countries all over the world and represented by 11 scientific sections. Membership is open to individuals of any nationality, engaging in or with an interest in ophthalmic and vision research. Applications for membership - available on www.ever.be - may be submitted at any time, membership is on calendar year basis and starts on January 1. Every member must select one of the 11 scientific sections that best represents his or her primary area of interest.

**The benefits of EVER membership are:**
- significantly reduced registration fees for annual meeting
- submission of abstracts at annual meeting
- organizing Special Interest Symposia (SIS) and Courses
- free electronic subscription to the EVER journal, Acta Ophthalmologica (IF 2.844)
- voting rights for the election of the Board Members
- travel grants and poster prizes
- quarterly E-Newsletter

**Elections 2016**

In 2016 new representatives of the scientific sections

- **IM** Immunology / Microbiology
- **PBP** Physiology / Biochemistry / Pharmacology

will be elected through electronic voting. Voting 2016 will close on October 6, midnight. The result of the elections will be announced at the General Assembly on Friday, October 7, 18:00 -18:30.

**Website: www.ever.be**

On this website, you can
- obtain up-to-date information about the scientific programme and the EVER 2016 meeting and view the status (session, hour, place) of your presentation
- pay on-line and print your invoice
- access general information about EVER
- access Acta Ophthalmologica, the EVER journal
- cast your vote for officers
- print CME certificate after each congress you attended
Speakers’ affiliation to scientific sections

<table>
<thead>
<tr>
<th>Section</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>G (Glaucoma)</td>
<td>16%</td>
</tr>
<tr>
<td>RV (Retina / Vitreous)</td>
<td>15%</td>
</tr>
<tr>
<td>COS (Cornea / Ocular Surface)</td>
<td>14%</td>
</tr>
<tr>
<td>NSPH (Neuro-ophthalmology / Strabismology / Paediatric / History)</td>
<td>8%</td>
</tr>
<tr>
<td>PBP (Physiology / Biochemistry / Pharmacology)</td>
<td>8%</td>
</tr>
<tr>
<td>MBGE (Molecular Biology / Genetics / Epidemiology)</td>
<td>8%</td>
</tr>
<tr>
<td>ACB (Anatomy / Cell Biology)</td>
<td>7%</td>
</tr>
<tr>
<td>PO (Pathology / Oncology)</td>
<td>7%</td>
</tr>
<tr>
<td>LC (Lens / Cataract)</td>
<td>6%</td>
</tr>
<tr>
<td>IM (Immunology / Microbiology)</td>
<td>6%</td>
</tr>
<tr>
<td>EOVS (Electrophysiology, physiological Optics, Vision Sciences)</td>
<td>4%</td>
</tr>
</tbody>
</table>

*G*  | 16% | *RV*  | 15% | *COS*  | 14% | *NSPH* | 8% | *PBP*  | 8% | *MBGE* | 8% | *ACB*  | 7% | *PO*  | 7% | *LC*  | 6% | *IM*  | 6% | *EOVS* | 4% |
EVER is the leading ophthalmological research association in Europe which covers all areas of ophthalmology and the visual sciences. One of the main activities of EVER is the organizing of a high quality research meeting every October at a location chosen for its access and its agreeable autumn climate. EVER collaborates closely with other societies and encourages them to convene annually with EVER.

In 2010, the EVER Foundation was created to raise money to organize EVER Research Fellowships to offer to young ophthalmologists or young vision scientists, especially from Eastern Europe or from developing countries outside Europe, the opportunity to gain experience in laboratory techniques and scientific research in leading European Departments for Vision and Eye Research. The duration of the fellowship is limited to 6 months.

**Fellowships 2016:**
1. Dr. Mahajan DEEPTI, India, host institute: Vision Lab, Cardiff Centre for Vision Sciences, Cardiff University, UK
2. Dr. Narine ADZHEMIAN, Russia - host institute: Medical University of Vienna, Austria

**Fellowships 2015:**
1. Dr. Sepehr FEIZI, Iran - host institute: Queens Medical Centre, Nottingham, UK
2. Dr. Sabina SAPETA, Poland - host institute: Medical University of Vienna, Austria

**Fellowships 2014:**
1. Dr. Ganne PRATYUSHA, India - host institute: Vision Lab, Cardiff Centre for Vision Sciences, Cardiff University, UK
2. Dr. Mohamed Shafik Mohamed ELALFY, Egypt - host institute: Queens Medical Centre, Nottingham, UK

**Fellowships 2013:**
1. Dr. Reka ALBERT, Hungary - host institute: Queens Medical Centre, Nottingham, UK
2. Dr. Minika JASIELSKA, Poland - host institute: Department of Experimental Ophthalmology at the Charite University Medicine in Berlin, Germany

Acta Ophthalmologica is the official scientific publication of the European Association for Vision and Eye Research (EVER) and of the five Nordic ophthalmological societies. Acta Ophthalmologica publishes clinical and experimental original articles, reviews, editorials, educational photo essays (Diagnosis and Therapy in Ophthalmology), case reports and case series, letters to the editor and doctoral theses. (IF 2.844)
Executive committee

Aki KAWASAKI
President

Bart P LEROY
Past President

Catherine CREUZOT
Secretary General

Andrew DICK
President Elect

Steffen HEEGAARD
Treasurer

Laurence DESJARDINS
Vice President

Marcela VOTRUBA
Programme Secretary

Gerhard GARHÖFER
Vice President

Leopold SCHMETTERER
EVER liaison

EVER office by Mecodi

Marlene VERLAECKT
Executive Officer

Lies VAN EYCKEN
Executive Assistant

Mieke AKKERS
Executive Assistant

Kapucijnenvoer 33, 3000 Leuven, Belgium - ever@ever.be

www.mecodi.eu

Website and onsite support

COVR
IT solutions for scientific and medical associations

www.covr.be
### Composition of the board 2016

#### Section chairs

<table>
<thead>
<tr>
<th>Name</th>
<th>Section</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kai KAARNIRANTA</td>
<td>Anatomy / Cell Biology</td>
</tr>
<tr>
<td>Rafael BARRAQUER</td>
<td>Lens / Cataract</td>
</tr>
<tr>
<td>Thomas FUCHSLUGER</td>
<td>Cornea / Ocular Surface</td>
</tr>
<tr>
<td>Jochen GRAW</td>
<td>Molecular Biology / Genetics / Epidemiology</td>
</tr>
<tr>
<td>Miguel CASTELO-BRANCO</td>
<td>Electrophysiology, physiological Optics, Vision Sciences</td>
</tr>
<tr>
<td>Dominique BREMOND-GIGNAC</td>
<td>Neuro-ophthalmology / Strabismology / Paediatric / History</td>
</tr>
<tr>
<td>Alain BRON</td>
<td>Glaucoma</td>
</tr>
<tr>
<td>Frédéric MOURIAUX</td>
<td>Pathology / Oncology</td>
</tr>
<tr>
<td>Andrew DICK</td>
<td>Immunology / Microbiology</td>
</tr>
<tr>
<td>Gerhard GARHÖFER</td>
<td>Physiology / Biochemistry / Pharmacology</td>
</tr>
<tr>
<td>Peter WIEDEMANN</td>
<td>Retina / Vitreous</td>
</tr>
</tbody>
</table>

#### EVER representatives in Acta Board

<table>
<thead>
<tr>
<th>Name</th>
<th>Section</th>
</tr>
</thead>
<tbody>
<tr>
<td>Constantin POURNARAS</td>
<td></td>
</tr>
<tr>
<td>Leopold SCHMETTERER</td>
<td></td>
</tr>
</tbody>
</table>

#### Senior advisory committee

<table>
<thead>
<tr>
<th>Name</th>
<th>Section</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jean-Jacques DE LAEY</td>
<td></td>
</tr>
<tr>
<td>Jost JONAS</td>
<td></td>
</tr>
<tr>
<td>Graham HOLDER</td>
<td></td>
</tr>
<tr>
<td>Einar STEFANSSON</td>
<td></td>
</tr>
</tbody>
</table>

#### Representatives

<table>
<thead>
<tr>
<th>Name</th>
<th>Section</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bozena ROMANOWSKA-DIXON</td>
<td></td>
</tr>
<tr>
<td>Stephanie BAILLIF</td>
<td></td>
</tr>
<tr>
<td>Representative East Europe</td>
<td></td>
</tr>
<tr>
<td>Local representative France</td>
<td></td>
</tr>
</tbody>
</table>
EVER 2016

Venue

EVER 2016 will be held at the Acropolis Convention Center in Nice, France

www.nice-acropolis.com

The scientific programme of the EVER congress starts on Wednesday, October 5 at 11:30 and concludes on Saturday, October 8 at 15:00.

Registration

Everyone attending the scientific sessions - whether or not an EVER member - must register and pay the registration fee. Onsite registration starts on Wednesday, Oct 5, 9:00.

Please note that:

- being or becoming an EVER member – or having an abstract accepted – does not imply that you are registered
- if you register as a member-in-training, you need to prove your traineeship with a document signed by the Head of your Department
- if you register as an Eye-care, Technician or Nurse, you need to prove your status

Registration fees on-site

<table>
<thead>
<tr>
<th></th>
<th>EUR</th>
<th>EUR *</th>
</tr>
</thead>
<tbody>
<tr>
<td>EVER member / Course invited speakers</td>
<td>455</td>
<td>390</td>
</tr>
<tr>
<td>Member-in-training</td>
<td>250</td>
<td>200</td>
</tr>
<tr>
<td>Non-member</td>
<td>800</td>
<td>645</td>
</tr>
<tr>
<td>Non-member-in-training</td>
<td>400</td>
<td>310</td>
</tr>
<tr>
<td>Eye-Care / Technician / Nurse</td>
<td>200</td>
<td>180</td>
</tr>
</tbody>
</table>

* Citizens of these listed countries only:
  Albania, Algeria, Armenia, Belarus, Bosnia and Herzegovina, Congo, Egypt, Georgia, Iran, Libya, Macedonia, Moldova, Montenegro, Morocco, Ouzbekistan, Pakistan, Serbia, Tunesia, Ukraine

Welcome reception

The Welcome reception is open for all participants and exhibitors.

- Wednesday 19:30 - 21:30 in the Exhibition area, Acropolis Convention Center

Coffee / tea / refreshments

Included in the registration fee are the coffee / tea and soft drinks offered throughout the whole meeting. In addition coffee & croissants will be served early morning.

Internet access

Wi-Fi internet access is available in the Convention Center.
Photographs

It is strictly forbidden to take photographs or videos of the presentations in all lecture halls. The hostess will ask you to leave the lecture hall immediately and your name will be noted.

No-shows

Please note that any first author, whose paper or poster has been accepted, will be prohibited from presenting papers at EVER for the next two years if a valid reason is not sent to the EVER office in writing.

CME - Continued Medical Education credits

The European Accreditation Council for Continuing Medical Education Institution of the UEMS, EACCME has granted 22 European CME credits (ECMEC) to the EVER 2016 congress on Oct 5 - 8 in Nice, France. CME credit certificates can be printed from the EVER website after the congress.

Liability

The organisers cannot accept liability for personal accidents, loss of or damage to private property of participants and accompanying persons either during, or directly arising from the Meeting. Participants must make their own arrangements with respect to health and travel insurance.

EVER 2016 Congress App

All congress information in a nutshell:

- About EVER
- Floorplan and sponsors
- My congress bag
- My schedule
- News Feeds
- Notes
- Session rating
- etc.
**Publication of the abstracts**

The abstracts of the EVER 2016 congress are published on-line in a special issue of Acta Ophthalmologica, the EVER journal. Access for members-only through EVER homepage.

**Section Business Meetings**

EVER Section Business Meetings of the scientific sections
Friday, 16:00 - 16:30

- ACB .............................................Gallieni 4
- COS .............................................Rhodes 2
- EOVS ..........................................Rhodes 1
- G ...............................................Rhodes 1
- IM .............................................Gallieni 1 & 2
- LC .............................................Gallieni 5
- MBGE ..........................................Gallieni 1 & 2
- NSHP ..........................................Rhodes 2
- PO ..............................................Rhodes 3
- PBP ..............................................Rhodes 3
- RV ..............................................Hermes

The sections
- COS - Cornea / Ocular Surface
- G - Glaucoma

will nominate at least 2 candidates for the succession of their representatives in the Board of EVER for elections in 2017.

*Agenda see page 107*

**EVER General Assembly**

Friday, 18:00 - 18:30 in room Hermes

*Agenda see page 113*

**Prize award ceremony and conclusion of the congress**

Saturday, 14:30 - 15:00 in room Hermes

*Agenda see page 133*

**Women 4 EVER**

Saturday, October 8 from 13:00 to 14:30 in Hermes

Women 4 EVER wishes to assist women in developing tools for career advancement and to foster gender equality in ophthalmology and visual science. We encourage mentorship, collaboration, and communication. In this informal and open session, we invite all interested members of EVER to come and meet colleagues, share experiences and ask for advice. It is also a venue where ideas about gender-based studies in ophthalmology may be developed. *See page 130.*
Meet the Experts

Thursday, October 6 from 16:00 - 17:00 in poster area

In an initiative to encourage dialogue amongst speakers and EVER members, we have launched a one hour session called “Meet the Experts”. This will be a table of 6-8 “guests” at a table headed by one of the EVER speakers. The idea is to provide a casual yet personal venue where colleagues, in particular the younger faction, can share comments and ideas with an expert. This initiative is scheduled on Thursday, October 6 from 16:00 - 17:00 in poster area. See page 73. Please sign in at the registration desk.

YOS for EVER - young ophthalmologist/scientist

Thursday, October 6 from 17:00 - 18:30 in Rhodes 2

EVER 2016 will introduce a new symposium entitled YOS for EVER. YOS is a well-recognized acronym for “young ophthalmologist” and as not only ophthalmologists attend EVER, YOS stands for “young ophthalmologist/scientist”. YOS for EVER represents the trainee and young specialist group within EVER. This is a networking assembly of students, residents, post-docs and junior scientists to focus on objectives and goals relevant to the early stages of career development. Such topics include board examinations, information exchange, research and/or educational programs, fellowship and job opportunities. The 2016 inaugural symposium will be organized by Gauti Jóhannesson, a young ophthalmologist/scientist and member of the organization committee for YOS sessions at the Nordic Ophthalmologic Congress. All interested parties are encouraged to attend as guidelines and objectives and representatives for this new subgroup will be discussed at this first meeting. Immediately following the symposium, there will be a reception with light food and beverages on site. See page 75.

EUPO course - European University Professors of Ophthalmology

Friday, October 7 and Saturday, October 8 in Rhodes 4.
Each year EUPO organises a 2 days course for residents in training. This year, the course is on Neuro-ophthalmology (Friday, Oct 7) and Strabismus (Saturday, Oct 8) organized by Aki Kawasaki

The EUPO programme can be consulted in pages 134-135.
EVER section Travel Grants

We are pleased to announce that the following 14 members have received an EVER section Travel Grant of 750 EUR each:

- **ACB - Daria AFANASYEVA - Russia**
  1375 - Angiogenic potential of orbital adipose derived stromal cells

- **COS - Mette CORRELL - Denmark**
  1146 - Graft functionality after DSAEK surgeries in Denmark from 2006 to 2009

- **COS - Wojciech CZAK - Poland**
  2673 - Communication between the researcher and the researched. Designing an application based study regarding effects of air pollution on ocular surface diseases

- **EOVS - Kevin Sean JENKINS - Australia**
  3567 - Systematic Assessment of Clinical Methods to Diagnose and Monitor Diabetic Retinal Neuropathy

- **G - Shiama BALENDRAM - United Kingdom**
  1162 - A Curry A Day Keeps Glaucoma Away? - A Curcumin Study

- **G - Kendrick Co SHIH - China**
  1163 - Transcorneal electrical stimulation prevents secondary retinal ganglion cell death after acute ocular hypertensive injury through modulation of microglia-mediated local inflammatory response

- **IM - Dafina DRAGANOVA - Belgium**
  3373 - Validation of an antiretinal antibody detection strategy for the diagnosis of autoimmune retinopathies

- **LC - Xiaodi QIU - China**
  2352 - Effects of histone acetylation on superoxide dismutase 1 gene expression in the pathogenesis of senile cataract

- **MBGE - Andrea GARCÍA LLORCA - Iceland**
  3585 - Autophagy is affected by Mitf in mouse primary RPE cells

- **NSPH - Ségolène ROEMER - Switzerland**
  1551 - Reduced post-illumination pupil response in patients with mild-moderate cataracts is associated with impaired sleep quality

- **PBP - Olga KUDRYAVTSEVA - Denmark**
  2381 - Ca2+ activity during ATP-induced tone changes in porcine retinal arterioles in vitro spreads along the processes of perivascular cells

- **PO - Joni TURUNEN - Finland**
  S087 - BAP1 germline mutations in uveal melanoma patients without family history of eye cancer

- **RV - David CORDEIRO SOUSA - Portugal**
  2685 - Hypoxia and retinal blood flow changes: a study using OCT-Angiography

- **RV - Koen WILLEKENS - Belgium**
  1566 - Robot assisted retinal vein cannulation in an in vivo porcine retinal vein occlusion model

The Travel Grant awards will be handed over during the Prize Award Ceremony on Saturday, 14:30 - 15:00 in room Hermes.
EVER Poster Prizes

Poster Prizes of 500 EUR will be awarded for the best posters across all sections. The winners will be chosen by the poster moderators and will be announced in the Prize Award Ceremony on Saturday, 14:30 - 15:00 in room Hermes. No prize will be given after the congress.

EVER Award Ceremony 2015
Acropolis Convention Center, 2nd floor

Floorplan
ARVO
Association for Research in Vision and Ophthalmology  www.arvo.org

In many senses the counterpart of EVER in North America, the purposes of ARVO are to encourage and assist research, training, publication, and dissemination of knowledge in vision and ophthalmology. EVER and ARVO are collaborating in many fields, including an ARVO symposium held every year in EVER and an EVER symposium held in ARVO since 2005. See page 88.

EBO
European Board of Ophthalmology  ebo-online.org

The European Board was founded in 1992 to guarantee the highest standards of care in ophthalmology in the countries of the European Union by ensuring that the training is raised to the best possible level. It makes recommendations regarding the standards and syllabus for training ophthalmologists, assesses the content and quality of training by site visits and the annual EBO Diploma Examination, facilitates the exchange of trainees and teachers, and promotes CME in ophthalmology. EBO works under the Section of Ophthalmology of the European Union of Medical Specialists (UEMS). Since 2007, EBO has organized review courses open to all delegates during the EVER congress. See pages 27, 31.

EUPO
European University Professors of Ophthalmology  www.eupo.eu

EUPO is the organizer of the annual structured subspecialty course for residents in training in Europe since 1988. Most of the ophthalmology curriculum is covered over a 4 year period to allow residents to get an overview of theoretical knowledge during their residency rotation. EUPO courses are held in different places in Europe. The EUPO 2016 course on Neuro-ophthalmology and Strabismus is organized in conjunction with the EVER congress in Nice, France. EUPO course in Rhodes 4 on Friday, October 7 and on Saturday, October 8. Programme EUPO course on pages 134-135.

FAN
European Fluorescein Angiography Club  www.fan-int.org

The FAN Club started as a friendly reunion of pioneers of Medical Retina, in the early days of fluorescein angiography and lasercoagulation of the retina. The FAN received a semi-official status, being invited to organize a session of Medical Retina Case Presentations during large meetings in Ophthalmology. The Club runs itself without official status, there is no membership fee, and no registration fee for the meetings. Upcoming meetings are decided within the group, trying to change the location from country to country, and offering all members the opportunity to organize at least once a full day reunion in their hospital. Since 2012, FAN has organised joint meetings open to all delegates during the EVER congress. See page 108.
FRO
Belgian Fund for Research in Ophthalmology  www.fro-online.org

The aim of the FRO association is to stimulate research in ophthalmology and in visual function by awarding grants to research projects carried out under order of Belgian institutions. The FRO candidates have presented their research work to an international jury during the EVER congress since 2002. See pages 118, 132.

GOA
Groupe Ophtalmo Allergo

In ocular surface pathologies the cooperation between clinical ophthalmology and allergology created the GOA. The GOA allowed the development of clinical research in ocular allergic disease. Vernal keratoconjunctivitis and atopic keratoconjunctivitis create severe ocular impairment that must be recognized and treated. See page 111.

OOG
The Ophthalmic Oncology Group  www.oog.eu

OOG is an independent scientific workgroup devoted to basic and clinical ophthalmic oncology. It has convened with EVER since 1998. The aims of the OOG are to improve the practice of ophthalmic oncology in Europe, develop internet-based databases to share scientific information, organise multicenter studies and quality control studies, and meetings and other activities with the aim of improving the treatment of eye tumours and knowledge about them. OOG encourages all EVER delegates to take part in its sessions. See pages 109, 117 and 131.

Optic Nerve Meeting  www.optic-nerve-online.com

Intended for basic scientists and clinicians to address important topics in translational research, including scientists in interdisciplinary areas such as neurology, neurodegenerations and autoimmunity. 2016 meeting: December 13-15, 2016 in Obergurgl, Austria. See page 92.
Sessions

- **BM**: Business Meeting
- **C**: Course
- **CIS**: Industry Sponsored Symposium
- **FP**: Free Paper session
- **GA**: General Assembly
- **JM**: Joint Meeting
- **KN**: Keynote lecture
- **SIS**: Special Interest Symposium
- **SOC**: Social
- **PS**: Plenary session

Symbols

- EVER section travel grant recipient
- Rapid fire presentation
- Conflict of interest disclosed

Scientific sections

- **ACB**: Anatomy / Cell Biology
- **COS**: Cornea / Ocular Surface
- **EOVS**: Electrophysiology, Physiological Optics, Vision Sciences
- **G**: Glaucoma
- **IM**: Immunology / Microbiology
- **LC**: Lens and Cataract
- **MBGE**: Molecular Biology / Genetics / Epidemiology
- **NSPH**: Neuro-ophthalmology/Strabismology / Paediatric Ophthalmology / History of Ophthalmology
- **PBP**: Physiology / Biochemistry / Pharmacology
- **PO**: Pathology / Oncology
- **RV**: Retina / Vitreous Section programme secretaries
Programme Secretary, Marcela VOTRUBA

2016 Section programme secretaries + representatives*

<table>
<thead>
<tr>
<th>Section</th>
<th>Secretaries and Representatives</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACB</td>
<td>Anatomy/Cell Biology, Goran PETROVSKI</td>
</tr>
<tr>
<td>COS</td>
<td>Cornea/Ocular Surface, Jean-Jacques GICQUEL</td>
</tr>
<tr>
<td>EOVS</td>
<td>Electrophysiology, Physiological Optics, Vision Sciences, Franziska RAUSCHER, Rebekka HEITMAR *</td>
</tr>
<tr>
<td>G</td>
<td>Glaucoma, Francesca CORDEIRO</td>
</tr>
<tr>
<td>IM</td>
<td>Immunology/Microbiology, Piergiorgio NERI, Joachim VAN CALSTER *</td>
</tr>
<tr>
<td>LC</td>
<td>Lens and Cataract, Stefan LÖFGREN</td>
</tr>
<tr>
<td>MBGE</td>
<td>Molecular Biology/Genetics/Epidemiology, Petra LISKOVA</td>
</tr>
<tr>
<td>NSPH</td>
<td>Neuro-ophthalmology/Strabismus/Paediatric Ophthalmology/History of Ophthalmology, Patrick YU-WAI-MAN</td>
</tr>
<tr>
<td>PBP</td>
<td>Physiology/Biochemistry/Pharmacology, Alexandre MOULIN</td>
</tr>
<tr>
<td>PO</td>
<td>Pathology/Oncology, Neville OSBORNE, Gerhard GARHÖFER *</td>
</tr>
<tr>
<td>RV</td>
<td>Retina/Vitreous, Stephanie BAILLIF, Anita LEYS *</td>
</tr>
</tbody>
</table>

EVER programme committee meeting in Leuven on June 11
Industry sponsored symposia - CIS

Thursday, October 6

**Théa Pharma**

12:40 - 13:40 | Rhodes 2

Demodex: innocent or guilty in blepharitis? .......................................................... 57

**Santhera Pharmaceuticals**

12:40 - 13:40 | Rhodes 1

Leber’s hereditary optic neuropathy (LHON): latest advances in diagnosis, staging and patient management................................................................. 56
### Courses throughout the EVER 2016 congress:

#### Wednesday, October 5

<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Level</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:30</td>
<td>Rhodes 1</td>
<td>B</td>
<td>A clinician’s guide to visual electrophysiology: a road map for neuro-ophthalmology</td>
</tr>
<tr>
<td>11:30</td>
<td>Rhodes 2</td>
<td>I</td>
<td>EBO course: Intraocular inflammation and infection (part I)</td>
</tr>
<tr>
<td>11:30</td>
<td>Gallieni 4</td>
<td>I</td>
<td>Tear fluid proteome</td>
</tr>
<tr>
<td>14:00</td>
<td>Hermes</td>
<td>I</td>
<td>Management of Aphakia</td>
</tr>
<tr>
<td>14:00</td>
<td>Rhodes 2</td>
<td>I</td>
<td>EBO course: Intraocular inflammation and infection (part II)</td>
</tr>
<tr>
<td>14:00</td>
<td>Rhodes 4</td>
<td>A</td>
<td>Optical principles of state-of-the-art ophthalmic instrumentation</td>
</tr>
<tr>
<td>16:50</td>
<td>Gallieni 4</td>
<td>B</td>
<td>High-resolution imaging of the anterior eye segment</td>
</tr>
</tbody>
</table>

#### Thursday, October 6

<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Level</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:30</td>
<td>Rhodes 2</td>
<td>I</td>
<td>Corneal dystrophies - diagnosis and treatment</td>
</tr>
<tr>
<td>11:00</td>
<td>Rhodes 3</td>
<td>I</td>
<td>Mistakes in the diagnosis of fundus tumors</td>
</tr>
<tr>
<td>14:30</td>
<td>Rhodes 3</td>
<td>B</td>
<td>ABC in retina structure and function</td>
</tr>
<tr>
<td>14:30</td>
<td>Rhodes 4</td>
<td>I</td>
<td>Challenges in management of orbital tumors</td>
</tr>
<tr>
<td>14:30</td>
<td>Gallieni 1+2</td>
<td>A</td>
<td>Update in clinical features and genetics in microphthalmia</td>
</tr>
<tr>
<td>17:00</td>
<td>Rhodes 2</td>
<td>B</td>
<td>YOS for EVER - Young Ophthalmologist/Scientist</td>
</tr>
</tbody>
</table>

#### Friday, October 7

<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Level</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:30</td>
<td>Gallieni 1+2</td>
<td>I</td>
<td>Ocular pulse amplitude - from pole to pole</td>
</tr>
</tbody>
</table>

#### Saturday, October 8

<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Level</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:30</td>
<td>Rhodes 2</td>
<td>I</td>
<td>Corneal infectious diseases</td>
</tr>
<tr>
<td>13:00</td>
<td>Rhodes 2</td>
<td>I</td>
<td>Maximising success in deep anterior lamellar keratoplasty</td>
</tr>
</tbody>
</table>
EVER 2016

Wednesday, Oct 5
Imaging of the human retina has undergone tremendous changes. Whereas decades these techniques have only been used experimentally, the introduction of OCT-based technology has gained widespread clinical use. It is particularly OCT angiography that has revolutionized ocular vascular imaging. Most likely the technique will replace classical fluorescein and ICG angiography in the near future. In addition, several investigators have worked on quantification of ocular blood flow. The present SIG will give an overview on these developments from a clinical view, but will also provide an update on latest technology.

SCHMETTERER L, NAGAOKA T

1111 11:30 Role of Glial Cells in Regulating Retinal Blood Flow during Flicker-Induced Hyperemia and Systemic Hyperoxia-Induced Hypoxemia in Cats
NAGAOKA T - Asahikawa

1112 11:48 Retinal Oximetry and Blood Flow

1113 12:06 OCT angiography: evaluation of the macular perfusion
POURNARAS C - Genève

1114 12:24 Retinal Oxygen Extraction
WERKMEISTER R, Aschinger G, Linzenmeier R, Schmetterer L - Vienna

1115 12:42 The oxygen saturation in retinal arterioles is predictive for the effect of intravitreal anti-VEGF treatment on diabetic macular edema
BEKT - Århus C

EOVS - A clinician’s guide to visual electrophysiology: a road map for neuro-ophthalmology

Beginner

Learning outcomes: at the end of the course the participant will be able to

· understand the purpose of the main visual electrophysiological tests (and their acronyms)
· recognise indications for visual electrophysiological tests
· inform patients of what they will experience
· understand the physiological principles underpinning each response
· recognise the response measurements and nomenclature associated with different tests
· interpret overall patterns of visual electrophysiological results to localise the site of visual pathway dysfunction
· prepare requests that optimise test selection and give context for result interpretation
· access ISCEV standards as a resource for test procedure and guidance

THOMPSON D, SMITH R

1121 11:30 The tests
THOMPSON D - London

1122 11:48 The indications
SMITH R - Aylesbury

1123 12:06 Retinal tests
ROBSON A - London

1124 12:24 Visual Evoked Potentials
LIASIS A - London

1125 12:42 In the neuro-ophthalmology clinic
SMITH R - Aylesbury
### IM - EBO course: intraocular inflammation and infection (part I)

**The aim of this course is to review major topics of intraocular inflammation and infection. MCQs will be proposed online before the course to evaluate the basic knowledge of the participants. The test will be followed by 6 consecutive general presentations for the understanding of different uveitis features. The course will be interactive allowing general discussion and the participation of the audience. MCQs will be discussed during each presentation. At the end of this course, participants will be prepared for the MCQ part of the EBO examination in uveitis.**

**BODAGHI B, HERBORT CP**

<table>
<thead>
<tr>
<th>Session</th>
<th>Time</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1131</td>
<td>11:30</td>
<td>Pathophysiology of uveitis</td>
<td>DICK A - Bristol</td>
</tr>
<tr>
<td>1132</td>
<td>11:45</td>
<td>Classification of uveitis</td>
<td>ANDROUDI S - Thessaloniki</td>
</tr>
<tr>
<td>1133</td>
<td>12:00</td>
<td>Signs and symptoms of uveitis</td>
<td>NERI P, Bisceglia P, Cesari C, Carrozzi G, Pirani V - Agugliano</td>
</tr>
<tr>
<td>1134</td>
<td>12:15</td>
<td>Laboratory work-up and specialized investigations</td>
<td>PLEYER U - Berlin</td>
</tr>
<tr>
<td>1135</td>
<td>12:30</td>
<td>Imaging in uveitis: techniques and indications</td>
<td>HERBORT C P - Lausanne</td>
</tr>
<tr>
<td>1136</td>
<td>12:45</td>
<td>Therapeutic management of uveitis</td>
<td>DICK A - Bristol</td>
</tr>
</tbody>
</table>

### COS - FP session - Corneal grafting

**GICQUEL J, THURET G**

<table>
<thead>
<tr>
<th>Session</th>
<th>Time</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1141</td>
<td>11:30</td>
<td>Immunosuppression with a subconjunctival implant releasing dexamethasone in a rabbit model of penetrating keratoplasty</td>
<td>CROUZET E, He Z, Perrache C, Basset T, Delavenne X, Peoc'h M, Gain P, Thuret G - Saint Priest en Jarez</td>
</tr>
<tr>
<td>1143</td>
<td>11:54</td>
<td>Mid-term clinical outcomes of collagen-phosphorylcholine cornea substitutes for therapeutic anterior lamellar keratoplasty</td>
<td>BUZNYK O, Islam M M, Iakymenko S, Pashechnikova N, Griffith M - Odessa</td>
</tr>
<tr>
<td>1144</td>
<td>12:06</td>
<td>Chondro-keratoprosthesis: an alternative to OOKP?</td>
<td>HOFFART L, Guyot L - Marseille</td>
</tr>
</tbody>
</table>
### LC - Controversies in cataract surgery pharmacology

The exciting evolution of best care practice in the use of pharmacological substances before, during, and after cataract surgery also creates controversies in the ophthalmic community. The dispersion of and adhesion to improved evidenced based treatments are hampered by local traditions, bureaucracy and national legislation. The speakers will present their take on past and current controversies in the use of pharmaceuticals relevant to cataract surgery.

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Title</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:30</td>
<td>LOFGREN S , GRZYBOWSKI A</td>
<td>Controversies in the use of NSAIDs</td>
<td>PLEYER U - Berlin</td>
</tr>
<tr>
<td>11:52</td>
<td>KUGELBERG M - Stockholm</td>
<td>Controversies in the use of steroids</td>
<td></td>
</tr>
<tr>
<td>12:14</td>
<td>LABETOULLE M - Le Kremlin Bicêtre</td>
<td>Controversies in the use of mydriatics</td>
<td></td>
</tr>
<tr>
<td>12:36</td>
<td>GRZYBOWSKI A - Olsztyn</td>
<td>Controversies in the use of antibiotics</td>
<td></td>
</tr>
</tbody>
</table>

### G - FP session - Advances in glaucoma

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Title</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:30</td>
<td>BRON A , NORMANDO EM</td>
<td>Racial differences in the extracellular matrix of the lamina cribrosa and the peripapillary sclera</td>
<td>Park HY L - Seoul</td>
</tr>
<tr>
<td>11:42</td>
<td>BALENDR A , Davis B M , Guo L , Cordeiro M F - London</td>
<td>A curry a day keeps glaucoma away? - A curcumin study</td>
<td></td>
</tr>
<tr>
<td>11:54</td>
<td>SHIH K C , Fu L , Lo A CY , Lai J S M - Island South</td>
<td>Transcorneal electrical stimulation prevents secondary retinal ganglion cell death after acute ocular hypertensive injury through modulation of microglia-mediated local inflammatory response</td>
<td></td>
</tr>
<tr>
<td>12:06</td>
<td>LEAL I , Cordeiro Sousa D , Moreira S , Dionisio P , Abegao Pinto L , Marques-Neves C - Lisbon</td>
<td>Normobaric hypoxia induces changes in mean ocular perfusion pressure</td>
<td></td>
</tr>
<tr>
<td>12:18</td>
<td>KHATIB T , Osborne A , Widdowson P , Martin K - Cambridge</td>
<td>Quantification of green fluorescent protein expression in mouse retinal ganglion cells following intravitreal injection of recombinant adeno-associated virus</td>
<td></td>
</tr>
<tr>
<td>12:24</td>
<td>HUANG O , Mehta J , Htoon H , Tan D , Wong T - Singapore</td>
<td>Incidence and risk factors of elevated intraocular pressure following deep anterior lamellar keratoplasty</td>
<td></td>
</tr>
<tr>
<td>12:30</td>
<td>VAN KEER K , Abegao Pinto L , Barbosa Breda J , Willekens K , Vandewalle E , Stalmans I - Leuven</td>
<td>A vascular comparison between primary open-angle glaucoma and normal-tension glaucoma</td>
<td></td>
</tr>
<tr>
<td>12:36</td>
<td>HORWITZ A , Petrovski B E , Petrovski G , Torp-Pedersen C , Kolko M - Copenhagen</td>
<td>A link between Diabetes Mellitus and Glaucoma — Danish Nationwide Study</td>
<td></td>
</tr>
</tbody>
</table>
Ocular surfaces are delicate structures of the anterior segment of the eye protected, nourished and lubricated by tear fluid. The system has its own regulatory mechanisms. Ocular surfaces are exposed environmental factors, topical ophthalmic drugs and affected by various ocular and systemic diseases. Inflammation and wound healing are vital processes involved in the defense mechanisms of the human body and pathogenesis of many eye diseases. It is also one of the most important factors in many ocular surgeries e.g. corneal, refractive and glaucoma surgery. Tear proteomics is a powerful tool to diagnose eye diseases and their risk factors. It is also a key to personalize the ocular therapies and health care processes. The course is focusing in the proteomics of the tear fluid and will give an practical overview of the technologies in this field.

### UUSITALO H

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>1171</td>
<td>11:30  When and why proteomic approach is needed?</td>
<td>UUSITALO H - Tampere</td>
</tr>
<tr>
<td>1172</td>
<td>12:00  Proteomics of tear fluid</td>
<td>BEUERMAN R - Singapore</td>
</tr>
<tr>
<td>1173</td>
<td>12:30  Practical examples of tear proteomic studies</td>
<td>HOLOPAINEN J - Helsinki</td>
</tr>
</tbody>
</table>
Wednesday, Oct 5 - First afternoon session

14:00 - 15:30 | HERMES

RV - Management of Aphakia

Management of aphakia still represents challenge as many options are available. Contact lenses correction will be detailed. Then, different intraocular lenses implantation will be presented, giving more details on advantages and inconveniences for each lens. Finally, complex reconstruction with aniridia implants will be discussed.

POURNARAS J, PAPPAS G

<table>
<thead>
<tr>
<th>Session</th>
<th>Time</th>
<th>Topic</th>
<th>Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>1311</td>
<td>14:00</td>
<td>Contact lenses</td>
<td>PLAINIS S - Heraklion</td>
</tr>
<tr>
<td>1312</td>
<td>14:15</td>
<td>Anterior chamber lenses</td>
<td>MOSCHOS M M - Athens</td>
</tr>
<tr>
<td>1313</td>
<td>14:30</td>
<td>Iris claw</td>
<td>POURNARAS J A - La Conversion</td>
</tr>
<tr>
<td>1314</td>
<td>14:45</td>
<td>Sleral structured iol</td>
<td>SIMCOCK P - Exeter</td>
</tr>
<tr>
<td>1315</td>
<td>15:00</td>
<td>Sclear embedded iol</td>
<td>PAPPAS G - Heraklion</td>
</tr>
<tr>
<td>1316</td>
<td>15:15</td>
<td>Aniridia implants</td>
<td>STAPPLERT - Liverpool</td>
</tr>
</tbody>
</table>

14:00 - 15:30 | RHODES 1

G - The ideal glaucoma rotation

Glaucoma is one of the leading causes of irreversible blindness. It is therefore a major part in Ophthalmology education and a major focus of Ophthalmology residency programmes. The syllabus in these programmes usually involves providing the residents with a set of skills, ranging from surgical procedures or treatment decision-making, they should master by the end of their glaucoma rotations. However, there is a great diversity between training centers and there is not a clear definition of what constitutes the core values in glaucoma training for the general Ophthalmologists. Accordingly, a much needed debate is needed between all players involved, from residents, Directors of training and Institutional organizations such as a the European Glaucoma Society.

ABEGAO PINTO L, SUNARIC MEGEVAND G

<table>
<thead>
<tr>
<th>Session</th>
<th>Time</th>
<th>Topic</th>
<th>Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>1321</td>
<td>14:00</td>
<td>The view of the doctor in training</td>
<td>SCOTT A - London</td>
</tr>
<tr>
<td>1322</td>
<td>14:18</td>
<td>The view of a director of training</td>
<td>GARCIA-FEIJOO J - Madrid</td>
</tr>
<tr>
<td>1323</td>
<td>14:36</td>
<td>The view of the EGS and the subspecialty exam</td>
<td>SUNARIC MEGEVAND G - Geneva</td>
</tr>
<tr>
<td>1324</td>
<td>14:54</td>
<td>How can we improve?</td>
<td>SUNARIC MEGEVAND G - Geneva</td>
</tr>
<tr>
<td>1325</td>
<td>15:12</td>
<td>What did we learn from this session?</td>
<td>ABEGAO PINTO L - Lisbon</td>
</tr>
</tbody>
</table>
### Wednesday, Oct 5 - First afternoon session

**IM - EBO course: intraocular inflammation and infection (part II)**

The first part on general aspects of uveitis will be followed by case presentations in different basic or more challenging situations. Important points will be discussed during each practical situation. The course will be interactive allowing general discussion and the participation of the audience. It will be intermediate and present entities that are frequently observed in routine. At the end of this course, participants will be prepared for the viva voce part of the EBO examination in uveitis.

**BODAGHI B, HERBORT CP**

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00</td>
<td>B27-associated uveitis, Fuchs uveitis</td>
<td>WILLERMAIN F - Bruxelles</td>
</tr>
<tr>
<td>14:18</td>
<td>Infectious uveitis</td>
<td>PLEYER U - Berlin</td>
</tr>
<tr>
<td>14:36</td>
<td>Behçet's disease, VKH, sarcoidosis</td>
<td>KHAIRALLAH M, Khochtali S, Abroug N - Monastir</td>
</tr>
<tr>
<td>14:54</td>
<td>Inflammatory choroiditis</td>
<td>HERBORT C P - Lausanne</td>
</tr>
<tr>
<td>15:12</td>
<td>Retinal vasculitis</td>
<td>ABU EL ASRAR A - Riyadh</td>
</tr>
</tbody>
</table>

**PBP - FP session - Drug delivery and biomarkers for ocular disease**

**SCHMETTERER L, HARDARSON S**

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:12</td>
<td>Toward rational design of gene carriers: a novel ex vivo model to study the vitreoretinal interface as a barrier</td>
<td>PEYNSHAERT K, Fradot V, Picaud S, De Smedt S, Remaut K - Ghent</td>
</tr>
<tr>
<td>14:24</td>
<td>Results of microinvasive cross-linking of rabbit posterior eye pole sclera</td>
<td>IOMDINA E N, Tarutta E, Semchishen V, Sianosyan A, Milash S - Moscow</td>
</tr>
<tr>
<td>15:00</td>
<td>In the search of biomarkers for thyroid associated orbitopathy (TAO)</td>
<td>TURCK N, Kishazi E, Dor M, Eperon S, Gracià M D L A, Fouda C, Oberic A, Hamédani M - Geneva</td>
</tr>
</tbody>
</table>
**Wednesday, Oct 5 - First afternoon session**

**14:00 - 15:30 | RHODES 4**

**EOVS - Optical principles of state-of-the-art ophthalmic instrumentation**

This single-speaker course is aimed to provide an overview of the optical principles of various state-of-the-art ophthalmic instruments, such as scanning laser ophthalmoscopy, optical coherence tomography, including adaptive optics, to make it easy for the clinician and scientist to understand the underlying concepts of various devices, even if not familiar with the particular technology. This course is designed for ophthalmologists in training or those in practice, aimed at addressing common optical pitfalls in general ophthalmology practice with easy-to-understand explanations enhanced by simple illustrations. Its goal is to make ophthalmic optics accessible and understandable with real-life, clinically relevant examples, such as why one should not switch myopes in their mid-life crises from wearing spectacles to contact lenses, or why aiming for a post-operative plano refraction with refractive or cataract surgery might not always yield the best vision or results.

**IRSCH K**

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Presenter</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>1351</td>
<td>Scanning Laser Ophthalmoscopy - Basic Optical Principles</td>
<td>IRSCH K - Paris</td>
<td></td>
</tr>
<tr>
<td>1352</td>
<td>Optical Coherence Tomography - Basic Optical Principles</td>
<td>IRSCH K - Paris</td>
<td></td>
</tr>
<tr>
<td>1353</td>
<td>Adaptive Optics - Basic Optical Principles</td>
<td>IRSCH K - Paris</td>
<td></td>
</tr>
</tbody>
</table>

**14:00 - 15:30 | GALLIENI 1+2**

**MBGE - Epidemiology of eye diseases**

To better understand mechanisms of development of ocular diseases, it is important to know their relationship to other diseases of the patients, to their genetic background, to their lifestyle, and to their whole environmental situation. The proportion of all these components is highly complex and cannot be resolved in small case-control studies. Therefore, large population-based cohorts are being developed at international and national levels to increase the power of such epidemiological studies. This Special Interest Symposium will share up-to-date information not only to stimulate discussions how to further improve epidemiological studies, but also to develop ideas for clinicians to include additional factors into their diagnostic and therapeutic considerations, and also for basic scientists to prove the molecular mechanisms behind epidemiological associations.

**GRAWF J**

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Presenter</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>1361</td>
<td>The Global Vision Database – modeling the current and changing burden of eye disease</td>
<td>BOURNE R - Cambridge</td>
<td></td>
</tr>
<tr>
<td>1362</td>
<td>The E3 consortium – European Eye Epidemiology</td>
<td>DELCOURT C - Bordeaux</td>
<td></td>
</tr>
<tr>
<td>1363</td>
<td>The Montrachet Study</td>
<td>CREUZOT C , Bron A , Binquet C - Dijon</td>
<td></td>
</tr>
<tr>
<td>1364</td>
<td>Molecular Genetics in Ocular Epidemiology</td>
<td>DEN HOLLANDER A - Nijmegen</td>
<td></td>
</tr>
<tr>
<td>Session</td>
<td>Title and Description</td>
<td>Presenter(s)</td>
<td>Location</td>
</tr>
<tr>
<td>---------</td>
<td>-----------------------</td>
<td>--------------</td>
<td>----------</td>
</tr>
<tr>
<td>14:00</td>
<td>Hypoxia and inflammation in human retinal cells</td>
<td>Arjamaa O, Aaltonen V, Piippo N, Csont T, Petrovski G, Kaarniranta K, Kivela A</td>
<td>Turku</td>
</tr>
<tr>
<td>14:12</td>
<td>Mitochondrial inhibition of retinal Müller cells alter glutamate homeostasis and their ability to sustain retinal ganglion cells</td>
<td>Skytt D, Vohra R, Toft-Kehler A, Gurubaran I S, Bergersen L H, Kolko M</td>
<td>Copenhagen</td>
</tr>
<tr>
<td>14:24</td>
<td>LACTATE: A valuable energy substrate in maintaining survival and function in the inner retina</td>
<td>Vohra R, Skytt D, Bergersen L H, Kolko M</td>
<td>Copenhagen</td>
</tr>
<tr>
<td>14:36</td>
<td>Mechanisms behind the protein aggregation-related inflammasome activation in RPE cells</td>
<td>Kauppinen A, Piippo N, Korhonen E, Hytti M, Kinnunen K, Kaarniranta K</td>
<td>Kuopio</td>
</tr>
<tr>
<td>14:48</td>
<td>Angiogenic potential of orbital adipose derived stromal cells</td>
<td>Afanasyeva D, Gushchina M, Borzenok S</td>
<td>Moscow</td>
</tr>
<tr>
<td>15:00</td>
<td>Description of the retinal vascular network by semi-automated computer software (SIVA) in the MONTRACHET study</td>
<td>Arnauld L, Binquet C, Guenancia C, Allassane S, Kawasaki R, Dainen V, Helmer C, Tzourio C, Bron A, Creuzot C</td>
<td>Dijon</td>
</tr>
<tr>
<td>15:12</td>
<td>Manufacturing of an ocular prosthesis based on the 3D printed anophthalmic socket</td>
<td>Ruiters S, Sun Y, De Jong S, Politis C, Mombaerts I</td>
<td>Leuven</td>
</tr>
</tbody>
</table>
15:40 - 16:30 | HERMES

Opening Ceremony

15:40 Welcome by the EVER President 2016
Aki KAWASAKI - Lausanne

15:50 Word from the EVER President
Highlights of EVER
Update on EVER in EU-EYE
Leopold SCHMETTERER - Vienna

16:00 EVER Past President lecture
Lessons from the Fascinating World of Bestrophinopathies
Bart LEROY - Ghent

End 16:30
16:50 - 18:20 | HERMES
MBGE/RV - Advances in gene-based therapies for ocular disorders

Gene-based therapies represent a very promising option for many inherited and acquired ocular disorders. The special interest symposium will focus on advances in gene therapy technologies, animal models that are a target for ocular gene therapy as well as current clinical gene therapy trials.

**LISKOVA P**

*1511* 16:50 Optimisation of RPE65 gene delivery for treatment of Leber congenital amaurosis patients

GEORGIADIS T - London

*1512* 17:12 Animal models for ocular gene therapies

ARSENIJEVIC Y, Kostic C - Lausanne

*1513* 17:34 Novel tissue-targeted localized gene therapy for corneal scarring and neovascularization


*1514* 17:56 Current gene therapy trials for inherited retinal disorders


---

16:50 - 18:20 | RHODES 1
G - FP session - New technologies in glaucoma

**CORDEIRO MF, ROUSSEAU A**

*1521* 16:50 Could 24-S-hydroxycholesterol play a role in Müller glial cells’ membrane dynamics in the rat

BRON A, Ferrero A, Gambert-Nicot S, Brétillon L, Acar N, Creuzot C - Dijon

*1522* 17:02 Reduced vascular response in patients with normal tension glaucoma in response to hypoxia

DALGAARD L M, Vibæk J, Jensen LT, Olsen NV, Kold M - Copenhagen

*1523* 17:14 Impact of gender-specific differences in corneal elasticity upon intraocular pressure measurements using vibration tonometry


*1524* 17:26 Temporal macular ganglion-cell inner plexiform layer thinning is a hallmark of early glaucomatous damage


*1526* 17:38 Primary Open Angle Glaucoma treated by High Intensity Focused Ultrasound (HIFU). Results at 18 months of a prospective pilot study on patients treated with the 2nd generation probe

ROULAND J F, Aptel F - Lille

*1527* 17:44 High-intensity focused ultrasound cyclocoagulation: a 6-month study

VANDEWALLE E, Somers A, Stalmas I - Leuven

*1528* 17:50 A comparison of visual field testing with a new automated perimeter, the Compass visual field analyser, and the Humphrey visual field analyser

Intraocular inflammatory disorders encompass a broad spectrum of diseases that are a major cause of severe visual impairment. They may be specific to the eye or be part of a systemic problem or a combination of both. In fact, there is frequently a blurring of distinction between these categories. In addition, a pseudo-inflammatory eye disease can mimic the clinical findings and pattern of a real posterior uveitis. Very often misdiagnosis is the first and major problem of posterior uveitis management. The aim of this special interest symposium is to present the hottest topics in diagnostic challenges for posterior uveitis and the differentiation between real inflammation and pseudo-inflammation of posterior uveal tract.

NERI P, HERBORT CP

16:50 - 18:20 | RHODES 2

**IM - Inflammatory versus non-uveitic posterior segment diseases**

1531 16:50 Inflammatory versus non-uveitic serous/exudative retinal detachments

GUPTA V

1532 17:08 Central serous chorioretinopathy misdiagnosed as posterior uveitis

KHAIROLLAH M, Kahloun R, Jelliti B - Monastir

1533 17:26 Central serous chorioretinopathy complicating inflammation suppressive treatment

HERBORT C P, Papadia M - Lausanne

1534 17:44 Primary vitreo-retinal lymphoma, an increasing pseudo-uveitis to be taken into account

NERI P, Cesare M, Baruffa D, Pirani V - Agugliano

1535 18:02 Inflammatory versus non-uveitic posterior segment diseases in paediatric patients

BODAGHI B - Paris

16:50 - 18:20 | RHODES 3

**FP - FP session - Surgery I**

SOUBRANE G, BAILLIF S

1541 16:50 Visual function response to ocriplasmin for the treatment of vitreomacular traction: results from the oasis study

JACKSON T L, Lescrauwaet B, Duchateau L, Verstraeten T - London

1542 17:02 Functional and anatomical changes after standard and half dose verteporfin PDT in central serous choroidopathy


1543 17:14 The retinal macroglia in hypercholesterolemic rabbits: neuroprotective effect of a non-lipid-lowering statin dose


1544 17:26 Therapeutic potential of non-viral MRNA delivery to Müller cells for neuroprotection

DEVOLDERE J, Peynshaert K, De Smedt S, Remaut K - Ghent

1545 17:38 Anti-VEGF therapies for retinal vein occlusion: real-world outcomes of a Portuguese multi-center study


1546 17:50 Incidence of macular oedema following pan-retinal photocoagulation using a multi-spot semi-automated pattern-scanning laser in one sit versus 4 monthly sits in mild proliferative diabetic retinopathy or pre-proliferative diabetic retinopathy

GABRIELLE P H, Massin P, Kodjikian L, Bron A, Creuzot C - Dijon
16:50 - 18:20 | RHODES 4

**NSPH - FP session - Neuro-ophthalmology and paediatric ophthalmology**

**BREMOND-GIGNAC D, BOSCHI A**

1551 16:50 Reduced post-illumination pupil response in patients with mild-moderate cataracts is associated with impaired sleep quality

  *ROEMER S, Munch M, Ladaïque M, Hashemi K, Kawasaki A - Lausanne*

1552 17:02 Consensus on guidelines for idebenone administration in Leber’s hereditary optic neuropathy (LHON)

  *CARELLI V, On behalf of the Consensus Study Group - Bologna*

1553 17:14 Relationship between immune response and ocular inflammation after intravitreal injection of rAAV2/2–ND4 (GS010) in Leber Hereditary Optic Neuropathy (LHON) patients


1554 17:26 Factors affecting the prognosis of visual acuity and visual fields in pituitary adenoma patients treated with endonasal endoscopic transphenoidal surgery

  *LIINAMAA J, Luomaranta T, Raapana A, Saarela V - Oulu*

1555 17:38 Neuro-ophthalmological manifestations of Behcet’s disease

  *ALGHAMI A, Bodaghi B, Wechsler B, Cacoub P, LeHoang P, Saadoun D, Toutou V - Puteaux*

1556 rf 17:50 Visual outcomes of fractionated radiotherapy in optic nerve sheath meningioma

  *KHEIR V, Borruat F X - Lausanne*

1557 rf 17:56 Automated evaluation of peripapillary choroidal thickness in nonarteritic anterior ischemic optic neuropathy

  *MUNOZ - NEGRETE F J, Rebolleda G, Perez Sarriegui A, De Juan V - Madrid*

---

16:50 - 18:20 | GALLIENI 1+2

**RV - FP session - Surgery II**

**LEY A S, HUSSAIN R**

1561 16:50 The Soft Shell Technique To Prevent Leakage of Perfluorocarbon Liquid Into The Subretinal Space


1562 17:02 Incidence and risk factors of cystoid macular edema after retinal detachment surgery

  *BERROD J P, El Kouhen N, Leroy B P, Conart J B - Vandoeuvre les Nancy*

1563 17:14 Retinal toxicity of intraocular silicone oil. A retrospective study

  *ROCHA DE SOUSA A, Roca A, Barbosa-Breda J, Falcão-Reis F - Porto*

1564 17:26 Heads-up eye surgery: pros and cons

  *LYTVYNCHUK L - Giessen*

1565 17:38 Vitreous and subretinal VEGF levels in fresh rhegmatogenous retinal detachment

  *SOZEN-DELIL F I, Cekic O - Istanbul*

1566 17:50 Robot assisted retinal vein cannulation in an in vivo porcine retinal vein occlusion model

### PBP - High-resolution imaging of the anterior eye segment

In this course, we aim to introduce and review different optical technologies allowing the non-invasive imaging of the anterior eye segment with a resolution in the micrometer or sub-micrometer range. At first, ultrahigh-resolution optical coherence tomography based on a broadband Ti:Sapphire laser will be introduced. Its application for both imaging of different features of the healthy and diseased eye as well as the investigation of surgical treatment will be shown. In the second part, the concepts of confocal and non-linear microscopy and the underlying physical principles of different contrast mechanisms will be presented. Exemplary experimental results based on various non-linear signals showing the ability to image structure of the cornea down to the cellular level are content of the presentations. Finally, the two modalities – OCT and IVCM – will be compared and their advantages and disadvantages for corneal imaging will be highlighted.

<table>
<thead>
<tr>
<th>Workshop</th>
<th>Time</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>1571</td>
<td>16:50</td>
<td>Introduction to Ultrahigh-Resolution OCT</td>
</tr>
<tr>
<td>1572</td>
<td>17:05</td>
<td>OCT Imaging in Glaucoma and PEX</td>
</tr>
<tr>
<td>1573</td>
<td>17:20</td>
<td>Imaging of Corneal Lesions and Wound Healing</td>
</tr>
<tr>
<td>1574</td>
<td>17:35</td>
<td>Linear and non-linear microscopy for AS imaging: principles and pathbreaking application</td>
</tr>
<tr>
<td>1575</td>
<td>17:50</td>
<td>Nonlinear microscopy for quantification of riboflavin diffusion in the cornea</td>
</tr>
<tr>
<td>1576</td>
<td>18:05</td>
<td>OCT and IVCM in Corneal Imaging</td>
</tr>
</tbody>
</table>
18:35 - 19:00 | HERMES
European Ophthalmology Heritage Lecture by Luc Missotten

Introduction by Marcela VOTRUBA

1611
Magnificat
Luc MISSOTTEN - Leuven

*Summary:* We will present some evidence showing that the use of a magnifying glass started in Greece in the fifth century BC.

Award presentation of the EVER Certificate of Honour

**Biography Luc MISSOTTEN:**
Professor emeritus of the Catholic University of Leuven, Belgium, he is one of the founding fathers of EVER. As the eldest amongst the EVER members may recall, the European Community Ophthalmic Research Association (ECORA) was founded by Professor Manfred Spitznas at the request of EUPO (European University Professors in Ophthalmology) and its first meeting was held in Bonn. Very soon ECORA joined forces with the Association of Eye Research of which Missotten was a past president and a prominent member and with other research associations. The new identity was called Joint European Research Meeting in Ophthalmology (JERMOV) and it held its first meeting in Montpellier in 1995. The meeting was successful. However two years later, because of financial problems JERMOV ceased to exist. Professor Missotten then created a temporary structure which he called EVER for EVER and organized the 1997 meeting. New statutes were written and EVER was born. Luc Missotten was its first secretary-general, post he kept till 2002. He was vice-president of the International Society for Eye Research, chair of the Scientific Committee of the Netherlands Ophthalmic Research Institute and President of the European Ophthalmological Society (1996-2000).


He is Doctor honoris causa of the University of Mansoura (Egypt) and a honorary member of various ophthalmological societies.
19:00 - 19:30 | HERMES

Keynote Lecture by Robert Maclaren

Introduction by Bart LEROY

1711

Developing new treatments for inherited retinal degenerations

Robert MACLAREN - Oxford

Summary:
Retinal diseases are currently the leading causes of untreatable blindness in Europe. Most commonly, incurable blindness occurs when photoreceptors are lost and therapeutic strategies therefore aim to prevent photoreceptor cell death by genetic correction of single gene disorders. Once photoreceptors have degenerated, alternative strategies are required to regenerate the retina using biological approaches and subretinal electronic devices have also shown great promise in demonstrating that blindness may be potentially reversible. This lecture will provide an update on the application of scientific discovery in clinical trials for retinal degeneration and provide insight into the fascinating age of discovery that lies ahead.

Award presentation of the EVER Certificate of Honour

Biography Robert MACLAREN:
Robert MacLaren is Professor of Ophthalmology at the University of Oxford and a retinal surgeon. His research interests focus on developing novel treatments for currently incurable retinal disease, particularly retinitis pigmentosa. His laboratory work has explored scientific concepts in retinal regeneration using developing neurons and photoreceptor transplantation. More recently he has been leading gene therapy clinical trials for choroideremia which are now ongoing in several EU countries, the USA and Canada. He is the academic founder of Nightstarx, a retinal gene therapy company based at the Wellcome Trust in London and he works closely with Retina Implant AG, in clinical trials of the electronic retinal implant.
Wednesday, Oct 5 - Welcome Reception

19:30 - 21:30 | EXHIBITION AREA

EVER Welcome Reception

Open to EVER participants and exhibitors
EVER 2016
Thursday, Oct 6
Thursday, Oct 6 - First morning session

### HERMES

**8:30 - 10:00 | RV - Diabetic retinopathy**

<table>
<thead>
<tr>
<th>Session</th>
<th>Time</th>
<th>Title</th>
</tr>
</thead>
</table>
| **2111** | 8:30 | Vitrectomy in treatment naive diabetic macular edema  
**MICHALEWSKA Z, Michalewski J, Bednarski M, Nawrocki J - Lodz** |
| **2112** | 8:48 | Novel diagnostic tools in DRP - from science to clinical relevance  
**BRUNNER S - Vienna** |
| **2113** | 9:06 | OCT Angio imaging of the pathologic changes in PDR  
**GLITTENBERG C - Vienna** |
| **2114** | 9:24 | Treatment of hard exudates in CSME in PDR using Micropulse mode  
**SAKSONOV S, Teslenko A, Vitovska O - Kyiv** |
| **2115** | 9:40 | 29G chandelier-assisted scleral buckling with new instruments  
**LYTVYNCHUK L, Binder S - Lviv** |

### RHODES 1

**8:30 - 10:00 | RHODES 1**

**G - You tube: different tubes for different glaucomas**

You Tube is a SIS about the main three surgical glaucoma techniques that use tubes. It is a short introductory symposium of the new and old tubes that nowadays are being used in clinics. The instructors introduce the different surgical techniques with videos and didactic images. “When and how”, with special focus in the niche for these procedures, and their specific indications.

<table>
<thead>
<tr>
<th>Session</th>
<th>Time</th>
<th>Title</th>
</tr>
</thead>
</table>
| **2121** | 8:30 | YouTube: Different tubes for different glaucomas. : XEN  
**ARCINIEGAS-PERASSO C A - Barcelona** |
| **2122** | 8:52 | YouTube: Different tubes for different glaucomas. : Ex Press  
**MUNOZ M - Barcelona** |
| **2123** | 9:14 | YouTube: Different tubes for different glaucomas. : Ahmed Valve  
**MILLA E - Barcelona** |
| **2124** | 9:36 | YouTube: Different tubes for different glaucomas. : Non valved Tube&Plate implants  
**DUCH S - Barcelona** |
COS - Corneal dystrophies - diagnosis and treatment

Corneal dystrophies are the group of hereditary, slowly progressive disorders affecting all corneal layers. In the past, histological examination was crucial in proper diagnosis of corneal dystrophies. In recent years, non invasive optical imaging systems such as optical coherence tomography (OCT) and confocal microscopy (CM) along with genetic testing have become a new standard procedures in the diagnostic process. Advances in diagnosis and treatment of corneal dystrophies including genetic analysis and confocal microscopy findings were included in the IC3D classification in 2008 and 2015. During this course we would like to present the current classification, methods of diagnosis including genetic testing, confocal microscopy and optical coherence tomography, as well as and different treatment options and its results.

WYLEGALA E, DOBROWOLSKI D

- Update on IC3D classification
  NOWINSKA A - Bytom

- Confocal microscopy findings in corneal dystrophies
  SMEDOWSKI A, Wylegala E - Katowice

- OCT in treatment planning
  JANISZEWSKA D - Katowice

- Photorefractive keratectomy for corneal dystrophies
  DOBROWOLSKI D - Katowice

- Surgical treatment of corneal dystrophies
  WYLEGALA E - Katowice

SIS - Drug delivery systems for the back of the eye. Translational research

Due to the aging of the population, the number of patients with chronic diseases affecting the back of the eye is increasing. Furthermore, there are rare diseases involving the retina that need therapeutic strategies to stop/delay degeneration. Nano-(1-1000nm) and microscale (1-1000μm) drug delivery systems are emerging tools for the efficient treatment of posterior segment diseases. These devices can contain small and large molecules including proteins and genes. The election of the most appropriate device must be done according to the disease and the intraocular target site. The movement of particles after injection is a critical issue to determine the potential clinical translation of the pharmaceutical particulate formulation. Also, biocompatibility and pharmacokinetic studies are important tools to assure the efficiency of the pharmaceutical approach.

HERRERO-VANRELL R, RUPENTHAL ID

- Stimuli-responsive systems for tuneable ocular drug delivery
  RUPENTHAL I D, Yasin N, Bisht R, Chen Y S, Jin J, Jaiswal J, Svirskis D - Auckland

- Multiloaded Microparticulate Drug Delivery Systems for the Treatment of Retinal Diseases

- Intravitreal mobility of nanoparticles: how to make a move toward successful ocular gene delivery?
  REMAUT K, Devoldere J, Peynshaert K, Martens T, Engbersen J, Braeckmans K, De Smedt S - Gent

- Ocular drug delivery and pharmacokinetics: Influence of drug properties and delivery systems
  KOMPPELLA U B - Aurora

- Ocular pharmacokinetics assessed by in-vivo microdialysis
  GARHÖFER G - Vienna
### Thursday, Oct 6 - First morning session

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Authors/Institutions</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:30</td>
<td>FP</td>
<td>Retinal structural changes before and after idiopathic epiretinal membrane peeling - a study using OCT segmentation</td>
<td>PRUENTE C, POURNARAS J</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>SOUSA F, Pinto J, Marques-Neves C - Lisbon</td>
</tr>
<tr>
<td>8:54</td>
<td></td>
<td>Mechanism of “Flap Closure” After the Inverted Internal Limiting Membrane Flap Technique</td>
<td>MICHALEWSKA Z, Boninska K, Michalewski J, Nawrocki J - Lodz</td>
</tr>
<tr>
<td>9:06</td>
<td></td>
<td>Accuracy of retinal layers optical coherence tomography automated segmentation before and after epiretinal peeling</td>
<td>MEDEIROS PINOTO J, Caiado F, Marques-Neves C - Lisbon</td>
</tr>
<tr>
<td>9:18</td>
<td></td>
<td>Unexplained vision loss with intra-ocular silicone oil tamponade in situ; a case series</td>
<td>SILVESTER A, Cazabon S - West Kirby</td>
</tr>
</tbody>
</table>

### SIS - GALLIENI 1+2

#### EOVS/MBGE - Doctor, I can’t see in the dark

The SIS will address the clinical problem of night blindness (nyctalopia). It will commence with the initial consultation and examination; what to look for and what questions to ask. It will then proceed to address the underlying causes of night blindness, both genetic and acquired, followed by a discussion of how electrophysiological testing can assist the diagnosis. The final presentation will discuss the effects on the patient of being night blind.

**HOLDER G**

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Authors/Institutions</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:30</td>
<td>The initial consultation</td>
<td>SPILEERS W - Leuven</td>
</tr>
<tr>
<td>8:52</td>
<td>Causes of night blindness</td>
<td>LEROY B - Ghent</td>
</tr>
<tr>
<td>9:14</td>
<td>The electrophysiology of patients with nyctalopia</td>
<td>HOLDER G - London</td>
</tr>
</tbody>
</table>
### ACB - Proteostasis in the pathogenesis of age-related macular degeneration

Age-related macular degeneration (AMD) is a complex chronic neurodegenerative disease associated with many environmental, lifestyle, and genetic factors. Oxidative stress and the production of reactive oxygen species seem to play a pivotal role in AMD pathogenesis. During aging accumulation and aggregation of misfolded proteins can be recognized in retinal pigment epithelial (RPE) cells. This lead to the degeneration of RPE that is a hallmark of AMD. Molecular chaperones, proteasomes and lysosomes are key elements to refold misfolded proteins or degrade damaged proteins in the RPE cells. Autophagy, a part of lysosomal clearance system, has a cytoprotective role in diseases associated with protein aggregates. Failure in proteostasis may be one of the underlying mechanisms responsible for the cascade of events leading to AMD. This SIS covers the major cytoprotective and degradative pathways in the RPE and summarizes evidence of their involvement in AMD.

**KAARNIRANTA K, UUSITALO H**

<table>
<thead>
<tr>
<th>Session</th>
<th>Time</th>
<th>Title</th>
<th>Authors</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>2171</td>
<td>8:30</td>
<td>Age-related changes of cystatin C and effects on protein turnover in RPE cells</td>
<td>PARAOAN L</td>
<td>Liverpool</td>
</tr>
<tr>
<td>2172</td>
<td>8:52</td>
<td>Cytoprotective alpha crystallins in the regulation of RPE cell proteostasis</td>
<td>KANNAN R</td>
<td>Los Angeles</td>
</tr>
<tr>
<td>2173</td>
<td>9:14</td>
<td>The marine n-3 PUFA DHA evokes cytoprotection by inducing autophagy and NFE2L2 in human retinal pigment epithelial cells</td>
<td>BJORKOY G</td>
<td>Trondheim</td>
</tr>
<tr>
<td>2174</td>
<td>9:36</td>
<td>Nrf2- and PGC-1α-deficient mice: A novel animal model for disturbed proteostasis and RPE degeneration</td>
<td>KAARNIRANTA K</td>
<td>Kuopio</td>
</tr>
</tbody>
</table>

### LC - Lens and IOL - optics and accommodation

Our SIS will present new findings related to the optical properties of the crystalline lens and new evidence for a possible relation between cortical cataract and accommodation forces. Furthermore, we will attempt to explain the optical imaging properties of new multifocal intraocular lenses. Some of which show benefits that must be put into realistic technical and clinical contexts, beyond their commercial names. We will give an update on light-adjustable intraocular lenses and conclude showing new developments of accommodative intraocular lenses.

**BARRAQUER RI, MICHAEL R**

<table>
<thead>
<tr>
<th>Session</th>
<th>Time</th>
<th>Title</th>
<th>Authors</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>2181</td>
<td>8:30</td>
<td>Optical properties of the lens: An explanation for the zones of discontinuity</td>
<td>Pierscionek B, Bahrami M, Hoshino M, Regini J, Uesugi K, Yagi N</td>
<td>Kingston</td>
</tr>
<tr>
<td>2185</td>
<td>9:42</td>
<td>Accommodative IOLs: An update on recent developments</td>
<td>VEGA-ESTRADA A, Alio J</td>
<td>Alicante</td>
</tr>
</tbody>
</table>
The pathogenic role of LRG1 in ocular neovascularisation: From discovery to targeted therapy

John GREENWOOD - London

Summary:
We have reported that the secreted glycoprotein, leucine-rich alpha-2-glycoprotein 1 (LRG1), promotes neovascularisation in various models of ocular disease (Wang et al., Nature 2014; 499: 306-311). LRG1 is up-regulated in many disease conditions and mediates its pro-angiogenic effect by modifying the TGFß signalling network. Loss of LRG1, or blocking its biological activity, results in attenuation of neovascular complications in the rodent models of laser-induced choroidal neovascularisation and oxygen-induced retinopathy. Recently, we have observed that loss of LRG1 results in vessel normalisation, suggesting that in the pathological setting LRG1 corrupts the normal physiological angiogenic process. Early indications suggest that LRG1 interferes with vascular recruitment of pericytes resulting in failure of vessel maturation. These findings have important implications in diseases such as diabetic retinopathy where there is a need to promote a normal functioning vasculature. Consistent with the concept of LRG1 causing vascular dysfunction, we have additionally observed that loss of LRG1 reduces vascular permeability in ocular inflammation. Together these findings have led us to develop a humanised blocking antibody that will be taken into clinical trials for the treatment of wet age-related macular degeneration. In this seminar I will present our work on LRG1 in ocular disease and describe the development of an anti-LRG1 therapeutic for clinical use.

Biography John GREENWOOD:
Professor John Greenwood holds the Hugh Davson Chair of Biomedical Research at the Institute of Ophthalmology, University College London. He obtained his PhD in 1984 from the Institute of Psychiatry, University of London following studies on the pathobiology of the blood-brain barrier (BBB). After leaving the Institute of Psychiatry he took up a postdoctoral fellowship within the BBB research group at King's College London. In 1990 he was awarded the Renee Hock Fellowship at the Institute of Ophthalmology to investigate the role of the blood-retinal barrier in inflammatory eye disease. In 1993, he was made Senior Lecturer and in 2000 was appointed Full Professor at the Institute of Ophthalmology. During the last 15 years he has been a member of the Institute Board of Management and for the last 8 years has been Head of the Department of Cell Biology. The Greenwood laboratory's primary focus is the role the vasculature plays in the pathogenesis of diseases of the retina and brain. His work spans the spectrum from fundamental research through to clinical trials. Research into the role the vascular endothelium plays in the pathogenesis of retinal and brain inflammation is a core component of the laboratory. Such work has been at the forefront of identifying and characterising novel endothelial cell mechanisms that facilitate the recruitment of leukocytes to the retina and brain, a critical step in the pathogenesis of diseases such as posterior uveitis and multiple sclerosis. This work established the principle of outside-in signalling in CNS endothelial cells that support leukocyte transvascular migration and has influenced the decision to trial statin therapy for the treatment neuroinflammatory disease. More recently a major emphasis has been to investigate the biology underpinning vascular dysfunction in diseases such as diabetic retinopathy and wet age-related macular degeneration (AMD) and to discover new therapeutic targets. This work has resulted in the identification and characterisation of a novel pro-angiogenic factor called leucine-rich alpha-2-glycoprotein 1 (LRG1) and has led to the development of a therapeutic antibody targeting this protein. In 2018 this therapy will enter into clinical trials for the treatment of wet AMD. This work has been conducted in close collaboration with Professor Stephen Moss at the UCL Institute of Ophthalmology.
Thursday, Oct 6 - Second morning session

**IM - OCT in inflammatory ocular diseases: beneath and beyond the retina**

Optical coherence tomography (OCT) has revolutionized the understanding and management of different ophthalmological diseases, including ocular inflammation. Although the retina has been the subject of the most intense investigation, others ocular structures can also be analyzed by this elegant technique. Indeed, very early, OCT was used to study the cornea and the optic disk. More recently, recent methodological developments have given access to the choroid. The aim of this SIS is to provide an overview of the information that can be provided by OCT in analyzing ocular tissues distinct from the retina, in the context of inflammatory diseases.

WILLERMAIN F, NERI P

**2311** 11:00 - 11:22  From time domain to high resolution and angio-OCT: an historical perspective
NERI P, Mariotti C, Pirani V, Bisceglia P, Giovannini A - Agugliano

**2312** 11:22 - 11:44  Anterior segment OCT in corneal diseases and surgery

**2313** 11:44 - 12:06  OCT as a Novel useful tool in corneal transplantation
THURET G, Gabison E, Guindolet D, Lepine T, Rolland J, Gain P - Saint Etienne

**2314** 12:06 - 12:28  Usefulness of OCT for imaging the choroid, the vitreous and the optic nerve during uveitis
DENNISTON A - Birmingham

**SIS**

11:00 - 12:30 | RHODES 1

**G - Mathematical modelling in glaucoma**

Glaucomatous optic neuropathies (GON) share as a hallmark a progressive loss of RGCs and their axons with the presence of visual field defects, structural and molecular changes in the optic nerve head and other cellular responses throughout the retina. The advancement of image analysis technologies has allowed a more precise and objective study of the cellular and morphological changes associated with GON. The Special Interest Symposium will present recent studies focussing on mathematical and automatic methods to identify and quantify cellular and structural changes that appear on the retinal layers and on the optic nerve head following various types of retinal or optic nerve injury glaucoma models. The SIS will provide ample opportunity for interaction among scientists attending the conferences.

VIDAL-SANZ M, CORDEIRO MF

**2321** 11:00 - 11:22  Tridimensional studies on the adult rat optic nerve head
PAZOS M, Yang H, Gardiner S, Cepurna W, Elaine J, Morrison J, Burgoyne C - Barcelona

**2322** 11:22 - 11:44  Counting microglial cells in the adult rodent retina

**2323** 11:44 - 12:06  Algorithms looking for patterns of cell loss in glaucoma models
DAVIS B - London

**2324** 12:06 - 12:28  Counting retinal neurons in the adult rat retina
Thursday, Oct 6 - Second morning session

**FP - RV session - Diabetes**

**SOUBRANE G , DE LAEY JJ**

2331 11:00 Alterations of retinal vessel size after single injection of intravitreal anti-VEGF for diabetic macular edema

AKPOLAT C , Kurt M , Cekic O - Istanbul

2332 11:12 Upregulated expression of heparanase in the vitreous of patients with proliferative diabetic retinopathy originates from activated endothelial cells and leukocytes


2333 11:24 In vivo measurement of increased vascular permeability after STZ induction of diabetes in rats by fluorescence angiography using the Micron IV

ALLEN C , Bates D - Nottingham

2334 11:36 Choroidal thickness in diabetic patients without diabetic retinopathy


2335 11:48 Tomographic analysis of the retinal layers in diabetic macular edema treated with dexamethasone intravitreal implant

MEDEIROS PINTO J , Prates Canelas J , Rosa R , Coelho C , Vaz-Pereira S - Lisbon

2336 11:54 Iluvien monotherapy for diabetic macular oedema in vitrectomised and non-vitrectomised eyes: one year data


2337 12:00 Deep learning approach for diabetic retinopathy screening

COLAS E , Besse A , Orgogozo A , Schmauch B , Meric N , Besse E - Paris

2338 12:06 Diabetic maculopathy screening in England; are we seeing too much?

BEGUM S , Macgregor C , Meredith P , Cansfield J , Meredith S - Portsmouth

**C - PO/RV - Mistakes in the diagnosis of fundus tumors**

Intermediate

This course will describe the diagnosis and management of fundus tumors insisting on the main difficulties: tumors developing in children, problems with the practical attitude in front of a suspicious choroidal naevus, difficulties in the diagnosis of achromatic tumors, special problem encountered in the diagnosis of intraocular lymphomas and and fo all these difficult cases the indications and results of the different imaging tools.

**DESJARDINS L , ZOGRAFOS L**

2341 11:00 Mistakes in the diagnosis of children intraocular tumors

CASSOUX N - Paris

2342 11:18 Suspicious choroidal naevi: when to observe , when to treat

KIVELÄT - Helsinki

2343 11:36 Difficulties in the diagnosis of achronic fundus lesions and hemorrhagic lesions

DESJARDINS L - Paris

2344 11:54 Problems in the diagnosis of intraocular lymphoma

CASSOUX N - Paris

2345 12:12 Indications and interpretation of various imaging techniques

ZOGRAFOS L - Lausanne
Thursday, Oct 6 - Second morning session

11:00 - 12:30 | RHODES 4

LC - FP session - Lens and cataract

ZHANG K, MAKLEY L

2351 11:00 The αA-crystallin gene expression in differentiating lens fiber cells, FGF signaling, and transcriptional factories

2352 11:12 Effects of histone acetylation on superoxide dismutase 1 gene expression in the pathogenesis of senile cataract
QIU X, Rong X, Jiang Y, Li D, Lu Y - Shanghai

2353 11:24 Evolution of cataract surgery, past, present and future
BARRAQUER J - Barcelona

2354 11:36 Genetic and phenotypic traits of staphylococcus epidermidis strains causing post-cataract endophthalmitis compared to commensal conjunctival flora
CHIQUET C, Aptel F, Musson C, Boisset S, Maurin M - Grenoble

11:00 - 12:30 | GALLIENI 1+2

MBGE/NSPH - Mitochondrial optic neuropathies - disease mechanisms and therapies

Primary inherited optic neuropathies are a group of blinding genetic disorders in which optic atrophy secondary to loss of retinal ganglion cells is a clinical key feature. The commonest causes world-wide is mutation in mitochondrial DNA (causing Leber’s Hereditary Optic Neuropathy) and OPA1 mutations (causing Autosomal Dominant Optic Atrophy: ADOA). 60-80% of patients with autosomal dominant optic atrophy have mutations in the OPA1 gene. Inherited optic neuropathy is an ‘orphan’ disease. However, the disease prevalence is not so low (1: 20,000 to 35,000), and it is estimated that there are 5000 to 8000 distinct rare diseases, affecting 6-8% of the population of the European Union (27-36 million people).

Recent trials of the drug idebenone, a co-enzyme Q10 analogue, in patients with the mitochondrial optic neuropathy, Leber’s hereditary optic neuropathy, have shown the first glimmer of hope for the treatment of this group of patients. At this exciting time this SIS will focus on disease mechanisms and potential avenues towards therapy.

VOTRUBA M, YU-WAI-MAN P

2361 11:00 The genetic pathophysiology of dominant optic atrophy

2362 11:18 Looking for a sensitive biomarker for genetically determined neurodegenerative diseases through the window of the eye

2363 11:36 OCT angiography in mitochondrial optic neuropathies
BARBONI P, Baldacci N - Bologna

2364 11:54 Perturbed mitochondrial homeostasis in LHON: a new target for rescue strategy
CARELLIV - Bologna

2365 12:12 Personalised therapies for mitochondrial optic neuropathies - myth or reality?
YU-WAI-MAN P - Newcastle upon Tyne
Scleral lenses represent a paradox in contact lens care: Even though they offer a great deal of advantages for patient and doctor in a so many scenarios of ocular surface dysfunction and disease - they are only used in a minority of cases. This may be due to the fact that Scleral lenses seem to represent the historic type of a large rigid ‘foreign body’ that rests on the sclera and vaults the cornea. However, modern lens materials & designs nowadays make Sclerals an easy to use and versatile tool for daily practise with ideal wearing comfort and medical safety in contrast to the vast majority of (mainly soft) cosmetic contact lenses that can often give rise to problems. Sclerals are a highly underestimated medical tool. Their tear-fluid filled lake over the cornea makes them an ideal tool for optical restoration of irregular corneas, particularly in keratokonus, for the prevention of further wounding, for the restoration of ocular surface integrity in dry eye disease of different type and as a measure to improve or even heal corneal recurrent erosions, ulcers, opacities and scars without the need to undergo surgery or even keratoplasty. Long term experience of ophthalmologists from around the world will be introduced in this SIS.

**KNOP E, KNOP N**

*2371 11:00* The ocular surface anatomy under cover - its interaction with a scleral lens  
**KNOP E, Knop N - Berlin**

*2372 11:18* Keratokonus - the killing application for most contact lenses is the prototypical job for sclerals  
**NAU C, Schornack M - Minnesota**

*2373 11:36* It’s not just keratokonus - some general fitting techniques for scleral lenses in so many scenarios  
**CARRASQUILLO K G - Boston**

*2374 11:54* Moderate to severe dry eye - a promising indication for scleral lenses  
**DOAN S, Delcampe A - Paris**

**2375 12:12** Are scleral lenses safe for the meibomian gland?  
**MEKKI M B, Yahiaoui S, Titah O, Belaoudmou R, Taibi A, Bouguerfa R - Algiers**

**FP**

*11:00 - 12:30 | GALLIENI 5*

**PBP - FP session - Oxygen delivery and regulation of vascular tone**

**OSBORNE N, GARHÖFER G**

*2381 11:00* Ca2+ activity during ATP-induced tone changes in porcine retinal arterioles in vitro spreads along the processes of perivascular cells  
**KUDRYAVTSEVA O, Bek T - Aarhus**

*2382 11:12* Vasodilation by cell membrane permeable but not impermeable carbonic anhydrase inhibitors of precontracted retinal arteries  
**EYSTEINSSON T, Hardarson A O, Carta F, Supuran C T - Reykjavik**

*2383 11:24* Automation and improved repeatability of retinal oximetry  
**HARDARSON S, Karlsson R A, Olafsdottir O B, Eliasdottir T, Bek T, Stefánsson E - Reykjavik**

*2384 11:36* Correlation between retinal and mixed venous oxygen saturation  
**VAN KEER K, Abegão Pinto L, Stalmans I, Vandewalle E - Leuven**

*2385 11:48* The effect of systemic tamsulosin hydrochloride on choroidal thickness and pupil diameter sizes  
**DOGAN M, Kutluksaman B, Keles I, Halat A O - Afyonkarahisar**

*2386 12:00* The assessment of Ocular Blood Flow with Laser Speckle Flowgraphy in healthy Caucasian  

*2387 12:06* Quantitative assessment of retinal permeability in the diabetic Akimba mouse: validation of a promising animal model for diabetic retinopathy  
**HU TT, Vanheukelom V, De Vriese A, Feyen J H M - Heverlee**
Leber's hereditary optic neuropathy (LHON): latest advances in diagnosis, staging and patient management

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:40</td>
<td>Introduction</td>
<td>KLOPSTOCKT - Germany</td>
</tr>
<tr>
<td>12:45</td>
<td>Advances in identifying patients with LHON: Early diagnosis</td>
<td>LAGREZE W D - Germany</td>
</tr>
<tr>
<td>12:55</td>
<td>Advances in understanding of the disease: Pathogenic mechanisms for neuronal degeneration</td>
<td>TIRANTI V - Italy</td>
</tr>
<tr>
<td>13:05</td>
<td>Advances in understanding of the disease: Clinical staging</td>
<td>CARELLI V - Italy</td>
</tr>
<tr>
<td>13:15</td>
<td>Advances in patient care: Raxone a new treatment option for patients with LHON</td>
<td>KLOPSTOCKT - Germany</td>
</tr>
<tr>
<td>13:35</td>
<td>Co-Chairman’s summary and Q&amp;A</td>
<td>CARELLI V - Italy</td>
</tr>
</tbody>
</table>
### 12:40 - 13:40 | RHODES 2

**Demodex: innocent or guilty in blepharitis?**

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker/Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:40</td>
<td><strong>Introduction</strong></td>
</tr>
<tr>
<td>12:45</td>
<td>Demodex background and epidemiology aspects</td>
</tr>
<tr>
<td></td>
<td><strong>MERAYO-LLOVES J - Spain</strong></td>
</tr>
<tr>
<td>13:00</td>
<td>Demodex: ocular implications</td>
</tr>
<tr>
<td></td>
<td><strong>KAYA S - Austria</strong></td>
</tr>
<tr>
<td>13:15</td>
<td>Management of Demodex in ophthalmology</td>
</tr>
<tr>
<td></td>
<td><strong>JAMES ET - United Kingdom</strong></td>
</tr>
<tr>
<td>13:15</td>
<td>Conclusion</td>
</tr>
</tbody>
</table>
Keynote Lecture by Shigeru KINOSHITA

Summary:
It is important for clinician scientists to acquire the advanced knowledge and novel technology needed to create completely new areas of translational research, ultimately aimed at application in the clinical setting. For instance, devastating ocular surface disorders such as Stevens-Johnson syndrome are very difficult to treat properly. Today, thanks to recent advancements in corneal biology and immunology, the state-of-the-art corneal regenerative medicine such as autologous cultivated oral mucosal epithelial transplantation is applied to treat and, in general, well restore ocular surfaces devastated by disease. A similar type of translational research, based on the basic understanding and clinical application of corneal endothelial cell biology, is being used to develop the novel therapy of ‘cultured corneal endothelial cell injection’ into the anterior chamber for corneal endothelial dysfunction such as Fuchs endothelial corneal dystrophy. For this purpose, non-proliferative corneal endothelial cells from donated corneas can be induced to proliferate, without inducing cell state transition (CST). In clinical research started in December 2013, all the cases performed this procedure have already shown promising results. It is our hope that ophthalmology-related translational research, such as that described above, will receive official governmental approval based on accumulated data of the safety and efficacy of the procedures.

Award presentation of the EVER Certificate of Honour

Biography Shigeru KINOSHITA:
Dr. Shigeru Kinoshita, a clinician scientist, graduated from Osaka University Medical School in 1974, and has served as the Professor and Chair of Ophthalmology at Kyoto Prefectural University of Medicine since 1992. Because of his stepping down from the Chair of Ophthalmology in March 2015, He was elected the Professor and Chair of Frontier Medical Science and Technology for Ophthalmology at Kyoto Prefectural University of Medicine in April 2015. And, he has been continuously working as a distinguished clinician scientist.

In the early 1980s at Harvard Medical School, he, in collaboration with Dr. Richard A. Thoft, established the concept of centripetal movement of corneal epithelium, and his groundbreaking work has shed new light on the importance of limbal epithelium. His series of findings has had an enormous impact on this subject and has afforded much insight, ultimately contributing to the development of the corneal stem cell theory set forth by Tuen-Tien Sun. Based on these concepts, Dr. Kinoshita developed a new surgical procedure for in vivo corneal epithelial transplantation that has led to epithelial stem cell transplantation for ocular surface rehabilitation. Over the past 30 years, his primary interest has been focused on the translational research of new therapeutic modalities for severe corneal diseases. Following this path, his group has recently established the system of cultivated mucosal epithelial stem cell transplantation for severe ocular surface disorders such as Stevens-Johnson syndrome and chemical injury, and cultivated corneal endothelial cell transplantation for bullous keratopathy. His group also proved the clinical efficacy of Rho-associated protein kinase (ROCK)-inhibitor topical application for partial endothelial dysfunction, aiming at the development of novel therapies for corneal endothelial dysfunction.

Kinoshita is a recipient of the 1999 Alcon Research Institute Award, the 2008 Castroviejo Medal Lecturer of the Cornea Society, the 2009 ARVO Gold Fellow, the 2010 Claes H. Dohlman Conference Address of the TFOS, the 2010 Meibom Lecturer in Germany the Doyne Memorial Lecturer of the 2011 Oxford Ophthalmological Congress in United Kingdam, the 2011 Elsemay Bjorn Lecture in Finland, Schepens Eye Research Institute Almunus Awardee 2011, the Peter Herberg Lecture at IMCLC2012, the Richard Lindstrom Lecture, CLAO, ASCRS 2014, Charles D. Kelman Innovator Award, ASCRS 2015, and the Friedenwald Award Lecturer at the ARVO 2016. He served as an ARVO Program Committee Member in the Cornea Section between 1996 and 1999, the ARVO Trustee of the Cornea Section between 2006 and 2011, and the ARVO Vice President in 2010-2011.
### IM/RV - Challenges and controversies in ophthalmology: When the patient overlap between different subspecialties

The evolution of tertiary care ophthalmology is clearly towards the development of subspecialist with a very specific domain of competence. However, in several diseases the clinical presentation requires an experience in multiple subspecialties. The aim of this SIS is, based on clinical cases, to join different sections to understand how they differently approach the same disease.

**CASPERS L, WILLERMAIN F**

<table>
<thead>
<tr>
<th>Session</th>
<th>Time</th>
<th>Title</th>
<th>Presenters</th>
</tr>
</thead>
<tbody>
<tr>
<td>2611</td>
<td>14:30</td>
<td>Controversies between retinal dystrophies and uveitis - the point of view of the retina specialist. Does electrophysiology help?</td>
<td>LEROY B, Holder G - Ghent</td>
</tr>
<tr>
<td>2612</td>
<td>14:45</td>
<td>Controversies between retinal dystrophies and uveitis - the point of view of the uveitis specialist. Does retinal antibody detection help?</td>
<td>WILLERMAIN F, Draganova D, Leroy B P, Caspers L, Postelmans L, Corazza F - Bruxelles</td>
</tr>
<tr>
<td>2613</td>
<td>15:00</td>
<td>Controversies between lymphoma and uveitis - the point of view of the ophthalmologist</td>
<td>TOUTOUV - Paris</td>
</tr>
<tr>
<td>2614</td>
<td>15:15</td>
<td>Controversies between lymphoma and uveitis - the point of view of the neuro-oncologist</td>
<td>TOUTOUV, HOUILLIER C - Paris</td>
</tr>
<tr>
<td>2615</td>
<td>15:30</td>
<td>Controversies between how to handle uveitis and glaucoma. The point of view of the uveitis specialist</td>
<td>KESTELYN P - Gent</td>
</tr>
<tr>
<td>2616</td>
<td>15:45</td>
<td>Controversies between how to handle uveitis and glaucoma. The point of view of the glaucoma specialist</td>
<td>BRON A - Dijon</td>
</tr>
</tbody>
</table>

### G/PBP - OCT spectralis in neurodegeneration - Young investigator presentations

Experts from different fields will discuss the use of the spectralis in neurodegeneration including: Glaucoma, Alzheimer’s, Down’s, Parkinson’s, Multiple Sclerosis

**CORDEIRO MF, NORMANDO EM**

<table>
<thead>
<tr>
<th>Session</th>
<th>Time</th>
<th>Title</th>
<th>Presenters</th>
</tr>
</thead>
<tbody>
<tr>
<td>2623</td>
<td>15:14</td>
<td>Fluorescence lifetime imaging</td>
<td>DYSLI C - Bern</td>
</tr>
<tr>
<td>2624</td>
<td>15:36</td>
<td>Auto fluorescence</td>
<td>HERMANN P - Bonn</td>
</tr>
</tbody>
</table>
Graves’ Orbitopathy is one of the most frequent inflammatory disorders of the orbit, but still with a puzzling pathogenesis. Diagnostic evaluation and management are also challenging.

New diagnostic approach, with a comprehensive differential diagnosis will be presented. The updated EUGOGO (European Group of Graves’ Orbitopathy) guidelines and medical management as the possibility of new molecules for the immunosuppression therapy will be discussed. Various pathogenesis hypotheses and their possible consequence on the GO management will also be considered.

BOSCHI A, BALDESCHI L

**2631** 14:30  Update in Graves’ Orbitopathy
LUDGATE M - Cardiff

**2632** 14:52  Differential Diagnosis of Graves’ Orbitopathy
BALDESCHI L - Bruxelles

**2633** 15:14  Euthyroid Graves’ Orbitopathy
BOSCHI A - Bruxelles

**2634** 15:36  Update in medical management of Graves’ orbitopathy
SALVI M - Milan

---

An understanding of the anatomy and physiology of the retina are essential in order to help in the diagnoses and treatment of various types of retinal diseases. Generally, only a limited amount of information is available in ophthalmic textbooks with the reader being unaware of more recent advances. The aim of this course is therefore to provide some more in-depth information on retinal structure and function to hopefully facilitate in an understanding in, for example, imaging diagnostic technologies like OCT and adaptive optics. Moreover, the newer available methods that include gene and stem cell treatments are aimed at preserving specific retinal cell-types and this requires knowledge related to the functional and morphological relationship between neurons, glial cells and the retinal vascular. In addition, an understanding of the relationship between retinal physiology and circadian rhythms cannot be ignored. The course should benefit clinicians, basic scientists and physiologists and will concentrate on retinal glial cells, the important relationship between photoreceptors and retinal pigment epithelial cells, the significance of ganglion melanopsin cells and the unique characteristics of the ON/OFF pathway of the retina.

GRZYBOWSKI A, OSBORNE N

**2641** 14:30  General structure and function of the retina
GRZYBOWSKI A - Olsztyn

**2642** 14:48  Retinal vasculature structure and function
SCHMETTERER L - Vienna

**2643** 15:06  The RPE/photoreceptor complex
OSBORNE N - Oxford

**2644** 15:24  Retinal glial cells
OSBORNE N - Oxford

**2645** 15:42  The ON/OFF system pathway of the retina
CASTELO-BRANCO M - Coimbra
The purpose of this course is to emphasize the diagnostic and surgical challenges in orbital tumors. Given the variety of structures confined to orbit, orbital tumors constitute a wide spectrum of lesions which pose numerous challenges for the clinician in terms of accurate diagnosis and management. A systematic approach is necessary to understand the pre-operative evaluation, classification, surgical planning and management of orbital tumors. In this course we will provide a general overview of diagnostic challenges including clinical features, imaging characteristics, pathological evaluation and surgical challenges in orbital tumors.

**TUNC M**

**2651** 11:30 Clinical evaluation in orbital tumors  
*MOURIAUX F - Rennes*

**2652** 11:52 The art of orbital imaging  
*TUNC M - Ankara*

**2653** 12:14 Orbital pathology: Differential diagnostic challenges  
*HEEGAARD S - Copenhagen*

**2654** 12:36 Surgical management in orbital tumors  
*BRISCOE D - Afula*

**14:30 - 16:00 | GALLIENI 1+2**

**NSPH - Update in clinical features and genetics in microphthalmia**

Microphthalmia is a rare and panocular disease. This rare ocular disorder can occur as unilateral or bilateral. Anophthalmia is at the extreme of the malformative manifestations. Microphthalmia is a developmental and genetic ocular disease. Axial length is reduced with severe hyperopia and ocular globe anomalies are common. Genetic components are exposed with update of new genes. Syndromic manifestations in microphthalmia can be associated. Nanophthalmos is a specific form of microphthalmia and ocular complications must be known and anticipated. Exploration, imaging, medical and surgical care are specific and described to optimize the treatment of ocular complications.

**BREMOND-GIGNAC D , ATILLA H**

**2661** 14:30 Genetics in microphthalmia  

**2662** 14:52 Nanophthalmos clinical features and specific outcome  
*BREMOND-GIGNAC D - Paris*

**2663** 15:14 Optical coherence tomography findings of retinal folds in nanophthalmos  
*ATILLA H - Ankara*

**2664** 15:36 Specific gene in microphthalmia  
*ROZET J M , Fares-Taie L , Chassaing N , Gerber S , Kaplan J , Ragge N , Calvas P - Paris*
Thursday, Oct 6 - First afternoon session

**FP**

**COS - FP session - Ocular surface diseases update**

**LAZREG S, GICQUEL JJ**

2671 14:30 Effectiveness of platelet-rich plasma treatment in patients with chronic corneal erosions, associated with Herpetic keratitis  
*LOSHKAREVA A, Maychuk D - Moscow*

2672 14:42 Ocular surface involvement on GVHD patients  
*LAZREG S - Dar el Beida*

2673 14:54 Communication between the researcher and the researched. Designing an application based study regarding effects of air pollution on ocular surface diseases  
*CZAK W, Nowakowski J, Mulak M, Laba A, Misiuk - Hojlo M - Wroclaw*

2674 15:06 Correlations Fleischer deposits with topographic parameters at different deformations of the cornea  
*ANISIMOVA S, Anisimova S, Mistrukov A - Moscow*

2675 15:18 Severe ocular manifestations of rosacea in adult  
*HASSAIRI A, Limaiem R, Kortli M, Maamouri R, El Matri L - Tunis*

2676 15:24 Pollen Count Compared with Severity of Symptoms and Signs of Dry Eye Disease in Norway  
*EIDET J R, Tashbayev B, Chen X, Ræder S, Badian R, Uttheim Ø, Fostad I G, Dart D A, Uttheim T P - Oslo*

2677 15:30 Surface chemistry of the interactions of cationic nanoemulsions with human meibum films  
*DAULL P, Yokoi N, Nencheva Y, Georgiev G A - Evry*

---

**FP**

**RV - FP session - Imaging**

**DE LAEY JJ, STANGOS A**

2681 14:30 Normal values for fundus perimetry with the MAIA microperimeter and short-term repeatability evaluation  
*Baudin F, Assad G, Meillon C, Koehrer P, Bron A, Creuzot C - Dijon*

2682 14:42 High resolution adaptive optics retinal image analysis in early-stage central areolar choroidal dystrophy with a PRPH2 mutation  
*Gocho K, Itoh N, Akeo K, Hayashi T, Takahashi H - Inzai*

2683 14:54 Static and dynamic retinal vessel analyses in patients with stroke as compared to healthy control subjects  
*De Boever P, Palkovits S, Pertl L, Fazekas F, Kneihsl M, Trozic I, Goswami N, Weger M - MOL*

2684 15:06 Stereo OCT angiography in macular diseases  
*Mauget-Fayssse M, Wolff B, De Bat F, Vasseur V, Alonso A S - Paris*

2685 15:18 Hypoxia and retinal blood flow changes: a study using OCT-Angiography  
*Cordeiro Sousa D, Moreira S, Leal I, Dionisio P, Abegao Pinto L, Marques-Neves C - Lisbon*

2686 15:30 Static retinal vessel analysis in routine optometric practice  
*French C, Heitmar R - Birmingham*

2687 15:36 Trial study to automatically distinguish small haemorrhages in early diabetic retinopathy from image artefacts  
*Suzuki N, Yamane K - Numazu*
Thursday, Oct 6 - Poster session 1

**EOVS: Electrophysiology, physiological Optics, Vision Sciences**

**T001 - T013**

**LEROY B , HOLDER G**

**T001**
Normal Values for Amplitude of Accommodation among a Population of High School students in Iran

**T002**
Aberrations, accommodation and pseudoaccommodation in myopia and hyperopia
TARUTTA E, Harutyunyan S, Khandzhyan A, Khodzhabekyan N - Moscow

**T004**
Difference between manifest and cycloplegic refraction in healthy non-presbyopic patients
DEL BUEY M A, Lanchares E, Pinilla I, Almenara C, Perez I, Minge E, Cristobal J A - Zaragoza

**T005**
The Impact of efferent oculomotor signals on size and distance perception
KRASTEL H, Streuer A, Magerl W, Kubarko A, Jonas J B - Neckargemünd

**T006**
Early hydroxychloroquine retinal toxicity enhanced by multifocal electroretinogram and laser flare-cell meter
CELLINI M, Sebastiani S, Campos E - Bologna

**T007**
Analysis of macular sensitivity using multifocal electroretinogram and microperimetry in Central Serous Chorioretinopathy patients after half-dose photodynamic therapy

**T008**
Combination of global electroretinogram and sd-oct in the etiology of infantile nystagmus
BOULADI M, Bouraoui R, Limaie R, Chaker N, Mghaieth F, El Matri L - Tunis

**T009**
Onset-offset visual evoked potentials in the diagnosis of ocular albinism in infantile nystagmus
BOULADI M, Bouraoui R, Limaie R, Chaker N, Mghaieth F, El Matri L - Tunis

**T010**
Are Currently Available Tests Satisfactory for Color Vision Assessment?
ISIK M, Ozcerit AT, Erdurmus M, Inam O - Sakarya

**T011**
The Effect of Sports Participation on Quality of Life in Subjects with Low Vision
ILHAN B, IDIL A, Ilhan I, Erkan Turan K - Ankara

**T012**
Unilateral Carcinoma-Associated Retinopathy: Diagnosis, Serology and Treatment
ROELS D, Ueno S, Kondo M, Leroy B P - Ghent

**T013**
Systematic Assessment of Clinical Methods to Diagnose and Monitor Diabetic Retinal Neuropathy
JENKINS K S, Rowan A, Layton C - Brisbane
Thursday, Oct 6 - Poster session 1

16:00 - 17:00 | POSTER AREA

G: Glaucoma

**T014 - T064**

**PAZOS M, ABEGAO PINTO L**

**T014**

Long-term results of up to 6 years of mitomycin-c augmented non-penetrating deep sclerectomy for pseudoexfoliation glaucoma

YAZGAN S, Ates H, Guven Yilmaz S, Celik T - Zonguldak

**T015**

Filtering Blebs After XEN Implantation and Trabeculectomy: A Clinical and In Vivo Confocal Microscopy Study


**T016**

Ab Interno Collagen Stent implantation as a treatment option for open angle glaucoma

CRISOSTOMO S, Cardigos J, Costa L M, Basilio A L, Anjos R, Cardoso M, Gomes T - Lisbon

**T017**


BARBOSA BREA J, Gonçalves-Pinho M, Vasco Santos J, Rocha Sousa A, Freitas A - Porto

**T018**

Incidence and risk factors of elevated intraocular pressure following deep anterior lamellar keratoplasty

HUANG O, Mehta J, Htoo N, Tan D, Wong T - Singapore

**T019**

New drainage construction in the surgical treatment of glaucoma

SULEIMAN E, Kiseleva O, Zhuravleva A - Moscow

**T020**

EyeOP1 as a novel non-invasive surgical treatment of glaucoma: an Italian multicenter study


**T021**

Retrospective review of pressure reducing effect of iStent and Trabectome procedures combined with cataract surgery

TO TH M, Bazeer S, Gazzard G - London

**T022**

Canaloplasty with Stegmann's Canal Expander® for Open-angle Glaucoma

STANGOS A, Mameletzi E, Sunaric Megevand G - Geneva

**T023**

Ultrasound evaluation of Ahmed Glaucoma Valve: IOP versus tube patency

BONO V, Zeppa L, Costagliola C, Zeppa L - Avellino

**T024**

Macroscopic analysis of filtering bleb functionality after XEN Gel Stent implantation with Anterior Segment Optical Coherence Tomography

COSTA L, Cardigos J, Crisostomo S, Anjos R, Sa Cardoso M, Gomes T - Lisbon

**T025**

Trabeculectomy: long term visual field stability

BOBAT H, Lockwood A, Kirwan J F - Portsmouth

**T026**

Augmentation of corneal graft tissue with UV-riboflavin crosslinking: a pilot study in glaucoma drainage device patients

STONE D, Ahmad S, Craven R, Owaidehah O - Riyadh

**T027**

Case-finding for angle closure: the diagnostic value of simple tests for estimating limbal and central anterior chamber depth


**T028**

Integrated visual field and relative risk for quality of life loss

16:00 - 17:00 | POSTER AREA

G: Glaucoma

T014 - T064

T029  rf  Ultrasound treatment in patients with Primary Open-Angle Glaucoma with a second generation probe: Results of a Multicenter Clinical Trial
APTEL F , Rouland J F , Stalmans I , Denis P - Meylan

T030  rf  Transmission electron microscopy study of the collagen layers of the trabecular meshwork in glaucoma patients

T031  rf  A link between diabetes mellitus and glaucoma — Danish Nationwide Study
HORWITZ A , Petrovski B E , Petrovski G , Torp-Pedersen C , Kolk M - Copenhagen

T032  rf  Hemodynamic changes in eyes with early primary open-angle glaucoma measured by transpalpebral rheothresholdography

T033  rf  Primary Open Angle Glaucoma treated by High Intensity Focused Ultrasound (HIFU). Results at 18 months of a prospective pilot study on patients treated with the 2nd generation probe
ROULAND J F , Aptel F - Lille

T034  rf  Efficacy and patient tolerability of preservative-free latanoprost compared with preservative prostaglandin analogs in patients with ocular hypertension or glaucoma
EL AMEEN A , Vandermeer G , Pisella P J - Tours

T035  rf  Why risking the satisfaction and the compliance of your newly diagnosed glaucoma patient? The PASSY survey.
MUNOZ - NEGRETE F J , Erb C , Stalmans I , Lemij H - Madrid

T036  rf  High-intensity focused ultrasound cyclocoagulation: a 6-month study
VANDEWALLE E , Somers A , Vermorgen K , Stalmans I - Leuven

T037  rf  Introducing and measuring cornea and sclera deformability parameters on the basis of Schiotz tonometry: mathematical modeling and clinical evaluation in Primary Open Angle Glaucoma (POAG)
IOMDINA E N , Lyubimov G , Moiseeva I , Stein A , Kisselova O , Archakov A - Moscow

T038  rf  5-year Incidence of Lubricant Dependence in Medically and Surgically Treated Glaucoma Patients
IYER J , Lim F , Yang Z , Tong L , Wong T - Singapore

T039  rf  Effect of different lightning conditions on daily living activities of glaucoma patients

T040  rf  Follow-up of patients treated by prostaglandins eyedrops. Preliminary results from the FREE survey
GRABSKA-LIBEREK I - Warszawa

T041  rf  A descriptive subgroup analysis of within hospital glaucoma referral in a tertiary center in Portugal
LEAL I , Cordeiro Sousa D , Marques-Neves C , Abegao Pinto L - Lisbon

T042  rf  A comparison of visual field testing with a new automated perimeter, the Compass visual field analyser, and the Humphrey visual field analyser
Thursday, Oct 6 - Poster session 1

16:00 - 17:00 | POSTER AREA

G: Glaucoma

T014 - T064

**T043**
Efficacy & safety comparison between Cosopt & Xolamol: Branded & generic fixed combination of 2% Dorzolamide / 0.5% Timolol
ALI ALJASIM L, Edward D, Khandekar R - Riyadh

**T044**
Early & delayed effect of using steroid following SLT, randomised controlled trial
ALI ALJASIM L, Owaidhah O - Riyadh

**T045**
Use of glaucoma medications in Portugal: a cross-sectional nationwide study
CORDERO SOUSA D, Leal I, Nascimento N, Abegão Pinto L - Lisbon

**T046**
Ultrafiltration rate in hemodialysis does not affect mean ocular perfusion pressure or intraocular pressure in end-stage renal disease

**T047**
Dexamethasone induced glaucoma as part of chemotherapy for lymphoblastic lymphoma and colorectal cancer

**T048**
Müller cells increase survival of retinal ganglion cells - a coculture model of primary retinal ganglion cells and primary Müller cells
TOFT-KEHLER A K, Skytt D, Brandstrup C, Gurubaran I, Kolko M - Copenhagen

**T049**
Quantification of green fluorescent protein expression in mouse retinal ganglion cells following intravitreal injection of recombinant adeno-associated virus
KHATIB T, Osborne A, Widdowson P, Martin K - Cambridge

**T050**
Age related changes in axon guidance cues in the optic chiasm
GOMES ALVES DA CONCEICAO R, Barber A C, Martin K R - Cambridge

**T051**
Increased intraocular pressure causes deficiency in the level of ELAVL1/HuR cytoplasmic fraction in the retina

**T052**
The predegenerated nerves extract enhances the endogenous neuroprotective system of Retinal Ganglion Cells by modulating of BDNF expression in rat glaucoma model
PIETRUCHA-DUTCZAK M, Smedowski A, Lewin-Kowalik J - Katowice

**T053**
Association of polymorphic variants of miRNA processing genes DGC8 and XPOS with primary open-angle glaucoma risk in a Polish population

**T054**
Neuroprotective effects of EPA and DHA fatty acids in the DBA/2J hereditary glaucoma mouse model

**T055**
The vitreopapillary interface in healthy and glaucoma – The VPI study
WILLEKENS K, Pinto L A, Vandewalle E, Stalmans P, Stalmans I - Leuven

**T056**
Longitudinal changes in retinal nerve fiber layer thickness in a healthy caucasian population
POPA CHERECHEANU A, Barac C, Miu J, Roncea T, Niculae A, Duta S, Pirvulescu R - Bucharest
Thursday, Oct 6 - Poster session 1

16:00 - 17:00 | POSTER AREA

G: Glaucoma

T014 - T064

**T057**

A vascular comparison between primary open-angle glaucoma and normal-tension glaucoma

VAN KEER K, Abegão Pinto L, Barbosa Breda J, Willekens K, Vandewalle E, Stalmans I - Leuven

**T058**

Factors determining the prelaminar tissue thickness in glaucoma


**T059**

Lamina cribrosa displacement after trabeculectomy in pseudoexfoliation and primary open angle glaucoma

KADZIAUSKIENE A, Strelkauskaite E, Asoklis R, Lesinskas E, Schmetterer L - Vilnius

**T060**

Anterior segment parameters measured by ultrasound biomicroscopy in the subtypes of angle-closure

KIM Y Y, Yoo C, Cho S Y, Lee T E - Seoul

**T061**

Comparison of the pattern of peripapillary retinal nerve fiber layer damage between open-angle glaucoma and anterior ischemic optic neuropathy

HEO D W, Kim K N, Lee Y H, Kim C S - Daejeon

**T062**

Clinical precision for follow-up of glaucoma with PIMD-2 Pi

SANDBERG MELIN C, Malmberg F, Söderberg P - Uppsala

**T063**

Choroid thickened after non-penetrating deep sclerectomy


**T064**

Macular ganglion cell layer abnormalities in Spectral Domain(SD)- OCT outside glaucomatous neuropathy

MENDES M, El Chehab H, Bouteleux V, Agard E, Russo A, Dot C - Lyon
From perfect visual function to “legally” blind in one year: New mutations in progressive cone dystrophy


Patterned macular dystrophy as the first sign of maternally-inherited diabetes and deafness (MIDD)

**Esteban O , Ascaso J , Peiro B , Martinez M , Almenara C , Perez I - Zaragoza**

Stargardt disease phenotype-genotype correlation – first results of a Lithuanian cohort study

**Strupaite R , Cimbalistiene L , Ambrozaityte L , Utkus A , Asoklis R - Vilnius**

A Novel Homozygous c.1154+3_1151+6delAAGT mutation in CERKL Causes Autosomal Recessive Retinitis Pigmentosa with a Special Phenotype in a Consanguineous Tunisian Family


Oguchi disease due to a novel mutation in the GRK1 gene

**De Zaytijd J , Zeitz C , Leroy B P - Ghent**

Pseudodominance in a Czech family with Usher syndrome type II

**Kousal B , Dudačková L , Skalická P , Bujaková K , Lisková P - Praha**

OPA1 analysis in an international series of probands with bilateral optic atrophy

**LiskoVA P , Tesarova M , Dudačková L , Stepanka S , Kolarova H , Honzik T , Seto S , Votruba M - Prague**

Two novel KERA mutations causing cornea plana in a Czech family and associated phenotypes

**Skalicka P , Dukadova L , Liskova P - Prague**

Metallothionein polymorphisms in a Northern Spanish population with Age-Related Macular Degeneration (AMD)


Classification and heritability of macular pigment spatial profile phenotypes using two-wavelength fundus autofluorescence

**Huntjens B , Ctori I , Mahroo O , Williams K , Hammond C - London**

The zinc-metallothionein redox system in human retina and RPE


Retinal function and morphology in Mitf mutant mice

**Garcia LLorca A , Gudmundsdóttir Aspelund S , Ogumundsdóttir M H , Steingrimsson E , Eysteinsson T - Reykjavik**

The role of LRG1 in vessel normalization


Validation of the STARS risk assessment tool for age-related macular degeneration in an Algerian population

**Delcourt C , Lazreg S , Sanchez A , Bandello F , Nouri M T - Bordeaux**

Variations in normative foveal morphology SD-OCT data: A study of White, South Asian and Black ethnicities

**Ctori I , Huntjens B - London**
Thursday, Oct 6 - Poster session 1

MBGE - Molecular Biology/Genetics/Epidemiology

**T065 - T084**

**T080**
Diabetic retinopathy and hearing loss; Results from Korean National Health and Nutrition Survey (KHANES VI) (2010-2012)

**T081**
The German AugUR study: a population-based prospective study to investigate chronic diseases in the elderly with focus on age-related macular degeneration (AMD)

**T082**
Spectrum and outcomes of open globe injuries presenting to a tertiary Eye Centre in Singapore
GOH M J, Chaung J, Koh V, Sundar G - Singapore

**T083**
Wooden projectile caused eye injuries in Finland - Helsinki eye trauma study
HAAVISTO A K, Saharavand A, Leivo T, Holopainen J - Helsinki

**T084**
The prevalence of refractive errors among underserved rural areas in Iran
YEKTA A A, Hashemi H, Khabazkhoob M, Ostadimoghaddam H, Malekifar A, Nabovati P - Mahhad
OSBORNE N, HARDARSON S
T085
Hyperhomocysteinemia caused chorioretinal vasculopathy in an animal model
LEE Y J, Ke CY, Lin P K - New Taipei City

T086
Changes in choroidal thickness and mean ocular perfusion pressure with hemodialysis

T087
Functional end-arterial circulation of the choroid assessed by using fat embolism and electric circuit simulation

T088
Assessment of chorioretinal blood flow and vessel diameter by laser speckle flowgraphy in three animal models
WEI X, Barathi A, Sai B B, Balne P K, Khandelwal N, Agrawal R - Singapore

T089
Retinal vessel parameters in obstructive sleep apnea
HEITMAR R, Turnbull C, Blann A, Stradling J - Birmingham

T090
Visualizing retinal vessel dynamics of young type 1 diabetic patients using self-organizing map

T091
Coats’ syndrome is associated with reduced pressure autoregulation in retinal arterioles
HERBORG A, Bek T, Petersen L - Aarhus C

T092
The assessment of Ocular Blood Flow with Laser Speckle Flowgraphy in healthy Caucasian

T093
Quantitative assessment of retinal permeability in the diabetic Akimba mouse: validation of a promising animal model for diabetic retinopathy
HU TT, Vanheukelom V, De Vries A, Feyen J H M - Heverlee

T094
The venous oxygen saturation predicts the visual prognosis after anti-VEGF treatment of central retinal vein occlusion
JEPESEN S K, Bek T - Aarhus C

T095
Retinal venous oxygen saturation in healthy, atrophic and retinal vascular diseases

T096
Differential hypoxic response of human choroidal and retinal endothelial cells proposes tissue heterogeneity of ocular angiogenesis
MAMMADZADA P, Gudmundsson J, Kvanta A, Andre H - Stockholm

T097
Vessel Diameter Study: Intravitreal Versus Posterior Subtenon Triamcinolone Acetonide Injection For Diabetic Macular Edema
AKPOLAT C, Kurt M, Cekic O - Istanbul

T098
The preventive effects of the rhodiola rosea on ischemia-reperfusion injury in the RAT retina

T099
Experimental study of intraocular temperature distribution in the rabbit under various environmental conditions
Anatyshuk L, Pasytechnikova N, ZADOROZHNYY O, Kobylianskyi R, Nazaretyan R, Myrnenko V - Odessa
### Thursday, Oct 6 - Poster session 1

#### POSTER AREA

**PBP - Physiology/Biochemistry/Pharmacology**

T085 - T108

<table>
<thead>
<tr>
<th>Poster</th>
<th>Title</th>
<th>Speakers</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>T101</td>
<td>RESVEGA in exudative age-related macular degeneration</td>
<td>Kubicz A</td>
<td>Wroclaw</td>
</tr>
<tr>
<td>T102</td>
<td>Variation of accommodative process and anterior chamber parameters in diabetic patients</td>
<td>Costa L, Passos I, Pires G, Proença R, Amado D, Ferreira J</td>
<td>Lisbon</td>
</tr>
<tr>
<td>T103</td>
<td>In the search of biomarkers for thyroid associated orbitopathy (TAO)</td>
<td>Kishazi E, Dor M, Eperon S, Gracià M D L A, Fouda C, Oberic A, Hamédani M, TURCK N</td>
<td>Geneva</td>
</tr>
<tr>
<td>T105</td>
<td>Light-induced oxidative stress production in the rod outer segments</td>
<td>Panfoli I, Calzia D, Heinig N, Schumann U, Degan P, Traverso C E, Funk R HW, Roehlecke C</td>
<td>Genova</td>
</tr>
<tr>
<td>T106</td>
<td>Upregulated expression of proteolytic enzymes in the cultured retinal pigment epithelial cells of minipig transgenic for the human mutated huntingtin</td>
<td>Ardant T, Kocurova G, Hrnciarova E, Motlik J</td>
<td>Libechov</td>
</tr>
<tr>
<td>T107</td>
<td>The effect of systemic alfuzosin hydrochloride on choroidal thickness and pupil diameter sizes</td>
<td>Dogan M, Kutluksaman B, Karalar M</td>
<td>Afyonkarahisar</td>
</tr>
<tr>
<td>T108</td>
<td>A 5-minute time interval between two different dilating eyedrops increases their combined effect</td>
<td>Sagué P, Charlot F, Mouriaux F, Lux A L, Beraud G, Denion E</td>
<td>Caen</td>
</tr>
</tbody>
</table>

---

**Meet the Experts**

In an initiative to encourage dialogue amongst speakers and EVER members, we have launched a 45 minute session called “Meet the Experts”. This will be a table of 6-8 “guests” at a table headed by one of the EVER speakers. The idea is to provide a casual yet personal venue where colleagues, in particular the younger faction, can share comments and ideas with an expert.
Thursday, Oct 6 - Second afternoon session

17:00 - 18:30 | HERMES

**RV - Controversies in vitreoretinal practice**

This symposium will provide three relevant issues in Vitreoretinal practice: the potential treatment options for symptomatic vitreous opacities, the prophylactic use of antibiotics in intravitreal injections, and finally, the current preferred therapeutic approach for the management of age-related macular degeneration (AMD) and diabetic retinopathy. The speakers will analyze these topics, presenting and discussing both pro and con positions.

**GRZYBOWSKI A, ASCASO F**

<table>
<thead>
<tr>
<th>2711</th>
<th>17:00</th>
<th>Vitrectomy for vitreous floaters</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>ASCASO F - Zaragoza</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>2712</th>
<th>17:18</th>
<th>Laser for vitreous floaters</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>TASSIGNON M J - Edegem</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>2713</th>
<th>17:36</th>
<th>Antibiotics in intravitreal injections</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>GRZYBOWSKI A - Olsztyn</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>2714</th>
<th>17:54</th>
<th>Treat &amp; Extend vs PRN in AMD</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>PRUENTE C - Binningen</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>2715</th>
<th>18:12</th>
<th>Treat and Extend vs PRN in Diabetic retinopathy</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>POURNARAS C - Genèве</td>
</tr>
</tbody>
</table>

17:00 - 18:30 | RHODES 1

**G - Laser - the force reawakens. New concepts in established technology**

Laser treatments are important and effective in the modern management of glaucoma. In this session we will explore recent advances in inflow and outflow laser treatment options. Has Selective Laser Trabeculoplasty delivered the pressure lowering it promised with a new generation of medication free patients? Does diode laser have a role in the antiVEGF era of rubeotic glaucoma management? How can YAG laser assist glaucoma drainage devices?

This session will address all forms of laser treatments in glaucoma in an effort to maximise patient outcome and enhance your clinical practice.

**CRAWLEY L, BLOOM P**

<table>
<thead>
<tr>
<th>2721</th>
<th>17:00</th>
<th>Laser Trabeculoplasty - Is the glaucoma fraternity completely convinced?</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>GAZZARD G - London</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>2722</th>
<th>17:22</th>
<th>Inside out Diode laser for rubeotic glaucoma in the anti VEGF era</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>AHMED F - London</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>2723</th>
<th>17:44</th>
<th>Yag laser glaucoma treatments; iridotomies and beyond</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>CRAWLEY L - London</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>2724</th>
<th>18:06</th>
<th>Endoscopic laser- a direct view on the direct view</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>BLOOM P - London</td>
</tr>
</tbody>
</table>
EVER 2016 will introduce a new symposium entitled YOS for EVER. YOS is a well-recognized acronym for “young ophthalmologist” and as not only ophthalmologists attend EVER, YOS stands for “young ophthalmologist/scientist”. YOS for EVER represents the trainee and young specialist group within EVER. This is a networking assembly of students, residents, post-docs and junior scientists to focus on objectives and goals relevant to the early stages of career development. Such topics include board examinations, information exchange, research and/or educational programs, fellowship and job opportunities. The 2016 inaugural symposium will be organized by Gauti Johannesson, a young ophthalmologist/scientist and member of the organization committee for YOS sessions at the Nordic Ophthalmologic Congress. All interested parties are encouraged to attend as guidelines and objectives and representatives for this new subgroup will be discussed at this first meeting. Immediately following the symposium, there will be a reception with light food and beverages for those attending this session.

JOHANNESSON G
2731  17:00 Presentation skills for oral presentations
      JOHANNESSON G - Umeå
2732  17:22 How to fast track your research career
      BECHRakis N E - Innsbruck
2733  17:44 Tricks for the spotlight - handling media
      SOMNER J - Cambridge
2734  18:06 How to succeed with grant applications?
      DANIELSON P - Umeå

NSPH - Hot topic in ocular surface in children

Manifestations of ocular surface in children may be severe causing visual impairment. Vernal keratoconjunctivitis, Atopic Keratoconjunctivitis, severe dry eye manifestations of systemic pathology are rare diseases. Physiopathology of these diseases is reviewed and developed. Severe ocular surface disease in children is a challenge. Understanding and treatment is the key point. The pathogenesis remains unclear and classical tear substitute or antiallergic therapy often unsuccessful. An overview of the innovating new molecules, diagnosis and treatment are summarized. Furthermore molecules’ action can explain how the disease can be improved.

BREMOND-GIGNAC D , ATILLA H
2741  17:00 Topical cyclosporine-A in dry eye associated with chronic graft versus host disease
      ATILLA H - Ankara
2742  17:22 Severe clinical features in Vernal Keratoconjunctivitis
      LAZREG S - Dar el Beida
2743  17:44 Atopic Keratoconjunctivitis in children
      CHIAMBARETTA F - Clermont Ferrand
2744  18:06 Topical cyclosporine-A in Vernal Keratoconjunctivitis, when how and how long
      BREMOND-GIGNAC D - Paris
Thursday, Oct 6 - Second afternoon session

17:00 - 18:30 | RHODES 4

**PO - FP session - PO**

**MOURIAUX F, MOULIN A**

2751  17:00  The role of anterior segment optical coherence tomography (AS-OCT) and ultrasound biomicroscopy (UBM) in conjunctival nevi

LAWERS N, Janssens K, Mertens M, De Keizer R JW, De Groot V - Edegem

2752  17:06  Loss of 5 hydroxymethylcytosine in conjunctival melanoma

MOULIN A, Caseiro P, Schalenbourg A, Zografos L, Kaya G - Lausanne

2753  17:18  Outcomes after surgical resection of lower eyelid tumors and reconstruction using a septal chondromucosal graft and an upper eyelid skin flap


2754  17:30  Cyberknife treatment in adenoid cystic carcinoma of the lacrimal gland

TUNC M, Guney Y - Ankara

2755  17:42  4 Gy radiotherapy in 6 patients with orbit marginal zone lymphoma: A small case series

GRAEFF E - Basel

2756  17:54  Sequential bilateral optic nerve infiltration as the sole manifestation of relapsed T-cell lymphoblastic lymphoma: a case report


2757  18:00  Clinical and instrumental diagnostics in patients with orbital metastasis

SAAKYAN S - Moscow

2758  18:06  Grading iris color of post-mortem human eyes

MADIGAN M, Cionaca V, Sitiwin E, Ton HT - Sydney

---

17:00 - 18:30 | GALLIENI 1+2

**MBGE/NSPH - Syndromic retinopathies**

Syndromic retinopathies are complex disorders in which the retinal involvement is of is one of the key features of the disease also affecting other organs and tissues. The special interest symposium will provide an overview of the molecular genetic mechanisms underlying inherited syndromic retinopathies, advances in the field of genetic testing and present selected distinct clinical entities manifestating in children.

**LISKOVA P**

2761  17:00  Using iPSC cells to uncover cilia protein function and model disease

SCHWARZ N - London

2762  17:22  Searching for the molecular causes of syndromic inherited retinal degenerations

BUJAKOWSKA K - BostonMA

2763  17:44  Syndromic paediatric vitreoretinopathies

HENDERSON R - London

2764  18:06  Molecular genetic basis of Usher syndrome in the Czech population

LISKOVA P, Kousal B, Bujakowska K, Dudakova L - Prague
Ocular surfaces are delicate structures of the anterior segment of the eye protected, nourished and lubricated by tear fluid. Composition of the tear film is in essential role in the health of the anterior segment of the eye. The system has its own regulatory mechanisms. Ocular surfaces are exposed environmental factors, topical ophthalmic drugs and affected by various ocular and systemic diseases. Inflammation and wound healing are vital processes involved in the defense mechanisms of the human body and pathogenesis of many eye diseases. It is also one of the most important factors in many ocular surgeries e.g. corneal, refractive and glaucoma surgery. It consists of many overlapping processes like inflammation, fibroblast activation, ECM production and remodeling of the ECM and there are many mechanisms and mediators involved in it. Tear proteomics is a powerful tool to diagnose and detect mechanisms and drugable targets of the ophthalmic and systemic diseases. SIS is focusing in the proteomics and biomarkers of the tears and anterior surface of the eye in relation these diseases.

**UUSITALO H, BEUERMAN R**

<table>
<thead>
<tr>
<th>Session</th>
<th>Time</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>2771</td>
<td>17:00</td>
<td>Inflammation: The good and the bad</td>
<td>CALONGE M, Herreras J M, Stern M E - Valladolid</td>
</tr>
<tr>
<td>2772</td>
<td>17:22</td>
<td>Quantifying inflammation as a common component of eye disease</td>
<td>BEUERMAN R - Singapore</td>
</tr>
<tr>
<td>2773</td>
<td>17:44</td>
<td>Tear lipids in corneal stress and inflammation</td>
<td>HOLOPAINEN J - Helsinki</td>
</tr>
<tr>
<td>2774</td>
<td>18:06</td>
<td>Tear fluid biomarkers, conjunctival inflammation in glaucoma</td>
<td>UUSITALO H - Tampere</td>
</tr>
</tbody>
</table>

At present, cataract can only be treated with surgical removal of the non-transparent lens. There are no effective prophylactic or therapeutic treatments despite the many attempts to find a non-surgical cure for cataract. In this symposium we will receive an introduction on lens and eye transparency and non-transparency, in order to better understand the various types of cataract measures and end-points used by the other speakers. We will hear about pharmacological and photochemical interventions intended to reverse or decrease the degree of cataract or cataract-related parameters in various models.

**LOFGREN S, BARRAQUER RI**

<table>
<thead>
<tr>
<th>Session</th>
<th>Time</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>2781</td>
<td>17:00</td>
<td>Transparency of the lens and the eye</td>
<td>PRIETO P - Murcia</td>
</tr>
<tr>
<td>2782</td>
<td>17:15</td>
<td>Effects of a thiol antioxidant in various cataract models</td>
<td>ERCAL N, Maddirala Y, Carey J, Tobwala S - Rolla</td>
</tr>
<tr>
<td>2784</td>
<td>17:51</td>
<td>Photochemical reversal of cataract</td>
<td>KESSEL L - Glostrup</td>
</tr>
<tr>
<td>2785</td>
<td>18:09</td>
<td>Pharmacological restoration of transparency in cataract</td>
<td>MAKLEY L, Andley U, Gestwicki J - San Francisco</td>
</tr>
</tbody>
</table>
### Evening symposium: Modern understanding of dry eye

**18:30 - 19:30 | RHODES 2**

| **2831** | 18:30 | The last key highlights on dry eye  
**SULLIVAN DA - United States**  

| **2832** | 18:45 | Interrelationship between dry eye and MGD  
**LAZREG S - Algeria**  

| **2833** | 19:00 | Is dry eye more about the ocular surface than the tear film?  
**MESSMER EM - Germany**  

| **2834** | 19:15 | How are ocular surface cells protected in stressful situations?  
**CHIAMBARETTA F - France**
EVER 2016
Friday, Oct 7
**EVER 2016**

**Friday, Oct 7 - First morning session**

**SIS**

**8:30 - 10:00 | HERMES**

**RV - Confrontation of OCT-angiography and fluoresceine angiography**

OCT angiography became an emerging imaging modality particularly useful for the diagnosis and management of the retinal vascular pathologies. It is particularly useful for the investigations of various macular ischemic microangiopathies as well as for the diagnosis and management of age related macular degeneration. The aim this SIS is to bring together experts in order to clarify confrontation aspects of OCT-Angiography and fluorescein angiography in those macular pathologies.

**POURNARAS C, ZOGRAFOS L**

**3111** 8:30 OCT-A physics, instruments and limits of clinical application

*COSCAS F - Creteil*

**3112** 8:42 OCT-A in neovascular age related macular degeneration

*LUMBROSO B - Rome*

**3113** 8:54 OCT angiography in Retinal Angiomaticous Proliferation

*SOUBRANE G - Paris*

**3114** 9:06 Diabetic maculopathy: Confrontation of FA and OCT-A findings

*COSCAS G, Lupidi M, Fiore T, Cagini C, Coscas F - Creteil*

**3115** 9:18 OCT-A and FA findings in ocular Drepanocytosis

*AMBRESIN A - Lausanne*

**3116** 9:30 OCT-A versus FA guided focal laser, in macular ischemic microangiopathies

*POURNARAS C - Genève*

**3117** 9:42 OCT-A and FA in irradiation induced microangiopathy

*ZOGRAFOS L - Lausanne*

---

**SIS**

**8:30 - 10:00 | RHODES 1**

**G - New technologies in glaucoma surgery**

The surgical field of glaucoma is rapidly changing with the introduction of new devices and techniques. Is this the end for the good old trabeculectomy? First, an overview will be provided of new techniques like the Xen gel stent implant, the ultrasound cyclocoagulation and the iStent. Secondly, difficult cases will be presented and the panel will discuss the different treatment options and guide us through the mazes of the labyrinth of glaucoma treatment nowadays.

**VANDEWALLE E, STALMANS I**

**3121** 8:30 The role for the Xen gel stent implant in glaucoma treatment

*STALMANS I - Leuven*

**3122** 8:48 High-intensity focused ultrasound treatment for open angle glaucoma

*APTEL F - Meylan*

**3123** 9:06 Results for the Synergy trial: use of iStent in open angle glaucoma

*GARCIA-FEIJOO J, Voskanyan L, Martinez de la Casa J M - Madrid*

**3124** 9:24 How to tackle these difficult cases

*ABEGAO PINTO L - Lisbon*

**3125** 9:42 How to tackle these difficult cases

*VANDEWALLE E - Leuven*
### COS - Nanotechnology in ophthalmology

This SIS highlights nanotechnological approaches for therapies in cornea, retina and glaucoma.

<table>
<thead>
<tr>
<th>Session</th>
<th>Time</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>3131</td>
<td>8:30</td>
<td>Nanoparticles for ocular surface drug and gene delivery</td>
<td>Kompella UB, Griffith M</td>
</tr>
<tr>
<td>3132</td>
<td>8:48</td>
<td>Magnetized nanoparticles for transfection of the corneal endothelium</td>
<td>Fuchsluger T, Mykhailyk O, Christian P, Singer B, Czugala M</td>
</tr>
<tr>
<td>3134</td>
<td>9:24</td>
<td>Recent progress in microrobots for ophthalmic therapies</td>
<td>Ullrich F, Nelson B J</td>
</tr>
<tr>
<td>3135</td>
<td>9:42</td>
<td>Collagen biomaterials for cornea regeneration - how does it work</td>
<td>Griffith M, Reddy J, Liszka A, Lewis P N, Hayes S, Meek K M</td>
</tr>
</tbody>
</table>

### PO - Conjunctival tumors

Conjunctival neoplasms are rare tumours of benign or malignant nature, which are 1) often misdiagnosed; 2) associated with severe ocular morbidity when diagnosed too late and/or treated incorrectly; and c) associated with increasing mortality in some areas of the globe. Their diagnosis and treatment can be difficult requiring a multimodality approach. There has been much progress in our understanding of the pathogenesis of these tumours in recent years. In addition, major advances have occurred in treatment with the introduction of topical chemotherapy, adjunctive radiotherapy and microsurgical developments. This symposium will provide an overview of latest understanding of the epidemiology, pathology, imaging, TNM/AJCC clinical staging and treatment of these tumours. It will highlight the use of novel cell lines that will hopefully advance our understanding of some conjunctival malignancies. Finally, it will provide the opportunity for a panel discussion where specific clinical problems can be addressed.

<table>
<thead>
<tr>
<th>Session</th>
<th>Time</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>3141</td>
<td>8:30</td>
<td>Overview of the epidemiology and pathology of conjunctival tumours</td>
<td>Loeffler K U</td>
</tr>
<tr>
<td>3142</td>
<td>8:48</td>
<td>Diagnostic modalities of conjunctival tumours</td>
<td>Blasi M A</td>
</tr>
<tr>
<td>3143</td>
<td>9:06</td>
<td>Treatment of conjunctival tumours</td>
<td>Caujolle J P</td>
</tr>
<tr>
<td>3144</td>
<td>9:24</td>
<td>Cell lines of conjunctival tumours and their potential use in research</td>
<td>Jager M J, Cao J</td>
</tr>
<tr>
<td>3145</td>
<td>9:42</td>
<td>Update on the 8th Edition TNM staging system for conjunctival tumours</td>
<td>Coupland S</td>
</tr>
</tbody>
</table>
**EUPO session 1 - Neuro-ophthalmology**

**Common Optic Neuropathies in Adults: Diagnosis, Treatment and Prognosis**

EUPO Programme, see pages 134-135.

---

**8:30 - 10:00 | GALLIENI 1+2**

**LC - Ocular damage from ambient optical radiation**

The first speaker provides an overview of the ambient exposure of ocular tissues to optical radiation. The second speaker will review the current knowledge on the association between sun exposure and cataract. The third speaker will review evidence for apoptosis as a damage mechanism in ultraviolet radiation damage to the lens. The forth speaker will review the possibility that near-infrared radiation exposure from remote-controls and sensors contributes to cataract formation. Finally, the fifth speaker will provide an update on the possible threat to the retina caused by the ongoing conversion from incandescent sources to LED-sources for illumination.

**SODERBERG P, WEGENER A**

**3161** 8:30 Ambient exposure of the ocular tissues to optical radiation

*SODERBERG P, Yu Z, Talebizadeh N, Malmqvist L, Sandberg Melin C, Galichanin K - Uppsala*

**3162** 8:48 Update on epidemiological evidence for an association between sun exposure and cataract

*WEGENER A, Meyer L - Bonn*

**3163** 9:06 Evidence for apoptosis in the lens after in vivo exposure to ultraviolet radiation

*TALEBIZADEH N, Yu Z, Kronsclager M, Galichanin K, Soderberg P - Uppsala*

**3164** 9:24 Is the increasing exposure of the eye to near-infrared radiation from remote controls and sensors a threat to the lens?

*YU Z, Schumleister K, Talebizadeh N, Kronsclager M, Soderberg P - Uppsala*

**3165** 9:42 Is conversion of indoor illumination to LED-sources a threat to the retina?

*BEHAR-COHEN F - Paris*
EVER 2016 - programme book

Friday, Oct 7 - First morning session

**ACB - Stem cells and cell therapy advances in ophthalmology**

The anatomical and biological properties of stem cells in the eye have been the topic of in-depth research over the last few decades. Enormous advances in the cell and tissue isolation and cultivation techniques, as well as molecular characterization of the different cell populations have been achieved, next to the major advances made in the bioscaffolds’ engineering for cell delivery and treatment of eye diseases. Advances in the cell and gene therapy have reached culmination with the human cornea being at the top and holding great promise in treating eye disorders. The eye is indeed a golden mine for stem cells. This session will include lectures from European experts in the field with high international recognition and large collaborative networks.

**PETROVSKI G , MOE M**

**3171** 8:30 Challenges in the clinical applications of cornea limbal stem cells  
*FERRARI S - Venice*

**3172** 8:52 Regulating gene expression towards solving ocular surface diseases  

**3173** 9:14 Advances in corneal endothelium engineering for future transplantation applications  
*SHAHDADFAR A - Oslo*

**3174** 9:36 The future of stem cell and cell therapy in ophthalmology  
*Ferrari S , Moore T , Shahdadfar A , PETROVSKI G - Szeged*

**MBGE - Grand rounds in ophthalmic genetics**

This SIS will provide a forum to discuss clinical and molecular cases with peers and leaders from the field of ophthalmic genetics. The format is simple and is comparable to that of the Grand Rounds in departments of ophthalmology around the World. Both SIS organisers will be present, together with other leaders in the field of ophthalmic genetics.

Because of the format of the SIS, there will be no formal speakers set in stone from the outset, as all EVER participants will be free to submit cases during the meeting prior to this session. As such, the format will be similar to the FAN Club meeting. Nevertheless, we have indicated speakers who have declared their interest in presenting.

**LEROY B , HAMEL C**

**3181** 8:30 Cases  
*AUDE I - Paris*

**3182** 8:48 Cases  
*HAMEL C - Montpellier*

**3183** 9:06 Cases  
*LISKOVA P - Prague*

**3184** 9:24 Cases  
*HOLDER G - London*

**3185** 9:42 Cases  
*LEROY B - Ghent*
Summary:
Primary inherited optic neuropathies are a group of blinding genetic disorders in which optic atrophy secondary to loss of retinal ganglion cells is a key clinical feature. The commonest causes world-wide are mutation in mitochondrial DNA (causing Leber’s Hereditary Optic Neuropathy) and mutation in the nuclear gene, OPA1 (causing Autosomal Dominant Optic Atrophy: ADOA). 60-75% of patients with autosomal dominant optic atrophy have mutations in the OPA1 gene. The OPA1 protein is targeted to the mitochondria and is involved in regulation of mitochondrial fusion. A better understanding of mitochondrial function, including dynamics, is revealing that functional and structural changes in mitochondrial morphology are important factors in diseases of ageing in the eye and visual system. Key proteins have been discovered which control the balance of mitochondrial fusion and fission and have a range of other functions, such as controlling maintenance of mitochondrial DNA, cell death, autophagy, mitochondrial metabolism and redox signalling. A decline in mitochondrial function plays a role in the ageing process and increases the incidence of age-related disorders. Mitochondrial optic neuropathies are ‘orphan’ diseases but with the advent of recent trials of novel therapies in patients with the mitochondrial optic neuropathy, Leber’s hereditary optic neuropathy, there is the first glimmer of hope for the treatment of this group of patients.

Award presentation of the EVER Certificate of Honour

Biography Marcela VOTRUBA:
Marcela Votruba is a Professor in Ophthalmology at Cardiff University and a Consultant in Ophthalmology at the University Hospital of Wales. She was awarded an Open Scholarship to The Queen’s College, Oxford (1981-1984) to read Physiological Sciences and obtained her BM BCh at Green College, Oxford (1987). After Primary FRCS (1989) she trained in ophthalmology at The Royal London Hospital, St Bartholomew’s Hospital, London, Bristol Eye Hospital and Moorfields Eye Hospital, London. She obtained a PhD (1999) at UCL in ophthalmic genetics, supervised by Professor Shomi Bhattacharya and Professor Tony Moore, using linkage analysis and positional cloning to identify the OPA1 gene, causing dominant optic atrophy. She has held Wellcome Trust and MRC Clinician Scientist Fellowships and is a former Consultant at Moorfields Eye Hospital and a Visiting Research Scholar at the National Eye Institute, National Institutes of Health, USA.

Her research focuses on ophthalmic genetics and mitochondrial diseases. She is particularly interested in the role of mitochondria in optic neuropathy and retinal degeneration. Her Mitochondria & Vision Lab in The Cardiff School of Optometry & Vision Institute focuses on in vitro and in vivo approaches to modelling mitochondrial dysfunction leading to retinal ganglion cell loss and on genes and proteins involved in the regulation of mitochondrial morphology, with a strong emerging interest in novel therapies. She runs a genetic eye disease clinic and a retinal clinic at the Cardiff Eye Unit, University Hospital, Wales. Since 2014 she has been the Head of the School of Optometry & Vision Sciences at Cardiff University, Wales, UK.
Friday, Oct 7 - Second morning session

11:00 - 12:30 | HERMES

ARVO@EVER - Animals in ocular oncology

COUPLAND S

3311 11:00 Introduction and overview on animal models used in ocular oncology

JAGER M J - Leiden

3312 11:12 Use of the chick embryo model in uveal melanoma

KALIRAI H - Liverpool

3313 11:24 Uveal melanoma patient-derived xenografts

DECAUDIN D - Paris

3314 11:36 Use of the zebrafish model in uveal melanoma

MIONE M - Karlsruhe

3315 11:48 Orthopedic xenograft mice model of retinoblastoma

CASSOUX N - Paris

3316 12:00 Intraocular lymphoma models

FRENKEL S - Jerusalem

3317 12:12 Summary and future directions

COUPLAND S - Liverpool

11:00 - 12:30 | RHODES 1

RV - FP session - AMD & miscellaneous

SOUBRANE G, LEYS A

3321 11:00 The immunohistochemical identification and localization of homocysteine in the human retina with the features of age related macular degeneration

OZIMEK M, Choragiwicz T, Junemann A, Rejdak R - Lublin

3322 11:12 Treatment of neovascular age-related macular degeneration with anti-VEGF agents: predictive factors of long-term visual outcomes


3323 11:24 Characterization, structural analysis, evolution of AMD drusenoid deposits “L”, Lipid type and “P”, Protein-cellular type, with multimodal imaging and morphology-structural software

GONZALEZ C - Toulouse

3324 11:36 Optimization of storage of differentiated retinal pigment epithelial cells


3325 11:48 Incidence of retinal vein occlusions (RVO) in patients treated with oral anticoagulants or antiplatelet drugs for cardioembolic or atherothrombotic prevention


3326 11:54 Frequency doubling technology perimetry and retinal fiber layer correlation in type 2Diabetics without retinopathy

ALDAHAM S, Martin-Ridaura M D C, Puell M C - Madrid

3327 12:00 Correlation between choroidal and retinal thickness in diabetic patients without diabetic retinopathy


3328 12:06 SD-OCT for study of retinal layers segmentation in patients under Hydroxychloroquine treatment

### COS - FP session - Corneal transplantation from the lab to the OR

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>FP 3331</td>
<td>How to make better, safer and easier endothelial controls of long-term stored corneas with Specular Microscopy?</td>
<td>GICQUEL J, FUCHSLUGER</td>
</tr>
<tr>
<td>FP 3332</td>
<td>Effect of biochemical cues on proliferation, phenotype and migration of human corneal stromal cells</td>
<td>FERNANDEZ-PEREZ J, Ahearne M</td>
</tr>
<tr>
<td>FP 3333</td>
<td>Influence of material compliance on human corneal stromal cell behaviour</td>
<td>KELLY C, Ahearne M</td>
</tr>
<tr>
<td>FP 3334</td>
<td>Involvement of abnormally-activated CD44+ cells migrating from the iris to the center of the cornea in Fuchs Endothelial Corneal Dystrophy</td>
<td>HE Z, Thuret G, Jun A S, Muraine M, Kallay L, Toubeau D, Pereira S, Bergandi F, Gain P</td>
</tr>
</tbody>
</table>

### PO - Controversies in posterior uveal melanoma

The management of malignant melanoma of the posterior uvea (ciliary body and choroid) is still controversial in some points. This controversy has evolved because the peculiar and often unpredictable behavior of this tumor is poorly understood. This SIS meeting discusses some of the controversial issues, with emphasis on the debate.

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>SIS 3341</td>
<td>Fine needle aspiration biopsy or not?</td>
<td>CASSOUX N</td>
</tr>
<tr>
<td>SIS 3342</td>
<td>Endoresection or not?</td>
<td>BECHRASIS N E</td>
</tr>
<tr>
<td>SIS 3343</td>
<td>Cytogenetic or molecular analysis for prognosis?</td>
<td>JAGER M J</td>
</tr>
<tr>
<td>SIS 3344</td>
<td>Follow-up: which one and for whom?</td>
<td>DAMATO B</td>
</tr>
</tbody>
</table>
Friday, Oct 7 - Second morning session

11:00 - 12:30 | RHODES 4
EUPO session 2 - Neuro-ophthalmology
Systematic Approach to the Ocular Motor System

EUPO Programme, see pages 134-135.

11:00 - 12:30 | GALLIENI 1+2
PO/IM - Cytology of atypical inflammation or tumors

Diagnostic challenges in unsolved cases of inflammation or masses in the vitreous, retina or choroid. An inflammation can obscure or mask a malignant process. Some tumors start very indolent and mimic uveitis and present in the immunology clinic. In these difficult presentations it is important to detect the atypical components and act quickly following the modern techniques to exclude or confirm malignancies. In this SIS the atypical presentations which are suspicious for malignancies will be highlighted. A retinal or choroidal lymphoma with vitreous seeding is a typical diagnostic challenge. An atypical flat choroidal melanoma can be obscured by bleeding or inflammation. Paraneoplastic processes can mimic real neoplasms or inflammation and their typical clinical aspect will be explained. For challenging cases a biopsy can be necessary. The technical aspects of vitreous biopsies, handling and will be explained, highlighting the newer techniques. Even in very small samples it is nowadays possible to perform genetic analysis to confirm the diagnosis and add prognostic factors.

VAN GINDERDEUREN R, VAN CALSTER J

3361 11:00 Latest diagnostic possibilities in unsolved uveitis, suspicious for malignancy
NERI P, Arapi I, Pirani V, Giovannini A, Mariotti C - Agugliano

3362 11:18 How to recognize a masquerade syndrome? What is the differential diagnosis?
VAN CALSTER J - Leuven

3363 11:36 How to perform a vitreal, retinal or choroidal biopsy? What justifies an invasive technique?
VAN CALSTER J - Leuven

3364 11:54 Innovative pathology techniques for small tissue samples or cytology of vitreous biopsies
VAN GINDERDEUREN R - Leuven

3365 12:12 Applied genetic testing in ocular tumors
COUPLAND S - Liverpool
### EVER 2016 - Second morning session

**IM - FP session - Novelties in diagnosis and treatment in ocular immunology**

<table>
<thead>
<tr>
<th>Session</th>
<th>Time</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>3371</td>
<td>11:00</td>
<td>Diagnosis and management of cytomegalovirus anterior uveitis/endothelitis in immunocompetent patients in 2 European referral centers</td>
<td><strong>BODAGHI B, WILLERMAIN F</strong>&lt;br&gt;ANTOUN J, Caspers L, Groot-Mijnes J, Motulsky E, Dam-van Loon N HT, Makhoul D, Willermain F, Judice Relvas L - Brussels</td>
</tr>
<tr>
<td>3372</td>
<td>11:12</td>
<td>Presentation and management of cytomegalovirus retinitis in immunocompromised children</td>
<td><strong>DENIER C, Robert M, Adjadj E, Michel S, Aymard P A, Bremond-Gignac D</strong> - Paris</td>
</tr>
<tr>
<td>3373</td>
<td>11:24</td>
<td>Validation of an antiretinal antibody detection strategy for the diagnosis of autoimmune retinopathies</td>
<td><strong>DRAGANOVA D, Debaugnies F, Postelmans L, Caspers L, Willermain F, Corazza F</strong> - Bruxelles</td>
</tr>
<tr>
<td>3375</td>
<td>11:48</td>
<td>In vitro evaluation of anti HSV-1 siRNAs and in vivo evaluation of electroporation to transfect siRNAs on murine cornea</td>
<td><strong>ROUSSEAU A, Escriou V, Roy P, Poccardi N, Takissian J, Bigey P, Labetoulle M</strong> - Le Kremlin Bicêtre</td>
</tr>
</tbody>
</table>

---

**MBGE/LC - Radiation induced cataracts**

Radiation cataracts are a field of recent interest, following accumulating evidence in the literature that the lens is more radiosensitive than previously thought. Indeed the International Commission for Radiation Protection recently revised its judgement regarding the threshold for lens effects and occupational dose limits, with the new recommendations now incorporated into the EU Basic Safety Standard. It is intended that this session will highlight research gaps including mechanistic needs, and how also other research fields could contribute to radiation cataract research. Speakers will examine recent developments in our mechanistic understanding of radiation cataract initiation and development, including evidence for low dose radiation effects. In addition, speakers will explore the radiation protection aspects and the need for collaborative ‘molecular epidemiology’ research to full answer the remaining questions as to how low dose ionising radiation exposure causes cataracts.

<table>
<thead>
<tr>
<th>Session</th>
<th>Time</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>3381</td>
<td>11:00</td>
<td>Investigating the effect of low dose ionising radiation on epithelial progenitor cell niches</td>
<td><strong>AINSBURY L, WEGENER A</strong>&lt;br&gt;QUINLAN R, Kalligeraki A, Pai R, Wu J J, Inagaki M, Tanaka H - Durham</td>
</tr>
<tr>
<td>3383</td>
<td>12:00</td>
<td>Epidemiological needs to support lens mechanistic research</td>
<td><strong>AUVINEN A</strong> - Tampere</td>
</tr>
</tbody>
</table>
13:30 - 15:00 | HERMES

RV - Retinal detachment

Retinal detachment may occur in different conditions as in pseudophakic, myopic, diabetic eyes. Prevention of retinal detachment will firstly discussed. Then, the characteristics in each condition will be detailed in order to apply the best strategy for the management of our patients. Finally, retinal detachment associated with tumor cases will be discussed.

POURNARAS J, LE MERY

POURNARAS J, LE MERY

3511 13:30 Prevention of retinal detachment
STANGOS A - Geneva

3512 13:48 Pseudophakic retinal detachment
POURNARAS C - Genève

3513 14:06 Myopic Retinal detachment
BERROD J P - Vandoeuvre les Nancy

3514 14:24 Diabetic Retinal detachment
LE MERY - Paris

3515 14:42 Retinal detachment in ocular oncology
POURNARAS J A - La Conversion

13:30 - 15:00 | RHODES 1

G - EVER Obergurgl optic nerve meeting symposium: the ageing optic nerve

The theme of the 5th Obergurgl Optic Nerve Meeting in Dec. 2015 was “The ageing optic nerve” (Organizers: Jonathan Crowston, Melbourne; Franz Grus, Mainz; Keith Martin, Cambridge). The program featured leading researchers from ophthalmology, neuroscience and related fields. Speakers discussed the influence of oxidative stress, mitochondria, glia and autoimmunity on optic nerve health, as well as their ability to protect against degeneration or to slow it down. The emphasis was on ageing and its role in disease pathogenesis and treatment approaches. The conference brought together clinicians and basic scientists from different fields and highlighted translational research providing a platform for networking and stimulating discussions.

GRUS F, CROWSTON J, MARTIN K

3521 13:30 Autophagy and ageing in the retina
BOYA P - Madrid

3522 13:48 Repairing the ageing brain - neural ECM in regeneration and rehabilitation
KWOK J - Leeds

3523 14:06 Gene transfer of E2F2 induces in situ regeneration of retinal pigment epithelium
LUHMANN U, KAMPIK D, NISHIGUCHI K, BASCHE M, SMITH A J, ALI R R - Basel

3524 14:24 Stem cells in repairing optic nerve damage

3525 14:42 Retina proteomics provide new insights in glaucoma
FUNKE S, PERUMAL N, SCHMELTER C, TEISTER J, MARKOWITSCH S, BECK S, PFEIFFER N, GRUS F H -
13:30 - 15:00 | RHODES 2

COS/RV - Emerging solutions in ophthalmology

This SIS cross-sectional thematizes cutting-edge developments to approach unmet needs in ophthalmology.

**FUCHSLUGER T, STEFANSSON E**

3531 13:30  Presence of proteinase inhibitor-9 and granzyme B in healthy and pathological human corneas  
*JIRSOVA K, Reinstein Merjava S, Chudickova M, Holan V* - Prague

3532 13:48  Transduction of corneal endothelial cells with AAV2 vectors  
*GRUENERT A* - Erlangen

3533 14:06  Agonistic β2 receptor autoantibodies in ocular hypertension and open-angle glaucoma  
*HOHBERGER B* - Erlangen

3534 14:24  Automated intravitreal injection system for the efficient treatment of AMD  
*ULLRICH F* - Zürich

3535 14:42  Ocular drug delivery with cyclodextrin nanoparticles: Anterior segment advantages and posterior segm  
*STEFANSSON E* - Reykjavik

---

13:30 - 15:00 | RHODES 3

PO - Topical and intravitreal pharmacotherapy in ocular oncology

In ocular oncology, a great variety of therapeutic agents are used for topical chemotherapy of the conjunctival as well as for intravitreal specific chemotherapy. In addition, numerous anti-VEGF drugs are administrated in order to prevent or to treat irradiation induced side effects. The aim of this SIS is to bring together experts in ocular oncology in order to present a comprehensive overview of this subject.

**ZOGRAFOS L, DESJARDINS L**

3541 13:30  Topical chemotherapy for pigmented and epithelial tumors of the conjunctiva  
*DESJARDINS L* - Paris

3542 13:45  Neovascular glaucoma. Prevention and treatment with intravitreal anti-VEGF’s in ocular oncology  
*SCHALENBOURG A* - Lausanne

3543 14:00  Irradiation induced maculopathy. Pathogenesis and therapeutic approach with anti-VEGF’s  
*ZOGRAFOS L* - Lausanne

3544 14:15  Intravitreal pharmacotherapy of CME related to conservative management of uveal melanomas  
*BECHRAKIS N E* - Innsbruck

3545 14:30  Intravitreal chemotherapy for intraocular lymphomas  
*CASSOUX N* - Paris

3546 14:45  Retinal toxicity following intra-vitreal injections of melphalan  
*MUNIER F, Gaillard M C, Stathopoulos C, Beck-Popovic M* - Lausanne
EUPO session 3 - Neuro-ophthalmology
Uncommon but Important Causes of Visual Loss

EUPO Programme, see pages 134-135.

13:30 - 15:00 | RHODES 4
EUPO session 3 - Neuro-ophthalmology
Uncommon but Important Causes of Visual Loss

13:30 - 15:00 | GALLIENI 1+2
EOVS - FP session - Electrophysiology - protocols & applications

CASTELO-BRANCO M, KRASTEL H

3561  13:30  Flash adaptometry in congenital stationary night blindness
       KRASTEL H, Zyananow M, Mai M, Schlichtenbrede F - Neckargemünd

3562  13:42  Comparison of perceptual eye positions among patients with different degrees of
       anisometropia
       ZENG J, Yang C, Yang X, Yan L - Guangzhou

3563  13:54  Retinal microcysts associated with optic atrophy in children - visual electrophysiology
       studies

3564  14:06  Comparison of multifocal pattern ERG responses to luminance and chromatic
       contrast stimulations
       CHARLIER J - Perenchies

3565  14:18  A new electroretinogram function that can move the centre of the multifocal
       hexagonal stimulus array
       SUZUKI N, Yamane K - Numazu

3566  14:30  Analysis of macular sensitivity using multifocal electroretinogram and
       microperimetry in Central Serous Chorioretinopathy patients after half-dose
       photodynamic therapy
       Falcão-Reis F, Penas S - Porto

3567  14:36  Systematic assessment of clinical methods to diagnose and monitor diabetic retinal
       neuropathy
       JENKINS K S, Rowan A, Layton C - Brisbane
IM - How to publish your scientific work?

Scientific writing is not an easy task. This session aims to equip you with the basic knowledge and skills to transform your ideas and findings into a research article. It further will give you insights into the role as author, editor and reviewer in the publication process.

Who should attend?:
This session provides all individuals (at all levels) interested in scientific publishing an opportunity to deepen their knowledge.

What can you expect?:
The panelists will offer practical advice in the process of writing up. In addition, the personal view from authors and editors perspective will be given in a vivid discussion with the participants.

PLEYER U
3571 13:30 What do we need as author, editor and publisher?
DUA H S - Nottingham

3572 13:52 Essentials of a good article
STEFANSSON E - Reykjavik

3573 14:14 How to keep your work published?
KIVELÄ T - Helsinki

3574 14:36 The review process - Reviewer friend or foe?
PLEYER U - Berlin

MBGE - FP session - MBGE

BUJAKOWSKA K , SCHWARZ N

3581 13:30 Molecular study of the MFRP gene in patients with posterior microphthalmia (MCOP) supports its role in autosomal recessive MCOP pathogenesis

3582 13:42 Phenotype of maculopathy in primary hyperoxaluria type 1

3583 13:54 Molecular mechanisms of X-linked retinitis pigmentosa
ZHANG X, Shu X - Glasgow

3584 14:06 Gene transfer of prolyl hydroxylase domain 2 inhibits hypoxia-inducible angiogenesis in a model of choroidal neovascularization

3585 14:18 Autophagy is affected by Mitf in mouse primary RPE cells
GARCIA LLORCA A, Ogmundsdottir M H, Steingrimsson E, Eysteinsson T - Reykjavik

3586 14:30 Splice-site mutation in the Bmpr1b gene of the mouse causes optic nerve head dysgenesis and retinal gliosis
GRAW J, Yan X, Amarie O V, Puk O, Sabrautzki S, Klaften M, Thiele F, Fuchs H, Hrabe de Angelis M - Neuherberg
Friday, Oct 7 - Poster session 2

**NSPH - Neuro-ophthalmology/Strabismology/Paediatric/History**

**F001 - F047**

**BORRUAT F, BREMOND-GIGNAC D**

**F001**

Automated evaluation of peripapillary choroidal thickness in nonarteritic anterior ischemic optic neuropathy  
MUNOZ - NEGRETE F J, Rebolleda G, Perez Sarriegui A, De Juan V - Madrid

**F002**

Optical coherence tomography in patients with amyotrophic lateral sclerosis  

**F003**

Retinal nerve fiber layer atrophy in patients with multiple sclerosis: Longitudinal 5 years study  
GARCIA MARTIN E, Satue M, Rodrigo M J, Obis J, Cipres Alastuey M, Vilades E, Otin S, Polo V, Larroso J M, Pablo L, Gracia H - Zaragoza

**F004**

Assessment of visual function and structural retinal changes in Zen meditators  
GARCIA MARTIN E, Satue M, Rodrigo M J, Obis J, Cipres Alastuey M, Vilades E, Otin S, Polo V, Larroso J M, Pablo L, Gracia H - Zaragoza

**F005**

Reduction in peripapillary retinal thickness after Thalidomide Treatment in Patients with POEMS Syndrome  
HIROTAKAY, Toshiyuki O, Masayasu K, Takayuki B, Shuichi Y - Chiba

**F006**

Visual dysfunction and retinal changes in patients with multiple sclerosis  
RODRIGO M J, Obis J, Cipres Alastuey M, Vilades E, Garcia-Martin E - Satué M - Zaragoza

**F007**

Effects of current treatments in progressive retinal nerve fiber layer loss in multiple sclerosis patients  
SATUE M, Rodrigo M J, Obis J, Cipres Alastuey M, Vilades E, Garcia-Martin E - Zaragoza

**F008**

Evaluation of progressive visual dysfunction and degeneration of the retinal nerve fiber layer and macular thickness in patients with Parkinson disease.  
SATUE M, Rodrigo M J, Obis J, Cipres Alastuey M, Vilades E, Garcia-Martin E - Zaragoza

**F009**

Visual dysfunction and its correlation with retinal changes in patients with Alzheimer’s disease  
VILADES E, Garcia-Martin E, Satué M, Rodrigo M J, Obis J, Cipres Alastuey M - Zaragoza

**F010**

Visual dysfunction and its correlation with retinal changes in patients with Parkinson disease  
VILADES E, Garcia-Martin E, Satué M, Rodrigo M J, Obis J, Cipres Alastuey M - Zaragoza

**F011**

Optical CoherenceTomography to distinguish parkinson disease versus supranuclear progressive palsy  

**F012**

Analysis of retinal and choroidal thickness in the macular area in patients with Parkinson’s disease using swept-source optical coherence tomography  
OBIS J, Cipres Alastuey M, Vilades E, Garcia-Martin E, Satué M, Rodrigo M J - Zaragoza

**F013**

Analysis of the peripapillary retinal nerve fiber layer and choroidal thickness in patients with Parkinson’s disease using swept-source optical coherence tomography  
OBIS J, Cipres Alastuey M, Vilades E, Garcia-Martin E, Satué M, Rodrigo M J - Zaragoza

**F014**

Macular thickness and retinal layer measurements in multiple sclerosis patients using new Swept-Source Optical coherence tomography Triton device  
CIPRES ALASTUEY M, Vilades Palomar E, Garcia Martin E, Satué M, Rodrigo M J, Obis Alfaro J - Zaragoza
15:00 - 16:00 | POSTER AREA

**NSPH - Neuro-ophthalmology/Strabismology/Paediatric/History**

**F001 - F047**

**F015** Retinal nerve fiber layer measurements in multiple sclerosis patients using new Swept-Source Optical coherence tomography Triton device

*CIPRES ALASTUEY M, Vilades Palomar E, Garcia Martin E, Satué M, Rodrigo M J, Obis Alfaro J - Zaragoza*

**F016** Normative values for optical coherence tomography parameters in children and inter-examiner agreement of choroidal thickness measurements

*ERKAN TURAN K, Taylan Sekeroglu H, Baytaroglu A, Buzcu F, Karahan S - Ankara*

**F017** Early changes in mild Alzheimer’s disease in the neuroretinal rim segmentation


**F018** Maculopapillary analysis in the posterior pole in patients with mild Alzheimer’s disease


**F019** Visual outcomes of fractionated radiotherapy in optic nerve sheath meningioma

*KHEIR V, Borrut F X - Lausanne*

**F021** Papilledema secondary to internal jugular veins thrombosis in a peritoneal dialysis patient

*Braga J, Loureiro M, Barros P, Gomes A M, Meira D - Vila Nova de Gaia*

**F022** MonPack One and multiple sclerosis

*RODRIGO M J, Obis J, Cipres Alastuey M, Vilades E, Garcia-Martín E, Satué M - Zaragoza*

**F023** Wave-amplitude differences between corneal and conjunctival electrodes for multifocal electroretinogram

*MUNOZ - NEGRETE F J, Rebolleda G, Garcia Garcia A - Madrid*

**F024** Treatment of visual impairment in patients with Leber’s Hereditary Optic Neuropathy (LHON) using Idebenone (Raxone®)

*METZ G, Hasham S, Catarino C, Klopstock T - Liestal*

**F025** Clinical and radiological evidence of meningioma growth due to gestational or exogenous hormones: 2 cases


**F026** Pupillary reaction according to a balance autonomic nervous organ of vision in healthy children

*Bushuyeva N, Dukhayer S, Slobodianyk S - Odessa*

**F027** Paraneoplastic retinopathy and optic neuropathy with Waldenström Macroglobulinemia

*Ozturk N, Havelange V, Draganova D, Boschi A - Bruxelles*

**F028** Eye position under general anesthesia in orthophoric children


**F029** Learning curves for strabismus surgery in two ophthalmologists

*Moosang K - Chuncheon*

**F030** Surgical Effect of Medial Rectus Posterior pulley fixation in Esotropia greater at near fixation

*Choi HY, Jeon H - Busan*
F031 Strabismus in Children with Periventricular leukomalacia: MRI correlation
CHOI HY, Jeon H - Busan

F032 Normal Range of Eye Movement and Its Relationship to Age

F033 Surgical treatment of pediatric strabismus (PS): series of 148 patients
RAHMANIA N, Van Rompay T, Morfeq H, Promelle V, Milazzo S - Amiens

F034 Long term results of concomitant strabismus treatment based on operation preliminary modeling using three-dimensional biomechanical eye model
BUSHUYEVA N, Romanenko D - Odessa

F035 Accommodation and fusion in patients with constant and intermittent exotropia
BOYCHUK I, Aloui T - Odessa

F036 Early childhood blindness – etiologies and comorbidity
LOFGREN S, De Verdier K, Ek U, Fermel E - Stockholm

F037 Symmetric tarsal show is crucial in creating upper eyelid symmetry
DE GROOT V - Edegem

F038 Orbital cellulitis in a child with sickle cell anemia

F039 ROP laser treatment based on fluorescein angiography classification

F040 Normative values of retinal vessel oximetry in healthy children against adults
WAIZEL M, Kazerounian S, Türksever C, Todorova M G - Basel

F041 Evaluation of monotherapy of intravitreal Bevacizumab in retinopathy of prematurity stage 3 plus
SHIRZADEH S - Mashhad

F042 Phakic intraocular lens (Verisyse) implantation for correction of high anisometropia in pediatric patients
AUTRATA R, Krejcirova I, Griscikova L - Brno

F043 Excimer laser correction for myopic anisometric amblyopia in pediatric patients - Long term results
AUTRATA R, Krejcirova I, Griscikova L - Brno

F044 Comparaison of the Plusoptix A12 and the 2WIN with the Retinomax K-plus 3 in a pediatric population
BOUVIER R, Heripret A, Promelle V, Milazzo S - Amiens

F045 Rupture of Descemet's membrane associated with forceps delivery

F046 Congenital aniridia: an epidemiological approach on 105 patients
SALVIAT F, Robert M, Michel S, Bremont-Gignac D - Paris

F047 Does macular pigment optical density really matter in children?
ERKAN TURAN K, Cankaya A B, Teylan Sekeroglu H, Inam O, Karahan S - Ankara
<table>
<thead>
<tr>
<th>Poster ID</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>F048</td>
<td>Unexplained vision loss with intra-ocular silicone oil tamponade in situ; a case series</td>
<td>DE LAEY JJ, BAILLIF S</td>
</tr>
<tr>
<td>F049</td>
<td>Macular hole angle as a surgery prognostic factor</td>
<td>ROCHA DE SOUSA A, SILVESTER A, Cazabon S</td>
</tr>
<tr>
<td>F050</td>
<td>Novel clinical method for preventing condensation in noncontact wide-angle viewing systems</td>
<td>Kwon S, Choi D, Park I, Lee J P</td>
</tr>
<tr>
<td>F052</td>
<td>Late reopening of successfully treated macular holes after combined phaco-vitrectomy</td>
<td>IL MPEEL and gas</td>
</tr>
<tr>
<td>F053</td>
<td>Silicone oil tamponade in the treatment of persistent macular holes</td>
<td>GRAJEWSKI L, Carstens J, Krause L</td>
</tr>
<tr>
<td>F054</td>
<td>Unusual presentation of an intraocular foreign body with double – perforation and retention in lateral rectus muscle</td>
<td>PONOMARENKO M, Lochhead J</td>
</tr>
<tr>
<td>F055</td>
<td>Correlation between intraocular pressure and bottle heights during vitrectomy</td>
<td>MOOSANG K</td>
</tr>
<tr>
<td>F058</td>
<td>Static retinal vessel analysis in routine optometric practice</td>
<td>FRENCH C, Heitmar R</td>
</tr>
<tr>
<td>F059</td>
<td>Trial study to automatically distinguish small haemorrhages in early diabetic retinopathy from image artefacts</td>
<td>SUZUKI N, Yamane K</td>
</tr>
<tr>
<td>F060</td>
<td>Age macular degeneration: clinical, biological, morphologic, structural biomarkers for neovascular complication</td>
<td>GONZALEZ C</td>
</tr>
<tr>
<td>F061</td>
<td>Age macular degeneration: clinical, biological, morphologic, structural biomarkers for atrophy complication</td>
<td>GONZALEZ C</td>
</tr>
<tr>
<td>F062</td>
<td>Retinal astrocytic hamartomas: 2 cases of atypical clinical presentation</td>
<td>BOUTELEUX V, Tick S, El Chehab H, Mendes M, Agard E, Russo A, Dot C</td>
</tr>
<tr>
<td>F064</td>
<td>En-face Imaging of epiretinal membrane using swept source optical coherence tomography</td>
<td>KIM J T, Chung H</td>
</tr>
</tbody>
</table>
**Friday, Oct 7 - Poster session 2**

**POS**

**Retina/Vitreous**

**F048 - F114**

- **Visualization of neovascular changes by swept source OCT angiography**  
  **SZAFLIK J P**, **Szaflik M** - Warszawa

- **En face OCT of uncomplicated angiod streaks**  
  **PERESTRELO S** - Porto

- **Outer retinal reflectivity on En-face OCT as a new tool to detect early stage hydroxychloroquine maculopathy**  
  **VIOTTE A**, **Bigan G**, **Flores M**, **Girard C**, **Delbosc B**, **Saleh M** - Besancon

- **Modern diagnostic methods used in macular telangiectasia**  
  **ROMANOWSKA DIXON B**, **Karska Basta I**, **Lesniak A** - Krakow

- **Ganglion cell-inner plexiform layer thickness and visual improvement after vitrectomy for rhegmatogenous retinal detachment**  
  **LEE JY**, **Kim DY**, **Kim JY** - Jeju-siJeju-do

- **Spectral domain optical coherence tomography for detecting retinal arterial macroaneurysm**  

- **Enhanced visualization of retinal vasculature in fundus images through image processing**  
  **KIMYT**, **Choi S H** - Seoul

- **The effect of center shift on the measurement of macular thickness: A spectral domain optical coherence tomography study**  
  **KIM JY**, **SHIN K S**, **Lim H B**, **Shin I H** - Daejeon

- **Tomographic analysis of the retinal layers in diabetic macular edema treated with dexamethasone intravitreal implant**  
  **MEDEIROS PINTO J**, **Prates Canelas J**, **Rosa R**, **Coelho C**, **Vaz-Pereira S** - Lisbon

- **Deep learning approach for diabetic retinopathy screening**  
  **COLAS E**, **Besse A**, **Orgogozo A**, **Schmauch B**, **Meric N**, **Besse E** - Paris

- **Iluvien monotherapy for diabetic macular oedema in vitrectomised and non-vitrectomised eyes: one year data**  

- **Frequency doubling technology perimetry and retinal fiber layer correlation in type 2 diabetics without retinopathy**  
  **ALDAHAM S**, **Martín-Ridaura M D C**, **Puell M C** - Madrid

- **Diabetic maculopathy screening in England; are we seeing too much?**  
  **BEGUM S**, **Macgregor C**, **Meredith P**, **Cansfield J**, **Meredith S** - Portsmouth

- **Correlation between choroidal and retinal thickness in diabetic patients without diabetic retinopathy**  

- **SD-OCT for study of retinal layers segmentation in patients under Hydroxychloroquine treatment**  
  **COSTA L**, **Basílio A L**, **Proença R**, **Cunha J P**, **Vieira L**, **Flores R**, **Santos A** - Lisbon

- **Vitreous and serum VEGF levels after intravitreal injection of bevacizumab, ranibizumab and triamcinolone acetonide in patients with proliferative diabetic retinopathy**  
  **SOZEN-DELIL F I**, **Cekic O**, **Haklar G** - Istanbul
**POS**

**15:00 - 16:00 | POSTER AREA**

**RV - Retina/Vitreous**

**F048 - F114**

**F081** The change of Ganglion cell layer and Inner plexiform layer thickness in Type 2 DM with non-proliferative diabetic retinopathy

CHOI C., Mun S J - Iksan-si

**F082** Improvement of diabetic macular edema after micropulse laser therapy

EL MATRI L, Falfoul Y., Chebbi Z., Kortti M, El Matri K, Chebil A - Tunis

**F083** Novel OCT prognostic indicators in diabetic macular oedema

MANN R., Begum S., Mourtzoukos S - Portsmouth

**F084** Macular thickness in diabetic eyes without clinical macular edema


**F085** Contribution of wide field angiography to diabetic macular edema


**F086** Peripheral vessel leakage in diabetic retinopathy using Wide field retinal angiography

MAAMOURI R, Bourouai R, Fedra K, Hassaïri A, El Matri L - Tunis

**F087** The predictive value of retinal fixation for the visual outcome after anti-VEGF treatment of diabetic macular oedema with center involvement

STÆHR JAKOBSEN N, Ancher Larsen D, Bek T - Aarhus C

**F088** Selective Retina Therapy (SRT) for diabetes macular edema in Korean patients: 12-months results

PARK Y G, Roh Y J - Seoul

**F089** Comparison of efficacy of intravitreal ranibizumab and aflibercept in eyes with diabetic macular edema

OSHITARI T., Shimizu N, Takatsuna Y, Arai M, Sato E, Yamamoto S - Chiba

**F090** Factors influencing intravitrealBevacizumaband triamcinolone treatment in patients with diabetic macular edema

LEE MY - Uijeongbu-Si

**F091** Incidence of retinal vein occlusions (RVO) in patients treated with oral anticoagulants or antiplatelet drugs for cardioembolic or atherothrombotic prevention

FRUSCHELLI M., Fazio S., Capozzoli M., Chimenti G., Hadjistilianou T., Sicuranza A., Aprili L., Puccetti L - Siena

**F092** Analysis of SD-OCT prognostic factors in macular edema associated with retinal vein occlusion

BOURAOUI R, Bouladi M, Dhouib N, Mghaieth F, Limaïem R, Chaker N, El Matri L - Tunis

**F093** Correlation of foveal bulge on SD-OCT and visual acuity in resolved macular edema associated with branch retinal vein occlusion

BOURAOUI R, Dhouib N, Bouladi M, Zerei N, Maamouri R, Chaker N, El Matri L - Tunis

**F094** Electric shock-induced retinal vein occlusion: a propos of two cases

ASCA SO F J., Bartolomé I., Berniolles J., Esteban O., Martínez M., Almenara C., Sánchez I., Honrubia A., Núñez E. - Zaragoza

**F095** Treatment outcome of switching from ranibizumab to aflibercept in patients with central retinal vein occlusion

KONIDARIS V., Gorgoli K., Burgula S., Deane J., Banerjee S., Empeslidis T - Leicester
**EVER 2016 - programme book**

**Friday, Oct 7 - Poster session 2**

**POS**

**RV - Retina/Vitreous**

**F048 - F114**

**F096**
Relationship between visual outcomes and initial optical coherence tomographic findings in macular edema secondary to branch retinal vein occlusion after bevacizumab treatment
KWONY H, Kim ST, Ahn H - Busan

**F097**
Characteristics of retinal vein occlusion (RVO) patients with macular edema who lasted remission more than 6 months after single injection of intravitreal bevacizumab.
LEE MY - Uijeongbu-Si

**F098**
The 1 year outcome of intravitreal dexamethasone implant for macular edema secondary to central retinal vein occlusion
KIM HW, Chung IY, Lee JE, Kim K - Busan

**F100**
Changes in choroidal thickness after ranibizumab and aflibercept Therapy for treatment-naïve wet age-related macular degeneration

**F101**
Impact of intravitreal bevacizumab injections on perceived quality of life in a cohort of patients with exudative age related macular degeneration. Real life results at 4 years
MONTERO MORENO J A, Arnaiz C, Martinez-Perez L, De la Fuente A, Gonzalez Uruena C - Valladolid

**F102**
Prevalence and incidence of epimacular membranes in patients with wet AMD

**F103**
Spontaneous anatomical improvement on OCT findings in patients with neovascular age-related macular degeneration without anti-VEGF treatment.
KIM K H, Yang S J - Gangneung-siGangwon-do

**F104**
Comparison between Aflibercept, Ranibizumab intravitreal injection on Neovascular Age-related macular degeneration patients
KWONY H, Min J S, Ahn H - Busan

**F105**
Licence to save - A UK survey of anti-VEGF use for the eye in 2015

**F106**
The long-term effect of intravitreal bevacizumab injection in central serous chorioretinopathy
MUN S J, Choi C, Jeong J G - Jeonju

**F107**
Spironolactone in the treatment of nonresolving central serous chorioretinopathy: A comparative analysis
LEE JY, Kim DY, Kim JY - Jeju-siJeju-do

**F108**
Retinal microangiopathy as primary manifestation of systemic lupus erythematosus

**F109**
Ophthalmic findings before carotid endarterectomy in the ipsilateral and contralateral eye

**F110**
Short-term efficacy of intravitreal aflibercept depending on subtypes of polypoidal choroidal vasculopathy: polypoidal choroidal neovascularization or idiopathic choroidal vasculopathy
SAGONG M, Jeong S - Daegu
### Friday, Oct 7 - Poster session 2

**15:00 - 16:00 | POSTER AREA**

**RV - Retina/Vitreous**

**F048 - F114**

<table>
<thead>
<tr>
<th>Post</th>
<th>Title</th>
<th>Authors</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>F111</td>
<td>Vitreous and serum Hsp 70 levels in rhegmatogenous retinal detachment</td>
<td>SOZEN-DELIL F I, Cekic O, Haklar G</td>
<td>Istanbul</td>
</tr>
</tbody>
</table>
Friday, Oct 7 - Second afternoon session

16:00 - 17:30 | RHODES 4
EUPO session 4 - Neuro-ophthalmology
Recognizing the Emergencies: From Symptom to Diagnosis

EUPO Programme, see pages 134-135.
Friday, Oct 7 - Section Business Meetings

16:00 - 16:30
Section Business Meetings

- ACB ................. Gallieni 4
- COS .................. Rhodes 2
- EOVS ............... Rhodes 1
- G ..................... Rhodes 1
- IM .................... Gallieni 1+2
- LC .................... Gallieni 5
- MBGE ................. Gallieni 1+2
- NSPH ................. Rhodes 2
- PBP ................... Rhodes 3
- PO .................... Rhodes 3
- RV ..................... Hermes

**Agenda**

1. Report of the chair of section

2. Report of the programme secretary

3. Next year’s meeting:
   - nomination of the 2017 section programme secretary
     (different from the section chair)
   - proposals of 2017 Special Interest Symposia (SIS)
   - proposals of 2017 Courses
   - proposals for 2018 Keynote speakers

4. Comment on the EVER activities

5. Other business

In addition to the agenda, the sections COS and G will nominate at least 2 candidates for section chair 2017 - 2021
EVER 2016

**Friday, Oct 7 - Second afternoon session**

### 16:30 - 18:00 | HERMES

**FAN Club**

Cases with retinal imaging are presented and discussed with a panel. Each case presentation lasts for 10 minutes with 5 minutes for discussion. This session is open to all EVER delegates. Presenters at this session are welcome to bring a powerpoint presentation of a single interesting case on a USB memory key and load it up in the speakers room.

www.fan-int.org

---

### 16:30 - 18:00 | RHODES 1

**G - Implications of neuro-glial interactions in neurodegenerative diseases**

Retinal neurons rely on oxygen and nutrient supply as well as on the removal of toxic neurotransmitters and metabolites from the interstitial space. The maintenance of this homeostasis depends on tightly regulated neuro-glial interactions. Increasing evidence indicates that neurodegenerative conditions and optic nerve diseases are associated with dysfunctional glial cells leading to neuronal damage. However, the mechanisms that promote and maintain neuro-glial energy exchange are poorly understood. The proposed symposium seeks to create a multidisciplinary discussion on the importance of neuro-glial interaction and its regulation in the pathogenesis of optic nerve, retinal and brain neurodegenerative diseases.

**KOLKO M, WAAGEPETERSEN H**

<table>
<thead>
<tr>
<th>Session</th>
<th>Time</th>
<th>Presentation</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>3621</td>
<td>16:20</td>
<td>Is glutamate dehydrogenase in astrocytes one of the keys to control brain glutamate homeostasis?</td>
<td>WAAGEPETERSEN H - Copenhagen</td>
</tr>
<tr>
<td>3622</td>
<td>16:42</td>
<td>Is neurodegenerative retinal diseases the result of disturbed energy metabolism in Müller cells?</td>
<td>KOLKO M - Roskilde</td>
</tr>
<tr>
<td>3623</td>
<td>17:04</td>
<td>Current neuroprotective strategies in glaucoma – implications of neuro-glial interactions</td>
<td>CORDEIRO M F - London</td>
</tr>
<tr>
<td>3624</td>
<td>17:26</td>
<td>Optic nerve energy metabolism: the role of astrocyte glycogen</td>
<td>RANSOM B - Seattle</td>
</tr>
</tbody>
</table>
### Friday, Oct 7 - Second afternoon session

#### SIS  |  RHODES 2

**COS - Corneal neovascularization and immune privilege**

This SIS provides an overview of current developments in corneal neovascularization, anti-VEGF approaches and molecular mechanisms of the corneal immune privilege.

**HORI J, CHEN L, ZHANG H**

<table>
<thead>
<tr>
<th>Session</th>
<th>Time</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>3631</td>
<td>16:20</td>
<td>New insights into corneal lymphangiogenesis</td>
<td>CHEN L - Berkeley</td>
</tr>
<tr>
<td>3632</td>
<td>16:38</td>
<td>MIRNA-126 regulation in corneal neovascularization</td>
<td>ZHANG H -</td>
</tr>
<tr>
<td>3634</td>
<td>17:14</td>
<td>Molecular mechanisms of immune privilege of the cornea - as a potential of Immune checkpoint therapy</td>
<td>HORI J - Tokyo</td>
</tr>
<tr>
<td>3635</td>
<td>17:32</td>
<td>Corneal neovascularization: clinical aspects and the role of the immune system</td>
<td>BONINI S - Rome</td>
</tr>
</tbody>
</table>

---

#### SIS  |  RHODES 3

**PO: OOG Session 1**

**KIVELÄT, HADJISTILIANOUT**

<table>
<thead>
<tr>
<th>Session</th>
<th>Time</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>3641</td>
<td>16:30</td>
<td>Late intraocular relapses in retinoblastoma</td>
<td>HADJISTILIANOUT, Borri M, Defrancesco S, Munier F, Galluzzi P, Bracco S, Galimberti D, Menicacci F, Coriolani G - Sienna</td>
</tr>
<tr>
<td>3643</td>
<td>16:54</td>
<td>Intraarterial and intravitreal chemotherapy in the combined treatment in children with group C and D intraocular retinoblastoma</td>
<td>SAAKYAN S - Moscow</td>
</tr>
<tr>
<td>3645</td>
<td>17:18</td>
<td>Clinical and morphometric investigation of retinopathy in children with retinoblastoma treated with chemotherapy</td>
<td>SAAKYAN S - Moscow</td>
</tr>
<tr>
<td>3647</td>
<td>17:30</td>
<td>Unravelling the potential of secreted frizzled related protein 3 as a vascular marker</td>
<td>MADIGAN M, Gu R, Gilan P, Eamegdool S - Sydney</td>
</tr>
</tbody>
</table>
OPA is defined as the difference between systolic and diastolic intraocular pressure (IOP) and represents the pulsatile wave front produced by the varying amount of blood in the eye during the cardiac cycle. It is an important parameter in ocular blood flow and has been shown to vary be able to provide information concerning the autonomic nervous system input. Furthermore, it can be influenced by the structural properties of the eye, such as corneal thickness, and ocular rigidity, as well as with systemic variables like heart rate, blood pressure, and left ventricular ejection fraction.

The concept of this course is to provide the audience with a oriented review of the current data on OPA, its physiological meaning and how we measure it. The strenghts and caveats of the measurement of this parameter will be discussed as well as the potential of translating this information into clinical practice.

**ABEGAO PINTO L, MARQUES-NEVES C**

<table>
<thead>
<tr>
<th>Session</th>
<th>Time</th>
<th>Title</th>
<th>Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>3661</td>
<td>16:20</td>
<td>Fundamental principals and applied biophysics</td>
<td>MARQUES-NEVES C - Lisbon</td>
</tr>
<tr>
<td>3662</td>
<td>16:42</td>
<td>OPA analysis - oscillatory and autonomic influence</td>
<td>SCHMIDL D - Vienna</td>
</tr>
<tr>
<td>3663</td>
<td>17:04</td>
<td>Physiology and clinical relevance of this parameter</td>
<td>ABEGAO PINTO L - Lisbon</td>
</tr>
<tr>
<td>3664</td>
<td>17:26</td>
<td>Use of OPA in ocular blood flow studies</td>
<td>WILLEKENS K, Van Keer K, Vandewalle E, Molenberghs G, Pinto L A, Barbosa-Breda J, Stalmans I - Leuven</td>
</tr>
</tbody>
</table>

**HERBORT CP, NERI P**

<table>
<thead>
<tr>
<th>Session</th>
<th>Time</th>
<th>Title</th>
<th>Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>3671</td>
<td>16:30</td>
<td>EDI-OCT is less suited for close monitoring of primary stromal choroiditis when compared to Indocyanine green angiography</td>
<td>HERBORT C P, Balci O, Gasc A, Jeannin B - Lausanne</td>
</tr>
<tr>
<td>3672</td>
<td>16:42</td>
<td>Analysis of choroidal folds in Acute Vogt-Koyanagi-Harada disease using high-penetration optical coherence tomography</td>
<td>NAKAI K, Tsuboi K - Osaka</td>
</tr>
<tr>
<td>3673</td>
<td>16:54</td>
<td>Comparison of retinal and choroidal involvement in sarcoidosis chorioretinitis</td>
<td>EL AMEEN A, Herbolt C P - Evian</td>
</tr>
<tr>
<td>3674</td>
<td>17:06</td>
<td>Contribution of dual fluorescein and indocyanine green angiography to the appraisal of posterior involvement in birdshot retinochoroiditis and Vogt-Koyanagi-Harada disease</td>
<td>BALCI O, Jeannin B, Herbolt C P - Istanbul</td>
</tr>
</tbody>
</table>
Severe allergic conjunctivitis in children may be severe causing loss of quality of life and visual impairment. Vernal keratoconjunctivitis and atopic keratoconjunctivitis are rare diseases but must be distinguished because of their evolution. Imaging of these diseases and systemic treatment are reviewed and developed. An overview of the innovating diagnosis, new imaging techniques and treatment are summarized for a better comprehension of severe allergic ocular surface diseases.

**BREMOND-GIGNAC D, FAUQUERT J**

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:20</td>
<td>Atopic and vernal keratoconjunctivitis: differences and similarities</td>
<td>BREMOND-GIGNAC D - Paris</td>
</tr>
<tr>
<td>16:50</td>
<td>Imaging of allergic keratoconjunctivitis</td>
<td>CHIAMBARETTA F - Clermont Ferrand</td>
</tr>
<tr>
<td>17:20</td>
<td>Non-ocular treatments in ocular allergy</td>
<td>DELGADO L - Porto</td>
</tr>
</tbody>
</table>
Friday, Oct 7 - General Assembly

18:00 - 18:30 | Hermes
EVER General Assembly

1. President’s address by Aki Kawasaki
2. Minutes of the General Assembly 2015
3. Report of the Secretary General, Catherine Creuzot
4. Report of the Programme Secretary, Marcela Votruba
5. Report of the Treasurer, Steffen Heegaard:
   - approval of the accounts 2015
   - discharge to the directors
   - approval budget for 2016
6. Results of the elections
7. Presentation of the board 2017
8. Future congresses
9. Miscellanea
10. Handover of chain of office
EVER 2016
Saturday, Oct 8
**EVER 2016**

**Saturday, Oct 8 - First morning session**

### HERMES

**NSPH/RV - The first ones in ophthalmology**

This symposium will provide fascinating new insights into the first described case of some ophthalmological diseases and some of the great innovators and pioneers in diagnostic and therapeutic advances in Ophthalmology. This particular look to the history of our specialty begins with a paleopathological study of traumatic and infectious evidences of what seems to be the first documented case of orbital cellulitis in one the most complete and best preserved ancient hominid skulls ever found. The practice of Ophthalmology has a rich history that spans a lot of centuries. Since the first use of plants or surgery in the civilizations of the Fertile Crescent, the important discoveries have been generally simple, and one is apt to wonder why they were not made earlier. Then, we explore the beginnings of two important diagnostic imaging techniques: fluorescein angiography and ultrasonography. Finally, we include another example of historical interest: Charles-Michel Billard, the founder of Neonatology and an international figure in the field of Ophthalmology.

**GRZYBOWSKI A, ASCASO F**

**4111** 8:30  Homo heidelbergensis: the oldest case of odontogenic orbital cellulitis?  
ASCASO F, Adiego M I - Zaragoza

**4112** 8:48  The first cataract surgery  
GRZYBOWSKI A - Olsztyn

**4113** 9:06  The first steps in retinal angiography  
DE LAEY J - J - Gent

**4114** 9:24  The firsts in ophthalmic echography  
KIVELÄ T - Helsinki

**4115** 9:42  Charles-Michel Billard (1800-1832), the founder of neonatology and ophthalmology  
FRANCESCHETTI A - Meyrin

### RHODES 1

**COS - Keratoconus diagnosis and treatment in the clinical practice**

The applicability of treatment options for keratoconus and the prognosis of functional outcome and freezing of progression is mainly determined by the stage/severity of the disease. In early stages contact lenses are a viable option for visual rehabilitation, whereas progressed stages may require specialized rigid gas permeable contact lenses or keratoplasty. New options such as crosslinking and intracorneal ring segments aim to retard or even stop progression. However, they require a minimum of residual stromal thickness. Therefore, screening and early diagnosis of keratoconus is key in order to timely react with therapeutic options. Corneal topography and tomography as well as the assessment of corneal biomechanical properties are established tools for diagnosis of early keratoconus and a variety of indices are available assisting the ophthalmologist in keratoconus diagnosis. We will discuss the topographic, tomographic and biomechanical features of keratoconus, how keratoconus indices could assist clinical diagnosis and how keratoconus can be distinguished from other corneal conditions. In addition, we show the application of corneal tomography in the monitoring of corneal stabilization after crosslinking.

**SZENTMARY N, ZSOLOT NAGY Z**

**4121** 8:30  Central keratoconus and bilateral asymmetry of keratoconus  
LANGENBUCHER A, Szentmary N, Eppig T - Homburg

**4122** 8:48  Interpretation of keratoconus indices  
EPPIG T, Spira-Eppig C, Szentmáry N, Langenbucher A - Homburg/Saar

**4123** 9:06  Keratoconus, keratoglobus, keratotorus and pellucid marginal degeneration  
SZENTMARY N - Homburg/Saar

**4124** 9:24  Relevance of the posterior corneal surface for detection of early keratoconus and post-LASIK keratectasia  
WYLEGALA E - Katowice

**4125** 9:42  Corneal tomographical changes following crosslinking  
ZSOLOT NAGY Z - Budapest
Acanthamoeba keratitis, infectious crystalline keratopathy, fungal keratitis and atypical mycobacterial keratitis have emerged as important types of infectious keratitis. These corneal infections have often been associated with contact lens wear, with corneal surgery such as radial keratotomy or penetrating keratoplasty and with the uncontrolled use of topical steroids. The clinical setting of each of these infections is important in alerting the clinician to the possible diagnosis. There have been improvements in rapid diagnostic techniques for such infections in the last years. Treatment has also improved, but remains a difficult problem, especially for Acanthamoeba. In this course, we’ll give you an overview of recent developments in the clinical and histopathologic methods for diagnosis and treatment options of these corneal infections. We will also see how new techniques such as Amniotic Membrane Transplantation and Crosslinking can help the clinician, when facing severe cases.

**GICQUEL JJ, BREMOND-GIGNAC D**

**4131** 8:30  New breakthrough in severe corneal infections: GMA, cross linking

GICQUEL J - Saint Jean d’Angély

**4132** 9:00  Specificities of corneal infectious diseases in children

BREMOND-GIGNAC D - Paris

**4133** 9:30  Prevention of Herpes and Zoster keratitis

LABETOLLE M, Rousseau A - Le Kremlin Bicêtre

---

**8:30 - 10:00 | RHODES 3**

**PO: OOG Session 2 & Business Meeting**

**HEEGAARD S, CASSOUX N**

**4141** 8:30  BAP1 germline mutations in uveal melanoma patients without family history of eye cancer


**4142** 8:42  Chromosomal aberration predict uveal melanoma mutation status

KILIC E, Yavuzyligitoglu S, Drabarek W, Obulkasim A, Brands T, Eussen B, De Klein A - Rotterdam

**4143** 8:54  Inflammatory Cell Infiltrates in Metastatic Uveal Melanoma

KRISHNAY, McCarthy C, Kalirai H, Coupland S - Liverpool

**4144** 9:06  Histomorphological changes of uveal melanoma (UM) following proton beam therapy (PBR)

OURESHI S, Hussain R, Kalirai H, Heimann H, Coupland S - Liverpool

**4145** 9:12  UM Cure 2020 - A Consortium of European experts in Uveal Melanoma to identify new therapies for patients with metastatic disease


**9:18**  Business meeting
8:30 - 10:00 | EUPO session 5 - Strabismus
Paralytic Strabismus: Diagnosis, Evaluation and When to Treat

EUPO Programme, see pages 134-135.

8:30 - 10:00 | GALLIENI 1+2
FRO: Belgian Fund for Research in Ophthalmology 1

**TASSIGNON MJ, CASPERS L**

| **4161** | 8:30 | Neuroinflammation as fuel for axonal regeneration: unravelling the underlying molecular players |
| **ANDRIES L** - Leuven

| **4162** | 8:42 | Metabolomic profile of surgical glaucoma patients |
| **BARBOSA BREDA J** - Porto

| **4163** | 8:54 | The interplay between dendrite and axon regeneration in central nervous system repair: which way to grow? |
| **BECKERS A** - Leuven

| **4164** | 9:06 | Enhanced donor selection in the treatment of LSCD using advanced imaging techniques |
| **BEHAEGEL J** - Brussels

| **4165** | 9:18 | Intravitreal injection of mRNA containing nanoparticles to introduce sustained expression of neurotrophic factors in Müller cells |
| **DEVOLDERE J** - Ghent

| **4166** | 9:30 | Tissue engineering in Ophthalmology: Regenerating the anterior cornea using synthetic collagen-mimicking nanoscaffolds and Limbal Epithelial Stem Cells |
| **HAAGDORENS M** - Edegem

| **4167** | 9:42 | Role ofTonEBP in the inflammatory response of ARPE-19 cells subjected to hyperosmolar stress |
| **MASSET M** - Bruxelles

| **4168** | 9:54 | 3D printed recombinant human collagen scaffolds for corneal tissue engineering: an in vivo study of biocompatibility |
| **MATTHYSSEN S** - Edegem
Ophthalmic Research Lecture by Marie-José TASSIGNON

Introduction by José CUNHA-VAZ

4211
The cataract surgeon and the anterior interface

TASSIGNON MJ - Antwerpen

Summary:
Performing a posterior capsulorhexis on a routine basis related to the implantation of the bag-in-the-lens IOL has opened new frontiers in helping understanding the Berger space and its relation with the vitreous. It is only recent that this space could be observed live during surgery thanks to new OCT devices. This observation may open new understandings on the pathogenesis of vitreo-retinal complications after cataract surgery.

Award presentation of the EVER Certificate of Honour

Biography Marie-José TASSIGNON:

Marie-José Tassignon is born in 1952 in the French speaking part of Belgium. She was raised in French by her father and in Dutch by her mother. She completed her studies of medical doctor at the Free University of Brussels. She defended her PhD thesis in Leiden, The Netherlands, in 1990 and was appointed Chief of the Department of Ophthalmology of the Antwerp University Hospital and Chair of the Department of Ophthalmology of the Faculty of Medicine of the University of Antwerp in 1991. In 2007 she became Medical Director of the Antwerp University Hospital after having been Vice-Dean of the Faculty of Medicine of the University of Antwerp from 2003 to 2006. She is full professor at the University of Antwerp since 2003 and closely implicated in the national trainees educational program.

She was president and past-president of the European Society of Cataract and Refractive Surgeons (ESCRS) from 2004 until 2007 and was president and past-president of the European Board of Ophthalmology (EBO) from 2007 until 2008. She is member of 18 international societies in ophthalmology and was board member in 5 out of them. She was elected chair “L” of the International Academy of Ophthalmology (AOI) in 2007 and was elected chair “V” of the European Academy of Ophthalmology in 2008. She became Alumni of Pretoria University of South Africa in 2008 and full member of the Ukraine Academy of Medicine in 2012. She became member of the Royal Academy of Medicine of Belgium in 2009. She became boardmember of the International Council of Ophthalmology in 2016.

Seven patents have been approved out of which the patent of the original lens design called the bag-in-the-lens implantation technique and the caliper ring to perform a calibrated anterior capsulorhexis. This lens has been commercialized in Belgium in 2004 and is currently on its way to be accepted worldwide as technique to eradicate posterior capsule opacification. This technique has attracted quite some international ophthalmic surgeons as well as pediatric cataract surgeons to Antwerp since it eradicates the occurance of PCO in all patients regardless the age of surgery. It is also very attractive for vitreo-retinal surgeons because it keeps the visual axis free and is also attractive for complex optics intraocular lenses since it allows customized IOL centration.

Marie-José Tassignon was awarded the Kritzinguer award in 2003; the Binkhorts medal at ESCRs in 2011; the Norman Galloway award, Nottingham University, United Kingdom in 2014, the Academia Ophthalmologica Internationalis lecturer 2015; the Peter Eustace medal 2015 by European Board of Ophthalmology for excellence in education; the Montgomery lecture at the Royal College of Surgeons delivered by the Irish Council of Ophthalmology in 2015; the Tadeusz Krzawicz award at WOC 2016 and the Moroccan Ophthalmological award in 2016. She was honorary guest at the 27th International Congress of German Ophthalmic Surgeons, DOC in Nürnberg and guest professor at Michigan Eye Kellog’s University in 2013 and at Harvard Massachusetts Eye and Ear in 2014. She received three best paper awards at ASCRS and five best video awards at videorefractive, ESCRs and WOC. Marie-José Tassignon is author of 248 publications and of 23 chapters of 21 books but she is primarily mother of two children and grandmother of three grandchildren to date.
Saturday, Oct 8 - Second morning session

10:30 - 12:30 | RHODES 4

**EUPO session 6 - Strabismus**

*Case Presentations I: Odd and Unusual Things in Strabismus Amblyopia, Nystagmus and Secondary Strabismus*

EUPO Programme, see pages 134-135.
PETROVSKI G, KAARNIRANITA K

S001
Resvega induces autophagy and prevents ARPE-19 cell damage during proteasome inhibition

S002
Taking a roller coaster ride with autophagy markers p62 and LC3
KOSKELA A, Reinisalo M, Kaarniranta K - Kuopio

S003
Warfarin use among wet AMD patients

S004
Melissa officinalis L. extracts protect human retinal pigment epithelial cells against oxidative stress-induced apoptosis.
KANG S, Shin J A, Oh J, Rho C R - Daejeon

S005
Possible association with obesity-related loci and outcome of wet AMD

S006
HuR/ELAVL1 expression in the human cataractous lens
AMADIO M, Marchesi N, Govoni S, Pascale A, Petrovski G - Pavia

S007
SMA+perivascular cells evaluation in VEGF induced blood-retinal barrier breakdown in rabbit model
GRILLO-ANTONELLI S, Mauro V, Cimbolini N, Feraille L, Elena P P - La Gaude

S008
Blepharospams treated with eyelid suspension: long term follow up and outcomes
LATHIERE T, Robert P Y, Adenis J P - Limoges

S009
Unexpected orbital swelling after injection of hydrogel self inflating expanders
GRIVET D, Ronin C, Boutet C, Thuret G, Gain P - Saint-Etienne

S010
Surgical outcome of minimal resection with full thickness rotating suture technique for lower lid epiblepharon
Jeong H C, Sohn E J, Kwon Y H, AHN H - Busan

S011
Nasolacrimal duct reconstitution with radiofrequency: case report

S012
The digital slide scanner applied to the ocular anatomopathology
KASPI M, Grivet D, Forest F, Douchet C, Dumollard J M, Peoc’h M, Thuret G, Gain P - Saint Priest en Jarez

S013
Measuring scleral thickness with optical coherence tomography in osteogenesis imperfecta: a case report

S014
Comparison of the retinal measurements of standard and neurological SD-OCT applications in MS patients
PATERNO J J, Kaarniranta K - Kuopio

S015
Fate of donor sclera used to lengthen extraocular muscle in a rabbit model of strabismus surgery
CONDE C, Lindström M, Pedrosa Domellöf F - Umeå

S016
A new method of exophthalmometry
AFANASYEVA D, Gushchina M, Borzenok S - Moscow
| S017  | Thickness of chorioretinal complex in the fovea in teenagers with myopia  
BOYCHUK I, Shebil S, Ivanickaya E - Odessa |
|-------|----------------------------------------------------------------------------------|
| S018  | An investigation of the correlation between functional and structural changes in tilted and non-tilted high myopic eyes  
EHSAEI A, Moghadas Sharif N, Shoelbi N - Mashhad |
| S019  | Reflectometric analysis of normal and ex-premature foveal microstructure in SD-OCT images - a comparison to image analysis using directional OCT and manual segmentation  
SJOSTRAND J, Rosén R, Nilsson M, Popovic Z - Mölnadal |
| S020  | Comparative analysis of the morphometric parameters of the macular area of the retina in patients with refractive, axial, mixed and combined types of myopia  
BUSHUYEVA N, Maliieva O - Odessa |
| S021  | Manufacturing of an ocular prosthesis based on the 3D printed anophthalmic socket  
RUITERS S, Sun Y, De Jong S, Politis C, Mombaerts I - Leuven |
10:50 - 12:00 | POSTER AREA

COS - Cornea/Ocular Surface

S022 - S064

GICQUEL J, FUCHSLUGER

**S022**  
Surface chemistry of the interactions of cationic nanoemulsions with human meibum films  
DAULL P, YokoI N, Nencheva Y, Georgiev GA - Evry

**S023**  
Peter’s anomaly in twins: a rare incidence with novel associations  

**S024**  
Severe ocular manifestations of rosacea in adult  

**S025**  
Pollen count compared with severity of symptoms and signs of dry eye disease in Norway  

**S026**  
Graft functionality after DSAEK surgeries in Denmark from 2006 to 2009  

**S027**  
Erroneous measurement of the intraocular pressure with the goldmann aplanation tonometry in fuchs endothelial corneal dystrophy  

**S028**  
Peripheral refraction and retinal contour after FS-LASIK and orthokeratology  
TARUTTA E, Khodzhabekyan N, Khandzhyan A, Milash S - Moscow

**S029**  
A new approach of presbyopia over a myopic population: PresbyLASIK using the myopic SUPRACOR Algorithm (preliminary results about 12 eyes)  

**S030**  
Clinical evaluation of oculus keratograph corneal topographer in normal population  
EHSAEI A, Yazdani N, Ostadimoghadam H, Shahkarami L - Mashhad

**S031**  
The prospects of using the radiation for the assessment of corneal and scleral hydration  
IOMDINA E N, Seliverstov S, Sianosyan A, Teplyakova K, Rusova A, Goltsman G - Moscow

**S032**  
Comparison of MyoRing implantation with corneal collagen cross-linking in different combination for keratoconus treatment  
KAZAKBAEVA G, Bikbov M, Usubov E - Ufa

**S033**  
The evaluation of intrastromal MyoRing implantation with corneal collagen cross-linking in keratoconus treatment  
KAZAKBAEVA G, Bikbov M, Usubov E - Ufa

**S034**  
Assessment of postoperative corneal healing after epithelium-off cross-linking with a regenerating agent in progressive keratoconus patients  

**S035**  
Tree years outcomes of small incision lenticule extraction: mild to moderate myopia vs. high myopia  
KIM J R - Seoul

**S036**  
Electrospun polymer nanofibers as substrate/carrier for engineering of human corneal epithelium  
MOMTIZI L, Shahdadfar A, ZellThime H, Noer A, Nilsen O, Eidet J R - Oslo

**S037**  
Novel molecular design of culture substrates with amino acids  
MOMTIZI L, Shahdadfar A, ZellThime H, Noer A, Nilsen O, Eidet J R - Oslo
<table>
<thead>
<tr>
<th>S038</th>
<th>DNA damage in human limbal epithelial cells expanded ex vivo</th>
</tr>
</thead>
<tbody>
<tr>
<td>LORENZO CORRALES Y, Haug Berg K, Noer A, R. Collins A, Nikolaisen B - Oslo</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>S039</th>
<th>The effect of culture medium and carrier on explant culture of human limbal epithelium: a comparison of ultrastructure, keratin profile and gene expression</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pathak M, Olstad O K, Drolsum L, Moe M C, Katerina J, Nikolaisen B, NOER A - Oslo</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>S040</th>
<th>The effect of silica nanoparticle exposure on cultured human keratocytes</th>
</tr>
</thead>
<tbody>
<tr>
<td>YIM B, Park J, Park CY - Goyang-siGyeonggi-do</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>S041</th>
<th>Development of novel electrospun scaffolds for corneal tissue engineering</th>
</tr>
</thead>
<tbody>
<tr>
<td>KADOR K, Ahearne M - Dublin</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>S042</th>
<th>Ex-vivo porcine corneal storage using an innovative bioreactor</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>S043</th>
<th>OCT spectra for terrien marginal degeneration diagnosis</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>S044</th>
<th>AS-OCT utility for corneal lacerations in pediatric patients</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>S045</th>
<th>Terrien marginal degeneration presenting with corneal perforation</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>S046</th>
<th>Possible misdiagnosis of patients with ocular trauma in a Danish emergency room without ophthalmic assistance. A retrospective cohort study of 1824 patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>JAKOBSEN T M, Møller F, Storr-Paulsen T - Vejle</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>S047</th>
<th>Corneal perforation during laser assisted blepharoplasty</th>
</tr>
</thead>
<tbody>
<tr>
<td>LEE S, Moon D, Kang H - Daegu</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>S048</th>
<th>Management of acute corneal hydrops in keratoconus with pre-Descemet’s membrane sutures</th>
</tr>
</thead>
<tbody>
<tr>
<td>BREHON A, Stephan S, Nguyen Kim P, Cochereau I, Gabison E - Saint-Priest en Jarez</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>S049</th>
<th>Potential of High resolution Gabor-Domain optical coherence microscopy for early diagnosis of corneal disease</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>S050</th>
<th>Corneal imaging and densitometry measurements to monitor fuchs progression and treatments outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALZAHRANI K, Carley F, Brahma A, Morley D, Hillarby M C - Manchester</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>S051</th>
<th>Evaluation of the eyelid disorders in the daily ophthalmic practice in 9 European Countries: The MEIBUM® survey</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>S052</th>
<th>Semi-fluorinated alkanes for topical delivery of Cyclosporine</th>
</tr>
</thead>
<tbody>
<tr>
<td>AGARWALL P, Scherer D, Günther B, Rupenthal I - Auckland</td>
<td></td>
</tr>
<tr>
<td>S053</td>
<td>Effects of TRPM8 and TRPV1 agonists on the neural activity of corneal cold thermoreceptors in tear-deficient guinea pigs</td>
</tr>
<tr>
<td>S054</td>
<td>Caciclo® – neurotrophic keratopathy in systematic review</td>
</tr>
<tr>
<td>S055</td>
<td>Regression of corneal neovascularization associated with corneal epithelial defect after treatment with regenerating agents (Caciclo®)</td>
</tr>
<tr>
<td>S056</td>
<td>Management and treatment of contact lens keratitis</td>
</tr>
<tr>
<td>S057</td>
<td>Topical N-acetylcystein on patients with refractory filamentary keratitis</td>
</tr>
<tr>
<td>S058</td>
<td>Comparison of autologous platelet-rich plasma with autologous serum eye drop in corneal epithelial disorder</td>
</tr>
<tr>
<td>S059</td>
<td>Free living amoebae (FLA) keratitis</td>
</tr>
<tr>
<td>S060</td>
<td>Case of conjunctival amyloidosis with repeated subconjunctival hemorrhages</td>
</tr>
<tr>
<td>S061</td>
<td>Osmoprotective activity of alpha-lipoic acid and taurine on hyperosmolar stress in cultured human corneal and conjunctival epithelial cells</td>
</tr>
<tr>
<td>S062</td>
<td>Taurine exerts antioxidant and osmoprotecting activity: an in vitro and in vivo study</td>
</tr>
<tr>
<td>S063</td>
<td>The effect of silica nanoparticles on human corneal epithelial cells</td>
</tr>
<tr>
<td>S064</td>
<td>Subgroup analysis of two phase III studies of 0.1% cyclosporine A cationic emulsion (CsA CE) in patients with dry eye disease</td>
</tr>
</tbody>
</table>
NERI P, DICK A

**S065**  Macular OCT features in eyes with VKH disease  
DIWO E, Stoykova V, Massamba N, Le Hoang P, Bodaghi B - Paris

**S066**  Evolution of spectral-domain optical coherence tomography images in an acute stage of Vogt-Koyanagi-Harada disease  

**S067**  Changes of central macular thickness and retinal nerve fiber layer thickness in eyes with Vogt-Koyanagi-Harada disease: a 2-year follow-up study  
SHIN K S, Han Y S, Kim M S, Kim JY - Daejeon

**S068**  Ocular manifestations in dengue fever  
REMOND A L, Butel N, Fardeau C, Errera M H, Le Hoang P, Bodaghi B - Paris

**S069**  Evaluation of choroidal changes in patients with ocular toxoplasmosis using spectral domain optical coherence tomography  
AKPOLAT C, Murat M, Celebi N - Istanbul

**S070**  Ocular candidiasis in intravenous drug misusers  
LAM D, Belazzougui R, Fardeau C, Touitou V, Le Hoang P, Edel Y, Bodaghi B - Paris

**S071**  In vitro activity of Cacicol® on herpes simplex virus type 1: a promising adjunct therapy of herpetic corneal infections?  
LABETOULLE M, Rousseau A, Breckler M, Molet L, Boutouille D, Burrel S, Deback C - Le Kremlin Bicêtre

**S072**  Modern aspects of demodex blepharitis treatment  
Rykov S, PETRENKO O, Shargorodskaya I - Kyiv

**S073**  Unilateral painful external ophthalmoplegia as the first manifestation of combined anterior and posterior scleritis  
LÖFGREN S, ERCAL N

**S074**  
Comparison of several transport activities of lens epithelial cells from cataract and healthy dog  
OCHIAI H - Sagamihara Kanagawa

**S075**  
Exposure to subthreshold dose of UVR-B induces apoptosis in the lens epithelial cells and does not in the lens fiber cells  
GALICHANIN K, Yu Z, Talebizadeh N, Burmakin M, Söderberg P - Uppsala

**S076**  
Prevention and reversal of selenite-induced cataracts by N-acetylcysteine amide in Wistar rats  
Maddirala Y, Tobwala S, Karacal H, ERCALL N - Rolla

**S077**  
A dual therapeutic approach for the reversal of cataracts  
Beltz J, Pfaff A, ERCALL N - Rolla

**S078**  
Human anterior lens epithelium in presenile cataract- scanning and transmission electron microscopy study  
ANDJELIC S, Drašlar K, Hvala A, Hawlina M - Ljubljana

**S079**  
Composition of phacoemulsificated human lenses analyzed by infrared spectroscopy  
CHANIECKI P, Miszczyk J, Rekas M, Paluszkiewicz C - Krakow

**S080**  
Ocular tolerance in rabbits of intracameral administration of Mydramine, a fixed combination of tropicamide, phenylephrine, and lidocaine for cataract surgery  
OLMIERE C, Viaud-Quentric K - Clermont-Ferrand

**S081**  
Weill-Marchesani syndrome: displaced lens, displaced pupil, displaced diagnosis  
HUSSAIN N, Jeyabaladevan S, Macapagal M, Tumbocon J - Kingston upon Thames SURREY

**S082**  
Comparison of visual and refractive outcomes after implantation of a new diffractive trifocal toric lens, a trifocal lens and a monofocal toric lens  
MARECHAL M, Delbarre M, Beriguia M, Rambaud C, Benisty D, Charpentier S, Timsit A, Froussart-Maille F - Clamart

**S083**  
Clinical features of cataract extraction with negative power intraocular lens implantation in high myopia patients  
CHOI J B, SHIN W B, Kim M K - SEOUL

**S084**  
Implantable Collamer Lens to treat high myopia: efficiency and safety  

**S085**  
Outbreak of fungal endophthalmitis following cataract surgery  
MOON D, Lee S, You Y, Lee D - DAEGU

**S086**  
Eleven year review of risk factors and visual outcomes of patients with posterior capsule rupture (PCR) as a complication of cataract surgery at a district general hospital  
BEGUM S, Penwarden A, Saunders D, Balendra S I, Schulz C, Hunter M - PORTSMOUTH
10:50 - 12:00 | POSTER AREA
PO - Pathology/Oncology
S087 - S110

JAGER MJ, VAN GINDERDEUREN R

S087 rf BAP1 germline mutations in uveal melanoma patients without family history of eye cancer

S088 rf DNA methylation patterns in Uveal Melanoma derived FFPE samples correlate with survival
NESS C, Grüner C C, Meza Zepeda L, Moe M C, Noer A - Oslo

S089 rf Electroporation enhances chemosensitivity of uveal melanoma cells
FIorentzis M, Katopodis P, Kalirai H, Seitz B, Viestenz A, Coupland S E - Liverpool

S090 rf Uveal melanoma clonogenic response to proton beam irradiation
ROMANOWSKA DIXON B, Jasinska K, Michalik M, Madeja Z, Urbanska K, Elas M - Krakow

S091 rf Histomorphological changes of uveal melanoma (UM) following proton beam therapy (PBR)
QURESHI S, Hussain R, Kalirai H, Heimann H, Coupland S - Liverpool

S092 rf UM Cure 2020 - A consortium of European experts in uveal melanoma to identify new therapies for patients with metastatic disease

S093 rf Choroidal nevi classification using swept source optical coherence tomography and infrared reflectance patterns at different wavelengths

S094 rf Wide-field autofluorescence and scanning laser ophthalmoscopy: a tool for differential diagnosis of intraocular tumors
ESPOSTI G, Denaro R, Hadjistilianou T, Chimenti G, Esposti P L - Siena

S095 rf Transpalpebral near-infrared LED transillumination for anteriorly located intraocular tumors imaging
ZADOROZHNYY O, Korol A, Kustryn T, Nasinnyk I, Pasytechnikova N - Odessa

S096 rf The role of anterior segment optical coherence tomography (AS-OCT) and ultrasound biomicroscopy (UBM) in conjunctival nevi
LAUWERS N, Janssens K, Mertens M, De Keizer R J W, De Groot V - Edegem

S097 rf Clinical and morphometric investigation of retinopathy in children with retinoblastoma treated with chemotherapy
SAAKYAN S - Moscow

S098 rf Congenital malignant ciliary body medullipithelioma in two newborns
HADJISTILIANOŬT, Mittica P, Bagaglia S, Fruschelli M, Menicacci C, Fusco F, Defrancesco S, Borri M, Galluzzi P - Sienna

S099 rf Proton beam radiotherapy (PBR) for the treatment of retinal capillary haemangioblastoma

S100 rf Management strategies in vasoactive proliferative tumor of the retina
TUNC M - Ankara

S101 rf Intravitreal bevacizumab as an adjuvant treatment of choroidal metastasis
COSTA J, Braga J, Neves F, Meira D, Ribeiro L - Vila Nova de Gaia
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors, Affiliations</th>
</tr>
</thead>
<tbody>
<tr>
<td>S102</td>
<td>Primary intraocular lymphoma and flow cytometry analysis of the vitreous – a case report</td>
<td>ROMANOWSKA DIXON B, Karska Basta I, Kubicka-Trzaska A - Krakow</td>
</tr>
<tr>
<td>S104</td>
<td>Clinical and instrumental diagnostics in patients with orbital metastasis</td>
<td>SAAKYAN S - Moscow</td>
</tr>
<tr>
<td>S105</td>
<td>An analysis of IgG4-related ocular disease among idiopathic orbital inflammations and mucosa-associated lymphoid tissue lymphoma</td>
<td>Sohn E J, Roh M S, Kwon Y H, AHN H - Busan</td>
</tr>
<tr>
<td>S106</td>
<td>Orbital mucocoele: Orbital Masquerading Syndrome</td>
<td>TUNC M - Ankara</td>
</tr>
<tr>
<td>S107</td>
<td>First cases of ocular dirofilariasis caused by drofilaria repens in Belgium</td>
<td>SMETS M, De Potter P - Bruxelles</td>
</tr>
<tr>
<td>S108</td>
<td>Grading iris color of post-mortem human eyes</td>
<td>MADIGAN M, Cionaca V, Sitiwin E, Ton HT - Sydney</td>
</tr>
</tbody>
</table>
Women 4 EVER wishes to assist women in developing tools for career advancement and to foster gender equality in ophthalmology and visual science. We encourage mentorship, collaboration, and communication. In this informal and open session, we invite all interested members of EVER to come and meet colleagues, share experiences and ask for advice. It is also a venue where ideas about gender-based studies in ophthalmology may be developed.

CREUZOT C

13:00 Combined family life and ophthalmic oncology career
VAN GINDERDEUREN R, Leuven

13:30 Combining immunology, ophthalmology and personal life in Finland
KAUPPINEN A, Kuopio

14:00 Discussion

COS - Pseudophakic and phakic toric implants – from preoperative examination

Toric intraocular lenses (tIOL) are either implanted in the capsular bag in a regular cataract surgery or used as phakic or pseudophakic add-on tIOL in a refractive surgery procedure for correcting spherocylindrical refraction or for fine-tuning of refraction after cataract surgery. First, detailed clinical and instrument assisted diagnostics have to be performed for a proper indication as well as for calculating tIOL power. In this SIS we will discuss the diagnostic modalities such as corneal tomography and guide how to interpret the instrument data and how to derive a proper indication from clinical and instrument-based exams. In a next step, different options for calculating phakic and pseudophakic tIOL are shown and the calculation scheme is applied to clinical examples. In addition, we present an overview on WEB calculation platforms. In a next step, the peri- and intraoperative details of tIOL surgery is shown from axis marking to a proper positioning of the lens in the eye and axis alignment. In a last step, we show how to monitor the patient in the follow-up period and give advice for troubleshooting and how to deal with potential complications such as re-adjustment of the cylinder axis after rotation of the tIOL.

LANGENBUCHER A, SZENTMARY N, EPPIG T

4421 13:00 Spectrum of indications, patient selection, options for astigmatic corrections, pre- and postoperative patient care
SZENTMARY N - Homburg/Saar

4422 13:18 Instrument assisted diagnostics – biometry, topography and wave-front analysis
EPPIG T, Spira-Eppig C, Szentmary N, Langenbucher A - Homburg/Saar

4423 13:36 How to calculate pseudophakic and phakic toric implants?
LANGENBUCHER A, Szentmary N, Eppig T - Homburg

4424 13:54 Intraoperative optical coherence tomography (iOCT) assisted positioning of toric lens implants
WYLEGALA E - Katowice

4425 14:12 Surgical aspects of toric lens implantation and complication management
BARRAQUER R I - Barcelona
### COS - Maximising success in deep anterior lamellar keratoplasty

The most popular technique for deep anterior lamellar keratoplasty (DALK) is the ‘big bubble’ (BB) technique wherein air is injected in the cornea to create a bubble that separates Descemet’s membrane (DM) from the stroma. An attempt to create a BB often results in the cornea being filled with numerous small bubbles without the formation of a BB. Manual dissection is then required to complete the procedure. The goal of this course is to present an update on this popular surgical procedure and give tips and tricks from trained surgeons.

**DUA HS, GICQUEL JJ**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:00</td>
<td>Know your bubbles</td>
<td>DUA H S - Nottingham</td>
</tr>
<tr>
<td>13:30</td>
<td>What to do when no bubbles? and post operative pitfalls</td>
<td>GICQUEL J - Poitiers</td>
</tr>
<tr>
<td>14:00</td>
<td>Surgical tips through clips</td>
<td>SAID D - Nottingham</td>
</tr>
</tbody>
</table>

### PO: OOG Session 3

**ZOGRAFOS L, DESJARDINS L**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Author(s)</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:24</td>
<td>Dry eye syndrome following proton therapy of ocular melanomas</td>
<td>MASCHI C, Sara L, Peyrichon M L, Bailiff S, Herault J, Caujolle J P - Nice</td>
<td></td>
</tr>
<tr>
<td>13:36</td>
<td>Proton beam radiotherapy (PBR) for the treatment of retinal capillary haemangioblastoma</td>
<td>HUSSAIN R, Hassan S, Ho V, Kacperek A, Errington D, Heimann H - Liverpool</td>
<td></td>
</tr>
<tr>
<td>13:42</td>
<td>Case report of a choroidal ganglioneuroma</td>
<td>VAN GINDERDEUREN R, Missotten G - Leuven</td>
<td></td>
</tr>
<tr>
<td>13:54</td>
<td>Choroidal metastasis from thyroid cancer: a case series</td>
<td>MAMUNUR R, Kivelä T - Helsinki</td>
<td></td>
</tr>
<tr>
<td>14:06</td>
<td>Management strategies in vasoactive proliferative tumor of the retina</td>
<td>TUNC M - Ankara</td>
<td></td>
</tr>
</tbody>
</table>
EUPO session 7 - Strabismus

Nonparalytic Esodeviations and Exodeviations
Case Presentations II: Odd and Unusual Things in Strabismus

EUPO Programme, see pages 134-135.

13:00 - 14:30 | GALLIENI 1+2

FRO: Belgian Fund for Research in Ophthalmology 2

FRO candidates present their work to an international jury.

TASSIGNON MJ, CASPERS L

4461 13:00  AON therapy for restoration of defective splicing in genes mutated in hereditary blindness
NAESSENS S - Gent

4462 13:12  Exploring strategies to overcome the inner limiting membrane as a barrier for non-viral retinal gene therapy after intravitreal injection
PEYNSHAERT K - Ghent

4463 13:24  Copy number variation analysis and whole exome sequencing of three unique Belgian keratoconus families
VALGAEREN H - Edegem

4464 13:36  Regenerating the ocular surface using standardized, xeno-free, tissue-engineered conjunctival grafts for conjunctival reconstruction
VANACKER S - Antwerpen

4465 13:48  Targeting specific pathways to enhance human corneal endothelial proliferation in vitro
VAN DEN BOGerd B - Edegem

4466 14:00  Automated retinal vessel analysis to improve the detection and management of ophthalmic and systemic diseases
VAN KEER K - Leuven

4467 14:12  Hidden genetic variation in retinal dystrophies – exploring the contribution of copy number variations
VAN SCHIL K - Ghent

4468 14:24  Confocal and optical coherence bleb imaging pre-and after filtering surgery
WILLEKENS K - Leuven
14:30 - 15:00 | HERMES

Prize Award Ceremony & Closing Remarks

Chair: Andrew Dick, President EVER 2017

Introduction of the Award Ceremony by Marcela Votruba, Programme Secretary
- Travel awards presentation by the section chairs
- Poster prize presentations by the section chairs

Presentation and report of the scientific sections meetings

Conclusion of the congress by the President 2016 Aki Kawasaki
Friday 7 October 2016 in Rhodes 4

08:30  Common Optic Neuropathies in Adults: Diagnosis, Treatment and Prognosis
  Antonella BOSCHI, Valerie PURVIN
  08:30  Idiopathic [demyelinating] optic neuritis  PURVIN V
  08:50  Non-arteritic anterior ischemic optic neuropathy  SAARELA V
  09:10  Compressive optic neuropathy: pituitary adenoma  BOSCHI A
  09:30  Leber hereditary optic neuropathy  YU WAI MAN P
  09:50  Discussion
  10:00  Break

10:30  Case Presentations I: Odd and Unusual Things in Neuro-ophthalmology
  Valerie PURVIN, Ville SAARELA

11:00  Systematic Approach to the Ocular Motor System
  François-Xavier BORRUAT, Caroline TILIKETE
  11:00  Central disorders of ocular motility  BORRUAT FX
  11:25  Central disorders of ocular stability  TILIKETE C
  11:50  Myasthenia  LEE M
  12:15  Discussion
  12:30  Lunch

13:30  Uncommon but Important Causes of Visual Loss
  Fion BREMNER, Graham HOLDER
  13:30  Inorganic visual loss: toxicities  PURVIN V
  13:50  Acquired autoimmune retinopathies  HOLDER G
  14:10  Posterior reversible encephalopathy syndrome (PRES)  KAWASAKI A
  14:30  Neuromyelitis optica (NMO) and spectrum disorders  BREMNER F
  14:50  Discussion
  15:00  Break

16:00  Recognizing the Emergencies: From Symptom to Diagnosis
  Catherine VIGNAL CLERMONT, Michael LEE
  16:00  Transient monocular visual loss: carotid embolus vs giant cell arteritis  VIGNAL CLERMONT C
  16:20  Diagnosis and management of giant cell arteritis  LEE M
  16:40  Acute diplopia: third nerve palsy  BREMNER F
  17:00  Acute anisocoria: aneurysm vs Horner syndrome  KAWASAKI A
  17:20  Discussion

17:30  Case Presentations II: Odd and Unusual Things in Neuro-ophthalmology
  Patrick YU WAI MAN, Aki KAWASAKI

18:00  End
Saturday 8 October 2016 in Rhodes 4

08:30  Paralytic Strabismus: Diagnosis, Evaluation and When to Treat
       Oliver EHRT, Heimo STEFFEN

08:30  Acquired cranial nerve palsies
       STEFFEN H

08:55  Congenital cranial dysinnervation disorders
       KAESER PF

09:20  Surgical indications and management of paralytic strabismus
       EHRT O

09:45  Discussion

10:00  Break

10:30  Case Presentations I: Odd and Unusual Things in Strabismus
       Dominique BREMOND GIGNAC, Cameron PARSA

11:00  Amblyopia, Nystagmus and Secondary Strabismus
       Jan Tjeerd DE FABER, Pierre-François KAESER

11:00  Amblyopia: physiologic basis and management
       PARSA C

11:20  Screening strategies for amblyopia
       BREMOND GIGNAC D

11:40  Infantile nystagmus
       KAESER PF

12:00  Secondary and iatrogenic strabismus
       DE FABER JT

12:20  Discussion

12:30  Lunch

13:30  Nonparalytic Esodeviations and Exodeviations
       Rosario GOMEZ de LIANO, Marcel TEN TUSSCHER

13:30  Esotropia: Considerations in Infants and Adults
       TEN TUSSCHER M

13:55  Exodeviations
       GOMEZ DE LIANO R

14:20  Nonsurgical management of strabismus
       DE FABER JT

14:45  Discussion

15:00  Case Presentations II: Odd and Unusual Things in Strabismus
       Dominique BREMOND GIGNAC, Cameron PARSA

15:30  End
XXth EVER CONGRESS
EVER 2017 NICE
SEPTEMBER 27-30
www.ever.be
Awardees of the EVER Research Fellowships 2016

• Dr Mahajan DEEPTI, India
  host institute: Vision Lab, Cardiff Centre for Vision Sciences, Cardiff University, UK

• Dr Narine ADZHEMIAN, Russia
  host institute: Medical University of Vienna, Austria
SAVE THE DATE

www.soe2017.org

REGISTER and SUBMIT ABSTRACTS NOW!

EBO Diploma Examination 2017

Applications open October 2016

Venue:
Le Palais des Congrès de Paris

Website: ebo-online.org
The Obergurgl Optic Nerve Meeting

Focus Area -
Boosting optic nerve function

December 13-15
2016

www.optic-nerve-online.com

Organisation:
Jonathan Crowston
Professor of Ophthalmology, University of Melbourne

Franz Grus
Professor of Experimental Ophthalmology, Johannes Gutenberg University, Mainz

Keith Martin
Professor of Ophthalmology, University of Cambridge

Austria - Obergurgl
Hotel Edelweiss & Gurgl
February 5 – 8, 2017
Brisbane Convention and Exhibition Centre
Brisbane, Australia

Bridging disciplines and disparities: Connecting eye research with health outcomes

The sixth ARVO Asia meeting will explore the latest in basic, translational and clinical research through symposia, plenary, paper and poster sessions and special interest groups.

We discuss how we can build bridges that ensure our discoveries translate into effective prevention, diagnosis and treatments for patients with eye disease.

Chair: Mark H.B. Radford, MD, PhD
Co-chairs:
Justine R. Smith, FRANZCO, PhD, FARVO
Peter J. McCluskey, MD, FRANZCO

Early registration closes Dec. 12, 2016
Abstract submission: July 12 – Sept. 20, 2016
Online program available: Dec. 13, 2016

arvo.org/arvoasia
Important Dates

- **Abstract submission**
  October 14 – December 2, 2016

- **Early meeting registration**
  Opens September 19, 2016

Travel grants are available. Apply when submitting your abstract.
Karger publications in Ophthalmology available at the Wisepress booth.
Raxone is the first and only approved medication for Leber’s Hereditary Optic Neuropathy (LHON)

• LHON is a severe, progressive mitochondrial disease causing irreversible vision loss
• Raxone demonstrated:
  – Clinically relevant recovery (CRR) of vision in 30% of patients
  – Clinically relevant stabilisation (CRS) in 50% of patients
• Raxone has a safety and tolerability profile similar to placebo

References: 1. Raxone SmPC. September 2015. 2. Raxone EPAR. September 2015; from prospective studies and case collection (RHODOS, EAP; Table 12 EPAR).

To hear what Raxone can do for your Leber’s patients, visit Santhera at booth 101 or go to www.santhera.com
<table>
<thead>
<tr>
<th>Presenting First Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ABEGAO PINTO, L</strong>: 1325, 3124, 3663</td>
</tr>
<tr>
<td><strong>ABU EL ASRAR, A</strong>: 1335, 2332</td>
</tr>
<tr>
<td><strong>AFANASYEVA, D</strong>: 1375, S016</td>
</tr>
<tr>
<td><strong>AGARWAL, P</strong>: S052</td>
</tr>
<tr>
<td><strong>AHMED, F</strong>: 2722</td>
</tr>
<tr>
<td><strong>AHN, H</strong>: S010, S105</td>
</tr>
<tr>
<td><strong>AKPOLAT, C</strong>: 2331, S069, T097</td>
</tr>
<tr>
<td><strong>ALA-KAUHALUOMA, M</strong>: F109</td>
</tr>
<tr>
<td><strong>ALDAHAM, S</strong>: 3326, F076</td>
</tr>
<tr>
<td><strong>ALGHAMDI, A</strong>: 1555</td>
</tr>
<tr>
<td><strong>ALI ALJASIM, L</strong>: T043, T044</td>
</tr>
<tr>
<td><strong>ALLEN, C</strong>: 2333</td>
</tr>
<tr>
<td><strong>ALMENARA MICHELENA, C</strong>: F108, S066</td>
</tr>
<tr>
<td><strong>ALMOALLEM, B</strong>: 3581</td>
</tr>
<tr>
<td><strong>AMBRESIN, A</strong>: 3115</td>
</tr>
<tr>
<td><strong>ANDJELIC, S</strong>: S078</td>
</tr>
<tr>
<td><strong>ANDOH, T</strong>: S060</td>
</tr>
<tr>
<td><strong>ANDRE, H</strong>: 3584</td>
</tr>
<tr>
<td><strong>ANDRIES, L</strong>: 4161</td>
</tr>
<tr>
<td><strong>ANDROUDI, S</strong>: 1132</td>
</tr>
<tr>
<td><strong>ANGI, M</strong>: 3642</td>
</tr>
<tr>
<td><strong>ANISIMOVIĆ, S</strong>: 2674</td>
</tr>
<tr>
<td><strong>ANTOUN, J</strong>: 3371</td>
</tr>
<tr>
<td><strong>APTEL, F</strong>: 3122, T029</td>
</tr>
<tr>
<td><strong>ARINCINOVAS, C</strong>: 2121</td>
</tr>
<tr>
<td><strong>ARDAN, T</strong>: T106</td>
</tr>
<tr>
<td><strong>ARJAMAA, O</strong>: 1371</td>
</tr>
<tr>
<td><strong>ARNOLDS, L</strong>: 1376</td>
</tr>
<tr>
<td><strong>ARSENJEVIC, Y</strong>: 1512</td>
</tr>
<tr>
<td><strong>ASCASO, F</strong>: 2711, 4111, F070, F094</td>
</tr>
<tr>
<td><strong>ATILLA, H</strong>: 2663, 2741</td>
</tr>
<tr>
<td><strong>AUDO, I</strong>: 3181</td>
</tr>
<tr>
<td><strong>AUTRATA, R</strong>: F042, F043</td>
</tr>
<tr>
<td><strong>AUZENIN, A</strong>: 3383</td>
</tr>
<tr>
<td><strong>BAE, JH</strong>: F113</td>
</tr>
<tr>
<td><strong>BALCI, Ö</strong>: 3674</td>
</tr>
<tr>
<td><strong>BALDANSCHI, L</strong>: 2632</td>
</tr>
<tr>
<td><strong>BALENDRA, S</strong>: 1162</td>
</tr>
<tr>
<td><strong>BARRONI, P</strong>: 2363</td>
</tr>
<tr>
<td><strong>BARROSA BREDA, J</strong>: 4162, T017</td>
</tr>
<tr>
<td><strong>BARRAQUER, J</strong>: 2353</td>
</tr>
<tr>
<td><strong>BARRAQUER, RI</strong>: 4425</td>
</tr>
<tr>
<td><strong>BATSON, J</strong>: 1341</td>
</tr>
<tr>
<td><strong>BAUDIN, F</strong>: 2681</td>
</tr>
<tr>
<td><strong>BECHRAKIS, NE</strong>: 2732, 3342, 3544</td>
</tr>
<tr>
<td><strong>BECKERS, A</strong>: 4163</td>
</tr>
<tr>
<td><strong>BEGUM, S</strong>: 2338, F077, S086</td>
</tr>
<tr>
<td><strong>BEHAGHEL, J</strong>: 4164</td>
</tr>
<tr>
<td><strong>BEHAR-COHEN, F</strong>: 3165</td>
</tr>
<tr>
<td><strong>BEK, T</strong>: 1115</td>
</tr>
<tr>
<td><strong>BENSOUSSEAN, E</strong>: 4442</td>
</tr>
<tr>
<td><strong>BERNIOLLES, J</strong>: S027, S043</td>
</tr>
<tr>
<td><strong>BERROD, J</strong>: 1562, 3513</td>
</tr>
<tr>
<td><strong>BEUERMAN, R</strong>: 1172, 2772</td>
</tr>
<tr>
<td><strong>BITOUN, P</strong>: 1523</td>
</tr>
<tr>
<td><strong>BJORKOY, G</strong>: 2173</td>
</tr>
<tr>
<td><strong>BLASI, MA</strong>: 3142</td>
</tr>
<tr>
<td><strong>BLOOM, P</strong>: 2724</td>
</tr>
<tr>
<td><strong>BOBAT, H</strong>: T025</td>
</tr>
<tr>
<td><strong>BODAGHI, B</strong>: 1535</td>
</tr>
<tr>
<td><strong>BONINI, S</strong>: 3635</td>
</tr>
<tr>
<td><strong>BONO, V</strong>: T023</td>
</tr>
<tr>
<td><strong>BOSCHI, A</strong>: 2633</td>
</tr>
<tr>
<td><strong>BOULADI, M</strong>: T008, T009</td>
</tr>
<tr>
<td><strong>BOURAOUI, R</strong>: F092, F093</td>
</tr>
<tr>
<td><strong>BOURRE, R</strong>: 1361</td>
</tr>
<tr>
<td><strong>BOUTELEUX, V</strong>: F062</td>
</tr>
<tr>
<td><strong>BOUVIER, R</strong>: F044</td>
</tr>
<tr>
<td><strong>BOYA, P</strong>: 3521</td>
</tr>
<tr>
<td><strong>BOYCHUK, I</strong>: F035, S017</td>
</tr>
<tr>
<td><strong>BRAGA, J</strong>: F021</td>
</tr>
<tr>
<td><strong>BRANDL, C</strong>: T081</td>
</tr>
<tr>
<td><strong>BREHON, A</strong>: S013, S048</td>
</tr>
<tr>
<td><strong>BREMOND-GIGNAC, D</strong>: 2662, 2744, 3681, 4132</td>
</tr>
<tr>
<td><strong>BREUNIG, M</strong>: 3133</td>
</tr>
<tr>
<td><strong>BRISSOEO, D</strong>: 2654</td>
</tr>
<tr>
<td><strong>BRON, A</strong>: 1521, 2616</td>
</tr>
<tr>
<td><strong>Brunner, S</strong>: 2112</td>
</tr>
<tr>
<td><strong>BUCOLO, C</strong>: S062</td>
</tr>
<tr>
<td><strong>BUJELENS, T</strong>: 3374</td>
</tr>
<tr>
<td><strong>BUJAKOWSKA, K</strong>: 2762</td>
</tr>
<tr>
<td><strong>BUSHUYA, N</strong>: F026, F034, S020</td>
</tr>
<tr>
<td><strong>BUZNYK, O</strong>: 1143</td>
</tr>
<tr>
<td><strong>CALONGE, M</strong>: 2771</td>
</tr>
<tr>
<td><strong>CALVAS, P</strong>: 2661</td>
</tr>
<tr>
<td><strong>CANDI, A</strong>: T104</td>
</tr>
<tr>
<td><strong>CARDIGOS, J</strong>: 3327, F078, T015</td>
</tr>
<tr>
<td><strong>CARELLI, V</strong>: 1552, 2364, 2424, 2426</td>
</tr>
</tbody>
</table>
CARRASQUILLO, KG: 2373
CARVALHO, B: S011
CASSOUX, N: 2341, 2344, 3315, 3341, 3545
CASTELO-BRANCO, M: 2645
CAUJOLLE, JP: 3143
CELLINI, M: T006
CHANIECKI, P: S079
CHARJER, J: 3564
CHARPENTIER, S: S084
CHEN, L: 3631
CHIAMBARETTA, F: 2743, 2834
CHIquet, C: 2354
CHOI, C: F081
CHOI, H: F030, F031
CHOI, JB: S083
CIPRÉS ALASTUEY, M: F014, F015
COLAS, E: 2337, F074
CONDE, C: S015
CORDEIRO SOUSA, D: 2685, T045, T086
CORDEIRO, MF: 3623
COSCAS, F: 3111
COSCAS, G: 3114
COSTA, J: S101
COSTA, L: 1347, 3328, F079, T024, T102
COUPLAND, S: 3145, 3317, 3365, 4145, S092
COURRIER, E: S049
CRAWLEY, L: 2723
CREUZOT, C: 1363
CRISÓSTOMO, S: T016
CROUZET, E: 1141, S042
CTORI, I: T079
CVEKL, A: 2351
CZAK, W: 2673
DABASIA, P: T027
DALGAARD, LM: 1522
DALKE, C: 3382
DAMATO, B: 3344
DANIELSON, P: 2734
DAUll, P: 2677, S022
DAVIS, B: 2323
DE BOEVER, P: 2683
DE GROEF, L: 1344
DE GROOT, V: F037
DE LAEY, J: 4113
DE ZAEYTJUD, J: T069
DECAUDIN, D: 3313
DEL BUEY, MA: S055, T004
DELCOURT, C: 1362, T078
DELGADO, L: 3683
DEN HOLLANDER, A: 1364
DENIER, C: 3372
DENNISTON, A: 2314
DERVEAUX, T: 3582
DESRJARDINS, L: 2343, 3541, 3644
DEVOLDERE, J: 1544, 4165
DICK, A: 1131, 1136
DIWO, E: S065
DOAN, S: 2374, S051
DOBROWOLSKI, D: 2134, 2136
DOGAN, M: 2385, T107
DRAGANOVA, D: 3373
DUA, HS: 1576, 3571, 4431
DUCH, S: 2124
DYSLI, C: 2623
EHSAEI, A: S018, S030
EIDET, JR: 2676, S025
EL AMEEN, A: 3673, T034
EL MATRI, L: F082, T068
EPPIG, T: 4122, 4422
ERCAL, N: 2782, S076, S077
ERDURMUS, M: T098
ERKAN TURAN, K: F016, F047
ESPOSTI, G: S094
ESTEBAN, O: S073, T066
EYSTEINSSON, T: 2382
FENOLLAND, JR: 1528, T042
FERNÁNDEZ-NAVARRO, J: 1543
FERNÁNDEZ-PEREZ, J: 3332
FERRARI, S: 3171
FIorentzis, M: S089
FITZKE, FW: 2164
FRANCESCHETTI, A: 4115
FRENCH, C: 2686, F058
FRENKEL, S: 3316
FRUSCHELLI, M: 3325, F091
FUCHSLUGER, T: 3132
FUNKE, S: 3525
GABRIELLE, P: 1546
GALICHANIN, K: S075
GALLEG0, BI: 2322
GARCÍA LLORCA, A: 3585, T076
GARCIA MARTIN, E: F003, F004
GARCIA-FEIJOO, J: 1322, 3123
GARCIA-ZAMORA, M: F084
GARCIA, M: T073
GARIN, T: 3331
GARHÖFER, G: 2145
GAZZARD, G: 2721
GEORGIADIS, T: 1511
GIANNACCARE, G: T020
GICQUEL, J: 4131, 4432
GLITTENBERG, C: 2113
GOCHO, K: 2682
GOH, M: T082
GOMES ALVES DA CONCEICAO, R: T050
GONZALEZ, C: 3323, F060, F061
GRABSKA-LIBEREK, I: T040
Presenting First Authors

KWON, S: F050
KWON, YH: F096, F104
KYMIONIS, G: S034
LABBE, A: T039
LABETOULLE, M: 1153, 4133, S071
LAGALI, N: 3633
LAGREZE, WD: 2422
LAM, D: S070
LANGENBUCHER, A: 4121, 4423
LATHIERE, T: S008
LE MER, Y: 3514
LEAL, I: 1164, T041, T046
LEE, JE: T087
LEE, JY: F069
LEE, MY: F090, F097
LEE, Y: T085
LEMAITRE, S: 2753
LENAERS, G: 2361
LEONARDI, A: S064
LERAY, BP: 1412, 1514, 2162, 2611, 3185
LEWIS, A: 1124
LIINAMAA, J: 1554
LISKOVA, P: 2764, 3183, T071
LOCKWOOD, A: T047
LOEFFLER, K: 3141
LOFREN, S: F036
LORENZO CORRALES, Y: S038
LOSHKAREVA, A: 2671
MADIGAN, M: 2758, 3647, S108
MAKLEY, L: 2785
MAMMADZADA, P: T096
MAMUNUR, R: 4446
MANS, R: F083
MANOLI, P: F028
MARCELIS, W: F025
MOOSANG, K: F029, F055
MOSCHOS, M: 1312
MOULIN, A: 2752
MOURIAUX, F: 2651
MRUKWA-KOMINEK, E: S054
MULLER, M: S085
MUNIER, F: 3546
MUNOZ-NEGRET, FJ: 1557, F001, F023, T035
MUNOZ, M: 2122, T028
MUNOSSENS, S: 4461
NAESSENS, S: 4461
NAKAI, K: 3672
NAU, C: 2372
NERI, P: 1133, 1534, 2311, 3361
NESS, C: S088
NOER, A: S039
NORMANDO, EM: 2621
NOWINSKA, A: 2131
OBIS, J: F012, F013
OCCHIATO, H: S074
OLAFSDOTTIR, OB: T095
OLMIERE, C: S080
OSBORNE, N: 2643, 2644
OSHIKARI, T: F089
ÖZMEK, M: 3321
ÖZTÜRK, N: F027
PANFOLI, I: T105
PAPASTEFANOU, V: S093
PAPPAIS, G: 1315
PARK, J: S063
PARK, K: F088
PATERNO, J: S003, S005, S014
PAZOS, M: 2321
PESAROZZO, A: 3524
PERESTRELO, S: F066
PEREZ NAVARRO, I: S045, S056
PETRENKO, O: S072
PETROVSKI, K: 1342, 4462
PIA, A: 4441
PIERSCIONEK, B: 2181
PIETRUCHA-DUTCZAK, M: T052
PINNA, A: S059
PINTO PROENÇA, R: 2334
PLAINIS, S: 1311
PLEYER, U: 1134, 1151, 1332, 3574
PONOMARENKO, M: F052, F054
POURNARAS, C: 1113, 2715, 3116, 3512
POURNARAS, J: 1313, 3515
PRIETO, P: 2781
PRUENTE, C: 2714
QIU, X: 2352
QUINLAN, R: 3381
QURIC, S: S053
RAHMANIA, N: F033
RANSOM, B: 3624
REBOLLED, A: F011, T058, T063
REMAUT, K: 2143
REMONT, A: S068
RICOUARD, F: F102
ROBSON, A: 1123
ROCHA DE SOUSA, A: 1563, 3566, F049, T007
RODRIGO, MJ: F066, F022
ROELS, D: T012
ROEMER, S: 1551
ROJAS LOZANO, MP: F002
ROMANOWSKA DIXON, MP: B068, S090, S102
ROULAND, JF: 1526, T033
ROUSSEAU, A: 3375
ROZET, J: 2664
ROITERS, S: 1377, S021
RUPENTHAL, ID: 2141
SAAKYAN, S: 2757, 3643, 3645, S097, S104
SAGONG, M: F110
SAGUET, P: T108
SAID, D: 4433
SALOBRAR-GARCIA, E: F017, F018
SALVI, M: 2634
SALVIAT, F: F046
SÁNCHEZ MARÍN, JI: F056, S044
SANDBERG MELIN, J: T062
SAPETA, S: 1572
SATUE, M: F007, F008
SCHALENBOURG, A: 3542
SCHMETTERER, L: 1411, 2642
SCHMIDL, D: 1573, 3662
SCHWARZ, N: 2761
SCOTT, A: 1321
SEPETIS, A: T077
SHAHADAFAR, A: 3173
SHALABY, A: F105
SHIH, KC: 1163
SHIN, KS: F072, S067
SHIN, Y: F032, T080
SHIRZADEH, S: F041, S058
SILVESTER, A: 2155, F048
SIMCOCK, P: T134
SJÖSTRAND, J: S019
SKALICKÁ, P: T072
SKYTT, D: 1372
SMEDOWSKI, A: 2132, T051
SMETS, M: S107
SMITH, R: 1122, 1125
SODERBERG, P: 3161
SOMNER, J: 2733
SOBRANE, G: 3113
SOUSA NEVES, F: 1545, T065
SOUSA, F: 2151
SOZEN-DELIL, FI: 1565, F080, F111
SPILEERS, W: 2161
STACHS, O: 1574
STÆHR JAKOBS, N: F087
STALMANS, I: 3121
STANGOS, A: 3511, T022
STAPPLER, T: 1316
STENANSSON, E: 3535, 3572
STONE, D: T026
STRUAPAITE, R: T067
SUÁREZ, T: S061
SULILEMAN, E: T019
SULIVAN, DA: 2831
SUNARIC MEGEVA, G: 1323, 1324
SUZUKI, N: 2687, 3565, F059
SZAFLIK, JP: F065, T053
SZEKENTMARY, N: 4123, 4421
TALEBIZADEH, N: 3163
TARUTTA, E: S028, T002
TASSIGNON, MJ: 2712, 4211
THOMPSON, D: 1121, 3563
THURET, G: 2313
TIMSIT, A: S029
TIRANTI, V: 2423
TOFT-KEHLER, AK: T048
TOETH, M: T021
TOUITOU, V: 2613
TRIOLO, G: 1524
TUNC, M: 2652, 2754, 4447, S100, S106
TURCK, N: 1345, 1346, T103
TURUNEN, J: 4141, S087
ULLRICH, F: 3134, 3534
UUSITALO, H: 1171, 2774
VALGAEREN, H: 4463
VAN CALSTER, J: 3362, 3363
VAN DEN BOGERD, B: 4465
VAN GINDERDEUREN, R: 3364, 4445
VAN KEER, K: 1167, 2384, 4466, T057
VAN SCHIL, K: 4467
VANACKER, S: 4464
VANDEWALLE, E: 1527, 3125, T036
VEGA-ESTRADA, A: 2185
VIDAL-SANZ, M: 2324
VIGNAL-CLERMONT, C: 1553
VILADES, E: F009, F010
VIOTTE, A: F067
VOHRA, R: 1373
VOTRUBA, M: 3211
WAAGEPETERSEN, H: 3621
WAIZE, M: F040
WALPERT, M: 2622
WEGENER, A: 3162
WEI, X: T088
WERMEOISTER, R: 1114, 1571
WILLEKENS, K: 1566, 3664, 4468, T055
WILLERMAIN, F: 1331, 2612
WOZNIAK, P: 2386, T092
WYLEGALA, E: 2135, 4124, 4424
YAZGAN, S: T014
YEKTA, AA: T001, T084
YIM, B: S040
YU-WAI-MAN, P: 2365
YU, Z: 3164
ZADOROZHNYY, O: S095, T099
ZENG, J: 3562
ZHANG, H: 3632
ZHANG, K: 2783
ZHANG, X: 3583
ZOGRAFOS, L: 2345, 3117, 3543
ZSOLT NAGY, Z: 4125
All authors of abstracts are listed alphabetically

One letter and three digit numbers refer to posters
Four digit numbers refer to oral presentations
The digit numbers marked in bold indicate a first author abstract

AALONEN, V: 1371
ABEGÁO PINTO, L: 1164, 3327, F078, T041, 1325, 3124, 3663, 1167, 2334, 2384, 2665, T045, T057
ABROUG, N: 1333
ABU EL ASRAR, A: 1335, 2332
ACAR, N: 1521
ACOSTA, MC: S053
ACOU, M: F025
ADENIS, JP: S008
ADIEGO, M: 4111
ADJADJ, E: 3372
AERTS, I: 3644
AFANASYEVA, D: 1375, S016
AGARD, E: F062, T064
AGARWALL, P: S052
AGRAWAL, R: T088
AGUDO-BARRIUOSO, M: 2324
AHEREAN, M: 3332, 3333, S041
AHMAD, S: T026
AHMED, F: 2621, 2722
AHN, H: F096, F104, S100, S105
AHN, KS: T087
AHOLA, O: S003
AKEO, K: 2682
AKHTAR, S: T051
AKPOLAT, C: 2331, S069, T097
ALA-KAUHALUOMA, M: F109
ALASSANE, S: 1376
ALBA-BUENO, F: 2183
ALDAHAM, S: 3326, F076
ALGHAMD, A: 1555
ALI ALJASIM, L: T043, T044
ALI, RR: 3523
ALI, Z: 3633
ALIO, J: 2185
ALKAHTANI, A: 1145, 2765, S023, S103
ALLEN, C: 1341, 2333
ALLEN, E: 3172
ALMARZOKI, H: 1145, S023
ALMENARA MICHENA, C: S045, S056, S066
ALMENARA, C: F045, F056, F070, F094, F114, S027, S043, S044, T004, T066, F108
ALMOALEM, B: 3581
ALMUHTASEB, H: F057
ALONSO GARCIA, E: S011
ALONSO, AS: 2684
ALOUI, T: F035
ALQHAHTANI, A: 2756, S103
ALSObHI, E: 2756, S103
ALSULAMI, R: 2756, 1145, S023, S103
ALVAREZ, L: T075, T073
ALVES-FARIA, P: 3566, T007
ALVES, M: 2334
ALZAHRAHI, K: S050
ALZAHRAHNI, S: 1145, 2756, S023, S103
AMADIO, M: T051, S006
AMADO, D: 1347, T102
AMARIE, OV: 3586
AMAT-PERAL, P: F051
AMATI-BONNEAU, P: 2361
AMBRESIN, A: 3115
AMBROZAITE, Y: T067
AMRANE, M: S064
ANATYCHUK, L: T099
ANCHER LARSEN, D: F087
ANDJELIC, S: S078
ANDLEY, U: 2785
ANDOH, T: S060
ANDRE, H: T096, 3584
ANDRES-GUERRERO, V: 2142
ANDRIES, L: 1344
ANDROUDI, S: 1132
ANGI, M: 3644, S042
ANISIMOVA, S: 2674
ANISIMOVA, S: 2674
ANUS, R: T015, T016, T024
ANTON, A: T028
ANTOUN, J: 3371
ANUMANTHAN, G: 1513
APRILE, L: 3326, F091
APTEL, F: 1526, 2353, T033, 3122, T029
ARAII, M: F089
ARAPI, I: 3361
ARASHAKOV, A: T037
ARCINIEGAS-PERRASO, CA: 2121
ARDAN, T: T106
AREDE, C: T065
ARJAMAA, O: 1371
ARNAIZ, C: F101
ARNO, G: S051
ARNOULD, R: 1376
ARONSSON, M: 3584
ARRANZ, A: 2142
ARSENEVIC, Y: 1512
ASCASO, F: F045, F056, F070, F094, S045, S056, 2711, T011
ASCASO, FJ: S056, S066, F070, F094
ASCASO, J: F038, F114, S027, S043, S073, T066
ASHCINGER, H: 1114, 2386, T092
ASKOLIS, R: T059, T067
ASSAD, G: 2681
ATES, H: T014
ATILLA, H: 2663, 2741
ATKINSON, M: 3382
ATKINSON, S: 3172
AUBELE, M: 3382
AUCKBURALLY, M: F028
AUDO, I: 3181
AUTRATA, R: F042, F043
AVILÉS-TRIGUEROS, M: 2324
AYMARD, PA: 3372
AZIMI, A: T001
AZIZADEH, O: 3382
BABAEI-JADI, R: 1341
BABL, S: 3133
BADIAN, R: 2676, S025
BAE, JH: F113
BAEKELANDT, V: 1344
BAGAGLIA, S: 3646, S098
BAGNIS, A: T020
BAHARI, M: 2181
BAILLIF, S: 4442, 4443
BALCI, Ö: 3671, 3674
BALDUCCI, N: 2363
BALENDRA, SI: S086, 1162
BALNE, PK: T088
BANDELLO, F: T078
BANERJEE, S: F095
BARAC, C: T056
BARATA, A: 1546
BARTH, A: T088
BARBEAUX, P: T104
BARBER, AC: T050
BARBONI, P: 2363
BARBOSA-BREDA, J: 1167, T057, T017
BARBOSA-BREDA, J: 1563, 3664
BARILLÀ, D: F039
BARNHILL, R: 4145, S092
BARRAQUER, J: 2353
BARRAQUER, RI: 2182, 4425
BARROS, P: F021
BARTOLOMÉ, I: S043, F038, F045, F056, F070, F094, F108, S027, S044, S056, S066, S073
BARUFFA, D: 1534
BASCHE, M: 3523
BASEL, AL: 3328, F079, T016
BASSET, T: 1141
BATA, AM: 2386, T092
BATES, D: 2333
BATES, DO: 1341
BATSON, J: 1341
BAUDIN, F: 2681
BAUDOUIN, C: T039
BAYTAROGLU, A: F016
BAZEE, S: T021
BEATO, J: 3322
BECHRASKIS, NE: 2732, 3342, 3544
BECK-POPOVIC, M: 3546
BECK, S: 3525
BEDNARSKI, M: 2111
BEGUM, S: F083, 2388, F077, S086
BEK, T: 2381, 2383, F087, T091, T094, T095, 1115
BELAOUDDOU, R: 2375
BELAZZOUGUI, R: S070
BELMONT, C: S053
BELTZ, J: S077
BEN MRAD, A: 1142
BENISTY, D: S029, S082
BENITEZ DEL CASTILLO, JM: S051
BENNITT, J: 1514
BENSOUSSAN, E: 4442
BENZACKEN, L: 1523
BERAUD, G: T108
BERGANDI, F: 3334
BERGERSSEN, LH: 1372, 1373
BERGUIA, M: S029, S082, S084
BERNARD, A: 3331
BERNOLLES, J: F038, F045, F056, F070, F094, F108, S044, S056, S066, S073, S027, S043
BERROD, JP: 1562, 3513
BERTONE, C: F039
BESSE, A: 2337, F074
<table>
<thead>
<tr>
<th>Name</th>
<th>Page Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vasseur, V</td>
<td>2684</td>
</tr>
<tr>
<td>Vavl, M</td>
<td>2362</td>
</tr>
<tr>
<td>Vaz-Pereira, S</td>
<td>1545, 2336, F073</td>
</tr>
<tr>
<td>Vázquez-Alfageme, C</td>
<td>S093</td>
</tr>
<tr>
<td>Vázquez, LE</td>
<td>1524</td>
</tr>
<tr>
<td>Vega-Estrada, A</td>
<td>2185</td>
</tr>
<tr>
<td>Vega, F</td>
<td>2183</td>
</tr>
<tr>
<td>Vega, Z</td>
<td>T028</td>
</tr>
<tr>
<td>Vermorgen, K</td>
<td>1527, T036</td>
</tr>
<tr>
<td>Verstraeten, T</td>
<td>1541</td>
</tr>
<tr>
<td>Verticchio Vercellin, AC</td>
<td>F039</td>
</tr>
<tr>
<td>Viaud-Quentric, K</td>
<td>S080</td>
</tr>
<tr>
<td>Vibeck, J</td>
<td>1522</td>
</tr>
<tr>
<td>Vicente, A</td>
<td>2334, 3327, F078</td>
</tr>
<tr>
<td>Vidal-Sanz, M</td>
<td>2324</td>
</tr>
<tr>
<td>Vieira, L</td>
<td>3328, F079, T015</td>
</tr>
<tr>
<td>Viestenz, A</td>
<td>S089</td>
</tr>
<tr>
<td>Vigil Clermont, C</td>
<td>1553</td>
</tr>
<tr>
<td>Vikatmaa, L</td>
<td>F109</td>
</tr>
<tr>
<td>Vikatmaa, P</td>
<td>F109</td>
</tr>
<tr>
<td>Vilades Palomar, E</td>
<td>F014, F015</td>
</tr>
<tr>
<td>Vilades, E</td>
<td>F003, F004, F006, F007, F008, F022, F009, F010</td>
</tr>
<tr>
<td>Villades, E</td>
<td>F012, F013</td>
</tr>
<tr>
<td>Villegas-Pérez, MP</td>
<td>2324</td>
</tr>
<tr>
<td>Villota, E</td>
<td>T073</td>
</tr>
<tr>
<td>Viotte, A</td>
<td>F067</td>
</tr>
<tr>
<td>Vitoska, O</td>
<td>2114</td>
</tr>
<tr>
<td>Vohra, R</td>
<td>1372, 1373</td>
</tr>
<tr>
<td>Voskanyan, L</td>
<td>3123</td>
</tr>
<tr>
<td>Volruba, M</td>
<td>T071</td>
</tr>
<tr>
<td>Volruba, Mjau</td>
<td>3211</td>
</tr>
<tr>
<td>Vuorinen, I</td>
<td>S003</td>
</tr>
<tr>
<td>Waagepetersen, H</td>
<td>3621</td>
</tr>
<tr>
<td>Wagner, H</td>
<td>4441</td>
</tr>
<tr>
<td>Waizel, M</td>
<td>F040</td>
</tr>
<tr>
<td>Walczak, A</td>
<td>T053</td>
</tr>
<tr>
<td>Walpert, M</td>
<td>2622</td>
</tr>
<tr>
<td>Walraedt, S</td>
<td>3582</td>
</tr>
<tr>
<td>Walser, M</td>
<td>4441</td>
</tr>
<tr>
<td>Wang, S</td>
<td>2783</td>
</tr>
<tr>
<td>Wearmouth, SF</td>
<td>1341</td>
</tr>
<tr>
<td>Weber, BH</td>
<td>T081</td>
</tr>
<tr>
<td>Weber, DC</td>
<td>4441</td>
</tr>
<tr>
<td>Webster, A</td>
<td>3581</td>
</tr>
<tr>
<td>Wechsler, B</td>
<td>1555</td>
</tr>
<tr>
<td>Wegener, A</td>
<td>3162</td>
</tr>
<tr>
<td>Weger, M</td>
<td>2683</td>
</tr>
<tr>
<td>Wei, X</td>
<td>T088</td>
</tr>
<tr>
<td>Wellman, J</td>
<td>1514</td>
</tr>
<tr>
<td>Werkmeister, R</td>
<td>1114, 1571</td>
</tr>
<tr>
<td>Werkmeister, RM</td>
<td>2386, T092</td>
</tr>
<tr>
<td>Widdowson, P</td>
<td>1165, T049</td>
</tr>
<tr>
<td>Wilkens, K</td>
<td>1167, T057, 1566, 3664, T055</td>
</tr>
<tr>
<td>Willermain, F</td>
<td>3371, 3373, 3374, 1331, 2612</td>
</tr>
<tr>
<td>Williams, K</td>
<td>T074</td>
</tr>
<tr>
<td>Wilska, R</td>
<td>4141, S087</td>
</tr>
<tr>
<td>Witkowska, KJ</td>
<td>2386, T092</td>
</tr>
<tr>
<td>Wolff, B</td>
<td>2684</td>
</tr>
<tr>
<td>Wong, B</td>
<td>1112</td>
</tr>
<tr>
<td>Wong, D</td>
<td>1561</td>
</tr>
<tr>
<td>Wong, R</td>
<td>3524</td>
</tr>
<tr>
<td>Wong, T</td>
<td>1166, T018, T038</td>
</tr>
<tr>
<td>Wozniak, Pa</td>
<td>2386, T092</td>
</tr>
<tr>
<td>Wu, J</td>
<td>1561</td>
</tr>
<tr>
<td>Wu, JJ</td>
<td>3381</td>
</tr>
<tr>
<td>Wurst, W</td>
<td>3382</td>
</tr>
<tr>
<td>Wylegalis, E</td>
<td>2132, 4124, 4424</td>
</tr>
<tr>
<td>Xeroudaki, M</td>
<td>3633</td>
</tr>
<tr>
<td>Xie, Q</td>
<td>2351</td>
</tr>
<tr>
<td>Yagi, N</td>
<td>2181</td>
</tr>
<tr>
<td>Yagmur, M</td>
<td>S051</td>
</tr>
<tr>
<td>Yahiouei, S</td>
<td>2375</td>
</tr>
<tr>
<td>Yamamoto, S</td>
<td>F089</td>
</tr>
<tr>
<td>Yamane, K</td>
<td>2687, 3565, F059</td>
</tr>
<tr>
<td>Yan, L</td>
<td>3562</td>
</tr>
<tr>
<td>Yan, X</td>
<td>3566</td>
</tr>
<tr>
<td>Yan, Y</td>
<td>2783</td>
</tr>
<tr>
<td>Yang, C</td>
<td>3562</td>
</tr>
<tr>
<td>Yang, H</td>
<td>2321</td>
</tr>
<tr>
<td>Yang, SJ</td>
<td>F103</td>
</tr>
<tr>
<td>Yang, X</td>
<td>3562</td>
</tr>
<tr>
<td>Yang, YR</td>
<td>S057</td>
</tr>
<tr>
<td>Yang, Z</td>
<td>T038</td>
</tr>
<tr>
<td>Yasin, N</td>
<td>2141</td>
</tr>
<tr>
<td>Yavuz Yigitoglu, S</td>
<td>4142</td>
</tr>
<tr>
<td>Yazdani, N</td>
<td>S030, T001</td>
</tr>
<tr>
<td>Yazgan, S</td>
<td>T014</td>
</tr>
<tr>
<td>Yekta, AA</td>
<td>T001, T084</td>
</tr>
<tr>
<td>Yekta, R</td>
<td>T001</td>
</tr>
<tr>
<td>Yim, B</td>
<td>S063, S040</td>
</tr>
<tr>
<td>Yokoi, N</td>
<td>2677, S022</td>
</tr>
<tr>
<td>You, C</td>
<td>T060</td>
</tr>
<tr>
<td>You, Y</td>
<td>S085</td>
</tr>
<tr>
<td>YU-Wai-Man, P</td>
<td>2365</td>
</tr>
<tr>
<td>Yu, M</td>
<td>3584</td>
</tr>
<tr>
<td>Yu, Z</td>
<td>3161, 3163, S075, 3164</td>
</tr>
<tr>
<td>Yu, ZF</td>
<td>1514</td>
</tr>
<tr>
<td>Yubero, R</td>
<td>F017, F018</td>
</tr>
<tr>
<td>Zadorozhnyy, O</td>
<td>S095, T099</td>
</tr>
<tr>
<td>Zagorski, Z</td>
<td>S051</td>
</tr>
<tr>
<td>Zambarki, H</td>
<td>2336, F075</td>
</tr>
<tr>
<td>Zambrao, J</td>
<td>S109</td>
</tr>
<tr>
<td>Zeitz, C</td>
<td>T069</td>
</tr>
<tr>
<td>Zell Thime, H</td>
<td>S036, S037</td>
</tr>
<tr>
<td>Zeng, J</td>
<td>3562</td>
</tr>
<tr>
<td>Zenouda, A</td>
<td>T039</td>
</tr>
<tr>
<td>Zepa, L</td>
<td>T023, T023</td>
</tr>
<tr>
<td>Zerei, N</td>
<td>F093</td>
</tr>
<tr>
<td>Zhang, H</td>
<td>3632</td>
</tr>
<tr>
<td>Zhang, J</td>
<td>1341</td>
</tr>
<tr>
<td>Zhang, K</td>
<td>2783</td>
</tr>
<tr>
<td>Zhang, X</td>
<td>3583</td>
</tr>
<tr>
<td>Zhao, L</td>
<td>2783</td>
</tr>
<tr>
<td>Zhao, Y</td>
<td>2351</td>
</tr>
<tr>
<td>Zheng, D</td>
<td>2351</td>
</tr>
<tr>
<td>Zhu, J</td>
<td>2783</td>
</tr>
<tr>
<td>Zhuravleva, A</td>
<td>T019</td>
</tr>
<tr>
<td>Zimmermann, M, ME</td>
<td>T081</td>
</tr>
<tr>
<td>Zitzelsberger, H</td>
<td>3382</td>
</tr>
<tr>
<td>Zografos, L</td>
<td>2752, 4441, 2345, 3117, 3543</td>
</tr>
<tr>
<td>Zsolt Nagy, Z</td>
<td>4125</td>
</tr>
<tr>
<td>Zyganyow, M</td>
<td>3561</td>
</tr>
<tr>
<td>Country</td>
<td>Authors</td>
</tr>
<tr>
<td>-------------------------</td>
<td>---------</td>
</tr>
<tr>
<td>Algeria</td>
<td>2</td>
</tr>
<tr>
<td>Australia</td>
<td>3</td>
</tr>
<tr>
<td>Austria</td>
<td>9</td>
</tr>
<tr>
<td>Belgium</td>
<td>47</td>
</tr>
<tr>
<td>Canada</td>
<td>1</td>
</tr>
<tr>
<td>China</td>
<td>2</td>
</tr>
<tr>
<td>Cyprus</td>
<td>1</td>
</tr>
<tr>
<td>Czech Republic</td>
<td>6</td>
</tr>
<tr>
<td>Denmark</td>
<td>16</td>
</tr>
<tr>
<td>Finland</td>
<td>15</td>
</tr>
<tr>
<td>France</td>
<td>77</td>
</tr>
<tr>
<td>Germany</td>
<td>23</td>
</tr>
<tr>
<td>Greece</td>
<td>5</td>
</tr>
<tr>
<td>Hong Kong, China</td>
<td>1</td>
</tr>
<tr>
<td>Hungary</td>
<td>2</td>
</tr>
<tr>
<td>Iceland</td>
<td>5</td>
</tr>
<tr>
<td>India</td>
<td>2</td>
</tr>
<tr>
<td>Iran</td>
<td>3</td>
</tr>
<tr>
<td>Ireland</td>
<td>3</td>
</tr>
<tr>
<td>Israel</td>
<td>2</td>
</tr>
<tr>
<td>Italy</td>
<td>24</td>
</tr>
<tr>
<td>Japan</td>
<td>9</td>
</tr>
<tr>
<td>Lithuania</td>
<td>2</td>
</tr>
<tr>
<td>Netherlands, The</td>
<td>3</td>
</tr>
<tr>
<td>New Zealand</td>
<td>2</td>
</tr>
<tr>
<td>Norway</td>
<td>8</td>
</tr>
<tr>
<td>Poland</td>
<td>17</td>
</tr>
<tr>
<td>Portugal</td>
<td>19</td>
</tr>
<tr>
<td>Romania</td>
<td>1</td>
</tr>
<tr>
<td>Russia</td>
<td>9</td>
</tr>
<tr>
<td>Saudi Arabia</td>
<td>4</td>
</tr>
<tr>
<td>Singapore</td>
<td>6</td>
</tr>
<tr>
<td>Slovenia</td>
<td>1</td>
</tr>
<tr>
<td>South Korea</td>
<td>35</td>
</tr>
<tr>
<td>Spain</td>
<td>45</td>
</tr>
<tr>
<td>Sweden</td>
<td>15</td>
</tr>
<tr>
<td>Switzerland</td>
<td>24</td>
</tr>
<tr>
<td>Taiwan</td>
<td>1</td>
</tr>
<tr>
<td>Tunisia</td>
<td>6</td>
</tr>
<tr>
<td>Turkey</td>
<td>11</td>
</tr>
<tr>
<td>Ukraine</td>
<td>7</td>
</tr>
<tr>
<td>United Kingdom</td>
<td>70</td>
</tr>
<tr>
<td>United States</td>
<td>13</td>
</tr>
</tbody>
</table>
**Wednesday, October 5, 2016**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:30 - 13:00</td>
<td>PBP/RV - Retinal perfusion imaging</td>
<td>Hermes</td>
</tr>
<tr>
<td>14:00 - 15:30</td>
<td>RV - Management of Aphakia</td>
<td>Rhodes 1</td>
</tr>
<tr>
<td>15:30 - 16:00</td>
<td>Coffee break</td>
<td>Hermes</td>
</tr>
<tr>
<td>15:40 - 15:50</td>
<td>Openings Ceremony: Welcome by the President EVER 2016 - KAWASAKA</td>
<td>Hermes</td>
</tr>
<tr>
<td>15:50 - 16:00</td>
<td>Highlights of EVER / and Update on EVER in EU-EYE - SCHMUTTERER L</td>
<td>Hermes</td>
</tr>
<tr>
<td>16:00 - 16:30</td>
<td>EVER Past President lecture: Lessons from the Fascinating World of Bestrophinopathies - LEROY B</td>
<td>Hermes</td>
</tr>
<tr>
<td>16:30 - 16:45</td>
<td>Coffee break</td>
<td>Hermes</td>
</tr>
<tr>
<td>16:50 - 18:20</td>
<td>MBGE/RV - Advances in gene-based therapies for ocular disorders</td>
<td>Hermes</td>
</tr>
<tr>
<td>18:35 - 19:00</td>
<td>European Ophthalmology Heritage Lecture: Magnificat - MISSOTTEN L</td>
<td>Hermes</td>
</tr>
<tr>
<td>19:00 - 19:30</td>
<td>Keynote Lecture: Developing new treatments for inherited retinal degenerations - MACLAREN R</td>
<td>Hermes</td>
</tr>
<tr>
<td>19:30 - 19:30</td>
<td>EVER Welcome Reception</td>
<td>Exhibition area</td>
</tr>
</tbody>
</table>

**Thursday, October 6, 2016**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30 - 10:00</td>
<td>RV - Diabetic retinopathy</td>
<td>Hermes</td>
</tr>
<tr>
<td>10:00 - 10:20</td>
<td>Coffee break</td>
<td>Hermes</td>
</tr>
<tr>
<td>10:20 - 10:50</td>
<td>EVER Acta Lecture: The pathogenic role of LRG1 in ocular neovascularisation: from discovery to targeted therapy - GREENWOOD J</td>
<td>Hermes</td>
</tr>
<tr>
<td>11:00 - 12:30</td>
<td>IM - OCT in inflammatory ocular diseases: beneath and beyond the retina</td>
<td>Hermes</td>
</tr>
<tr>
<td>13:50 - 14:20</td>
<td>Keynote Lecture: Medical science and clinical research in corneal regenerative medicine - VANDEPUT T</td>
<td>Hermes</td>
</tr>
<tr>
<td>14:30 - 16:00</td>
<td>IM/RV - Challenges and controversies in ophthalmology: When the patient overlap between different subspecialties CASPERS L-WILLEMANN F</td>
<td>Hermes</td>
</tr>
<tr>
<td>16:00 - 17:00</td>
<td>Poster session 1: Electrophysiology, Physiological Optics, Vision Sciences</td>
<td>Poster area</td>
</tr>
<tr>
<td>16:00 - 17:00</td>
<td>Meet the Experts</td>
<td>Poster area</td>
</tr>
<tr>
<td>17:00 - 18:30</td>
<td>RV - Controversies in vitreoretinal practice</td>
<td>Hermes</td>
</tr>
<tr>
<td>18:30 - 20:00</td>
<td>Modern understanding of dry eye</td>
<td>Poster area</td>
</tr>
</tbody>
</table>
The power of simplicity

Rethinking glaucoma management

GALLOMA GE IMPLANT

Date of preparation: July 2016

Find a list of countries where XEN is available at the Allergan stand.

Adverse events should be reported to your local regulatory authority and Allergan office. XEN is not commercially available in France.

The power of simplicity

Hodges

E Galli 1 & 2

HERMES

Friday, October 7, 2016

08:30 - 10:00

08:30 - 09:30

09:30 - 10:00

Cosmos

09:30 - 10:00

09:30 - 10:00

09:30 - 10:00

09:30 - 10:00

10:00 - 10:20

10:20 - 10:50

10:50 - 11:20

12:00 - 13:00

13:00 - 14:30

14:30 - 15:00

15:00 - 15:50

15:50 - 16:20

16:20 - 17:00

17:00 - 18:30

18:30 - 19:00

Saturday, October 8, 2016

08:30 - 09:30

09:30 - 10:00

10:00 - 10:20

10:20 - 10:50

10:50 - 11:20

11:20 - 11:30

11:30 - 12:00

12:00 - 13:00

13:00 - 13:30

13:30 - 14:00

14:00 - 14:30

14:30 - 15:00

15:00 - 15:30

15:30 - 16:00

16:00 - 16:30

16:30 - 17:00

17:00 - 18:30

18:30 - 19:00

08:30 - 10:00

09:30 - 10:00

10:00 - 10:20

10:20 - 10:50

10:50 - 11:20

11:20 - 11:30

11:30 - 12:00

12:00 - 13:00

13:00 - 13:30

13:30 - 14:00

14:00 - 14:30

14:30 - 15:00

15:00 - 15:30

15:30 - 16:00

16:00 - 16:30

16:30 - 17:00

17:00 - 18:30

18:30 - 19:00

08:30 - 10:00

09:30 - 10:00

10:00 - 10:20

10:20 - 10:50

10:50 - 11:20

11:20 - 11:30

11:30 - 12:00

12:00 - 13:00

13:00 - 13:30

13:30 - 14:00

14:00 - 14:30

14:30 - 15:00

15:00 - 15:30

15:30 - 16:00

16:00 - 16:30

16:30 - 17:00

17:00 - 18:30

18:30 - 19:00

08:30 - 10:00

09:30 - 10:00

10:00 - 10:20

10:20 - 10:50

10:50 - 11:20

11:20 - 11:30

11:30 - 12:00

12:00 - 13:00

13:00 - 13:30

13:30 - 14:00

14:00 - 14:30

14:30 - 15:00

15:00 - 15:30

15:30 - 16:00

16:00 - 16:30

16:30 - 17:00

17:00 - 18:30

18:30 - 19:00

08:30 - 10:00

09:30 - 10:00

10:00 - 10:20

10:20 - 10:50

10:50 - 11:20

11:20 - 11:30

11:30 - 12:00

12:00 - 13:00

13:00 - 13:30

13:30 - 14:00

14:00 - 14:30

14:30 - 15:00

15:00 - 15:30

15:30 - 16:00

16:00 - 16:30

16:30 - 17:00

17:00 - 18:30

18:30 - 19:00

08:30 - 10:00

09:30 - 10:00

10:00 - 10:20

10:20 - 10:50

10:50 - 11:20

11:20 - 11:30

11:30 - 12:00

12:00 - 13:00

13:00 - 13:30

13:30 - 14:00

14:00 - 14:30

14:30 - 15:00

15:00 - 15:30

15:30 - 16:00

16:00 - 16:30

16:30 - 17:00

17:00 - 18:30

18:30 - 19:00

08:30 - 10:00

09:30 - 10:00

10:00 - 10:20

10:20 - 10:50

10:50 - 11:20

11:20 - 11:30

11:30 - 12:00

12:00 - 13:00

13:00 - 13:30

13:30 - 14:00

14:00 - 14:30

14:30 - 15:00

15:00 - 15:30

15:30 - 16:00

16:00 - 16:30

16:30 - 17:00

17:00 - 18:30

18:30 - 19:00

08:30 - 10:00

09:30 - 10:00

10:00 - 10:20

10:20 - 10:50

10:50 - 11:20

11:20 - 11:30

11:30 - 12:00

12:00 - 13:00

13:00 - 13:30

13:30 - 14:00

14:00 - 14:30

14:30 - 15:00

15:00 - 15:30

15:30 - 16:00

16:00 - 16:30

16:30 - 17:00

17:00 - 18:30

18:30 - 19:00

08:30 - 10:00

09:30 - 10:00

10:00 - 10:20

10:20 - 10:50

10:50 - 11:20

11:20 - 11:30

11:30 - 12:00

12:00 - 13:00

13:00 - 13:30

13:30 - 14:00

14:00 - 14:30

14:30 - 15:00

15:00 - 15:30

15:30 - 16:00

16:00 - 16:30

16:30 - 17:00

17:00 - 18:30

18:30 - 19:00
EVER would like to thank all of its past and present sponsors. We would especially like to thank the following companies, many of which are our long-term supporters, for their generous sponsorship in 2016. Thanks to their kind support, EVER can continue to encourage research and dissemination of knowledge concerning the eye and vision by means of meetings, publications and exchange of information.

EVER 2016 - programme book

22 CME